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Methane is an ideal alternative to petroleum refining as a chemical feedstock source since 
it is highly abundant an inexpensive. However, the lack of selective methane oxidation catalysts 
has limited such utilization. Starting from cytochrome P450 CYP102A1 (BM3) from Bacillus 
megaterium, which prefers C12-C20 fatty acids as its substrates, I investigated several protein 
engineering approaches to shift the enzyme’s substrate specificity toward small gaseous alkanes, 
with the ultimate goal of methane. By continuing previous directed evolution efforts in our 
group, a variant with wild-type-like affinity and catalytic efficiency for propane, P450PMO, was 
isolated. To alleviate the loss of protein thermostability (~ 10 oC) as a result of this approach, 
mutations were targeted to the BM3 active site with site saturation mutagenesis, targeted 
mutagenesis with a reduced set of amino acids, and computationally guided library designs. 
From these enzyme libraries, variants were identified that replicated much of the P450PMO 
activities with a minimal number of mutations while maintaining wild-type thermostability. 
Continuing the protein engineering with a high throughput ethane hydroxylation screen, 
variants with improved in vitro ethane hydroxylation activity were obtained. However, in whole-
cell ethane bioconversions, BM3-derived variants could not match the activity of a natural P450 
alkane hydroxylase, CYP153A6. To investigate the oxidation capability of the P450 oxo-ferryl 
porphyrin radical intermediate directly, I employed a variety of terminal oxidants to support 
P450 alkane hydroxylation reactions abridging the P450 catalytic cycle. In this study, the 
CYP153A6 oxo-ferryl intermediate was able to oxidize methane in reactions using 
iodosylbenzene, which demonstrated that direct methane-to-methanol conversion by a P450 
heme porphyrin catalyst at ambient conditions is possible and does not necessarily require the 




Selective hydroxylation of small alkanes is a long-standing problem for which few 
practical catalysts are available. The lack of catalysts that can efficiently convert gaseous alkanes 
into transportable liquid commodities has been a barrier to broader utilization of these resources. 
In particular, methane, the principal component of natural gas, is an ideal alternative to 
petroleum as a chemical feedstock source since it is highly abundant and inexpensive. Currently, 
methane is converted to methanol via an energy intensive, endothermic, and costly process that 
first converts methane into synthesis gas, followed by methanol synthesis from this intermediate. 
This process is economically feasible only on a large scale, which in combination with general 
transportation limitations of a gas commodity prevent methane recovery from many sources.  
The selective oxidation of small alkanes is difficult because of the inertness of the alkane 
C-H bond, which requires highly reactive radical or ionic species to cleave. However, as the 
desired partial oxidation products, alcohol and aldehyde, have weaker C-H bonds compared to 
the alkane, they are susceptible to further oxidation to CO2. While this transformation has been 
achieved only by a limited set of transition-metal-based catalyst systems, a variety of alkane 
hydroxylases found in alkanotrophic microorganisms support selective alkane oxidation at 
ambient conditions using oxygen as the oxidant. Chapter 1 of this thesis provides an introduction 
to enzymatic alkane oxidation by monooxygenases, highlighting the structure and mechanisms of 
three major enzyme classes, methane monooxygenases (MMOs), non-heme (di-iron) 
monooxygenases, and cytochrome P450s (P450s).   
MMOs enable methanotrophic bacteria to use methane as their sole carbon source, while 
non-heme (di-iron) monooxygenases and P450s enable microorganisms to grow on medium- and 
long-chain alkanes. These monooxygenases selectively oxidize alkanes into alcohols as the first 
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step in hydrocarbon metabolism. Unfortunately, since the majority of these hydroxylases 
function as a part of a larger enzyme complex and are membrane associated, their potential for 
industrial applications is limited. For these reasons, we have been engineering well-expressed, 
soluble, bacterial P450s, in particular CYP102A1 (BM 3) isolated from Bacillus megaterium, for 
small alkane hydroxylation. 
In addition to being well-expressed and soluble, BM 3 was chosen as the starting point 
for this protein engineering effort because it is a rare self-sufficient P450 with its heme 
(hydroxylase) and reductase domains fused on a single polypeptide. This unique domain 
architecture has been credited for BM3’s high catalytic rate acting on its preferred C12 to C20 
fatty acids substrates. Previous work in our laboratory (by Ulrich Schwaneberg, Edgardo T. 
Farinas, Anton Glieder, Matthew Peters, and Peter Meinhold) aimed at converting BM3 into a 
methane monooxygenase applied directed evolution –iterations of mutagenesis, recombination, 
and screening, to generate BM3 variants with improved alkane hydroxylation activity. Their 
overall strategy for shifting BM3’s substrate specificity was to enhance the promiscuous alkane 
hydroxylation activity of BM3 and subsequent variants starting with octane as the target 
substrate. Using a colorimetric screen with p-nitrophenoxy octane as a surrogate substrate in 
combination with monitoring cofactor consumption in the presence of octane, variants with 
improved activity for octane hydroxylation were identified. Limited activity toward propane, a 
substrate not hydroxylated by wild-type BM3 was also observed in later generation variants. At 
this point, selection pressure was shifted toward propane hydroxylation by screening for 
dimethyl ether demethylation in high-throughput as the surrogate activity. Using this screen and 
a combination of mutagenesis techniques, ethane hydroxylation activity was obtained with 
variant 35E11. At this point, I took over the P450 alkane hydroxylase project. 
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Chapter 2 describes the continuation of laboratory evolution efforts aimed at converting 
BM3 into a small alkane hydroxylase, starting from variant 35E11. As a result of the previous 
ten rounds of mutagenesis and screening, variant 35E11 displayed a significantly lower 
thermostability (T50 = – 11.6 oC) compared to the wild-type enzyme. To reverse this loss in 
thermostability, which is known to reduce the ability of a protein to acquire beneficial mutations 
that are destabilizing, known stabilizing mutations from a P450 peroxygenase were grafted onto 
variant 35E11 singly and in combination. The resulting thermostablized variant was subjected to 
a domain-based protein-engineering strategy (developed by Rudi Fasan), in which the three 
domains of BM3 were mutated individually using both random and site-saturation mutagenesis. 
Beneficial mutations identified through high-throughput screening for dimethyl ether 
demethylation were verified to improve propane and ethane hydroxylation in the context of the 
holoenzymes. Using this strategy, re-specialization of BM3 for propane hydroxylation was 
achieved with variant P450PMO, a proficient P450 propane monooxygenase. This variant displays 
substrate affinity and coupling of cofactor consumption rivaling those of the natural P450s with 
their preferred substrates. In addition, we were able to demonstrate in vivo propane 
hydroxylation using these BM3 variants in resting E. coli cells reaching activities surpassing 
those reported for natural alkane hydroxylases acting on their preferred substrates.   
In Chapter 3, we explored alternative mutagenesis approaches to engineer BM3 for small 
alkane hydroxylation. Instead of gradually shifting the BM3’s substrate specificity by enhancing 
its promiscuous alkane hydroxylation activity as done previously, we applied several semi-
rational library design approaches to mutate the BM3 active site in an attempt to acquire activity 
for small alkane hydroxylation directly from the wild-type enzyme. From screening of 
mutagenesis libraries created by combinatorial active site saturation with a reduced set of amino 
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acids and two structure-based computational library design approaches, we identified variants 
supporting both propane and ethane hydroxylation. Although, none of the obtained variants 
reached the level of specialization that was previously obtained with P450PMO, the range of 
obtained propane TON and coupling of cofactor consumption corresponds to those values of 
generalist intermediates of P450PMO lineage obtained after 10 – 12 rounds of mutagenesis and 
screening. These results suggest semi-rational library design can be an effective strategy to move 
away from a specialist enzyme toward generalist enzymes, but functional specialization still 
requires optimization through several rounds of random mutagenesis and screening. 
The BM3 variants we obtained with high activity on small alkanes hydroxylate propane 
and longer chain alkanes predominantly at the more energetically favorable subterminal position. 
In contrast, sMMO and other alkane hydroxylases utilized by microorganisms for alkane 
metabolism selectively oxidize at the terminal carbon to produce 1-alcohols. Since selective 
terminal hydroxylation has been difficult to achieve by engineering BM3, a sub-terminal 
hydroxylase, we investigated in Chapter 4 whether a small-alkane terminal hydroxylase could be 
obtained by directed evolution of a longer-chain alkane hydroxylase that exhibits this desirable 
regioselectivity. For this study, we engineered two alkane hydroxylases that prefer medium-
chain-length alkanes (C6 – C10), AlkB from P. putida GPo1 and CYP153A6 from 
Mycobacterium sp. HXN-1500, for enhanced butane hydroxylation activity using an in vivo 
growth-based selection system (developed by Daniel Koch). This system enabled selection for 
terminal alkane hydroxylase activity based on enhanced growth complementation of an adapted 
strain of P. putida. The resulting enzymes, AlkB-BMO1, -BMO2, and CYP153A6-BMO1 
conferred improved growth on butane as the sole carbon source and exhibited higher rates of 1-
butanol production in whole-cell butane bioconversions while maintaining their preference for 
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terminal hydroxylation. These results demonstrated the usefulness of this in vivo selection 
system, which could be generally applied to directed evolution of enzymes for small alkane 
hydroxylation. 
To apply selection pressure for the main goal of this research, selective hydroxylation of 
ethane and methane, we developed a high-throughput screen to directly assay for P450 alkane 
hydroxylation, described in Chapter 5. With the use of a pressurizable 96-well reactor, the P450 
alkane hydroxylation reaction was conducted in high throughput and the alcohol product was 
quantified spectroscopically by a coupled enzyme assay. Applying this screen to BM3 variants 
generated in our laboratory, we identified variant E31 as the best candidate for further 
engineering, since it displayed both the highest activity in the screen and wild-type-like 
thermostability. Subsequent rounds of site-saturation and random mutagenesis resulted in 
improved variants demonstrating the efficacy of the screen. However, none of the identified 
BM3 variants were able to produce ethanol or methanol in whole-cell alkane bioconversions 
using growth-arrested E. coli cells. In contrast, CYP153A6, a natural terminal alkane 
hydroxylase, was able to produce ethanol in whole-cell alkane bioconversions. The inability of 
BM3 variants to produce ethanol in vivo reflects their poor affinity for ethane and indicates they 
still lag behind a natural P450 alkane hydroxylase in terminal hydroxylation of small alkanes. 
The complete absence of methane oxidation activity in numerous BM3 variants evolved 
for propane and ethane hydroxylation activity led us to question if the P450 oxo-ferryl porphyrin 
radical intermediate, compound I, can oxidize the 105 kcal/mol methane C-H bond. In Chapter 6, 
we separated the substrate binding problem presented by the small size of methane from the 
challenge of the higher activation barrier of the reaction presented by the methane C-H bond by 
assaying the reactivity of compound I directly through terminal oxidant-supported P450 
x 
 
reactions. Using iodosylbenzene, 3-chloroperoxybenzoic acid, and hydrogen peroxide as 
oxidants, we investigated the ability of the compound I of five P450s (BM3, P450PMO, P450cam, 
CYP153A6, and CYP153A6-BMO1) to hydroxylate alkanes ranging from methane to octane. 
From these terminal oxidant-supported P450 reactions, we found the compound I of CYP153A6, 
and CYP153A6 BMO-1 to be able to break the methane C-H bond using PhIO as the oxidant. 
This demonstrates both the feasibility of P450 methane oxidation and the use of terminal 
oxidant-supported P450 reactions as an assay to investigate the compatibility of P450 active sites 
for small alkane oxidation. By chemically generating the active radical, we eliminated the 
requirement for substrate binding to initiate P450 catalysis, which enabled us to determine the 
innate substrate range of each P450 active site.   
Although the BM3 variants we generated could not hydroxylate methane, we have found 
other applications for which they excel, such as regioselective hydroxylation of non-activated 
carbon centers. The involvement of human P450s in the degradation of most drug compounds 
made us wonder if BM3 variants can be used to replicate or predict the metabolism patterns of 
human P450s and produce these metabolites on a preparative scale. In Chapter 7, we 
demonstrated that a small panel of BM3 variants covers the breadth of reactivity of human P450s 
by producing 12 of 13 mammalian metabolites for two marketed drugs, verapamil and 
astemizole, and one research compound. The most active enzymes could support preparation of 
individual metabolites for preclinical bioactivity and toxicology evaluations. Underscoring their 
potential utility in drug lead diversification, engineered BM3 variants also produce novel 
metabolites by catalyzing reactions at carbon centers beyond those targeted by animal and 
human P450s. Finally, we enhanced the production of a specific metabolite by directed evolution 
of the enzyme catalyst.  
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Chapter 8 details experimental procedures and materials used throughout the studies 
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Petroleum and natural gas are the primary energy resources currently utilized to meet the 
world’s energy needs (1). In addition to its use as a fuel source, the conversion of crude oil to 
olefins and aromatics through refining has also allowed petroleum to act as a major feedstock for 
the chemical industry. This ability to generate chemical precursors—through processes such as 
cracking, dehydrogenation, and reforming—differentiates petroleum from natural gas, which has 
been limited to usage as a fuel. However, as the world’s known reserves of crude oil are 
shrinking (2), the need to find alternative sources for chemical feedstocks, such as natural gas, is 
becoming more pressing. This search for alternative feedstocks is also motivated by the 
environmental impact of petroleum refining. As the reactions to produce olefins and aromatics  
from petroleum are endothermic, CO2 is released during both the generation of these chemical 
precursors and in the subsequent partial oxidation steps to produce the desired oxygenated 
compounds (e.g., aldehydes, alcohols, carboxylic acids). 
Methane, the principal component of natural gas, is an ideal alternative to petroleum 
refining, since it fulfills all the requirements for a chemical feedstock, including high abundance, 
low cost, and lower carbon footprint (CO2 emission) compared to petroleum refining. In addition 
to the methane available in known natural gas and coal sources, it can also be produced via 
biogas (3), by fermentation of organic matter (3), and vast quantities are stored as methane 
hydrates at the ocean floor (4). There are also economic incentives to convert methane into 
oxygenated products, as it is less expensive than petroleum-generated olefins and aromatics. 
Finally, the methane oxidation reaction is exothermic. Therefore replacing the highly 
endothermic petroleum refining processes with methane oxidation would also result in 
concurrent energy production with the chemical products instead of energy consumption. Despite 
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all these favorable factors, methane is still underutilized as a feedstock owing to a lack of 
economical and sustainable strategies for its selective oxidation (5). 
The selective oxidation of methane to oxygenated products represents a significant 
challenge, as the methane C-H bond is extremely inert (105 kcal/mol) (6). Therefore, highly 
reactive radical or ionic species are required to cleave the methane C-H bond.  However, as the 
desired partial oxidation products, methanol and formaldehyde, have weaker C-H bonds 
compared to methane, they are susceptible to further oxidation to CO2. To overcome these 
challenges, research toward partial methane oxidation and improved methane utilization has 
taken several different approaches: (1) the one-step oxidation of methane to methanol or 
formaldehyde, (2) oxidative and non-oxidative coupling of methane, (3) Fischer-Tropsch 
synthesis of hydrocarbons from synthesis gas (syngas), generated from steam reformation of 
methane. Currently, industrial conversion of methane to methanol falls into the latter category, 
utilizing an energy intensive, endothermic, and costly process to first convert methane into 
syngas, followed by methanol synthesis from this intermediate (1, 7).  While there is a variety of 
mixed metal-oxide heterogeneous catalysts capable of the desired methane partial oxidation (8) 
and coupling reactions (9 – 10), these catalysts currently lack the reactivity and selectively 
necessary for commercialization (5).   
The most hopeful strategy for selective methane oxidation is through electrophilic 
activation by late transition metal ions, such as Pt(II) (11), Pd (II) (12), Rh (13), and Hg(II) (14). 
These systems are derived from the landmark study by Shilov demonstrating the production of 
alcohol and alkyl-chloride using Pt(II) salts in aqueous solution (11) (see equation (1)). These 
systems have been shown to be capable of both stoichiometric and catalytic oxidation of 
methane. Their most attractive feature is a high selectivity for the partially oxidized product: i.e., 
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the reactivity for the methane C-H bond is substantially greater than that of a product C-H bond, 
such as H-CH2OH or H-CH2SO4H (15). The mechanism of the Shilov systems occurs in three 
steps: (1) electrophilic activation of the R-H bond by Pt(II) to form a Pt(II)-alkyl intermediate, 
(2) oxidation of the Pt(II)-alkyl complex by [PtCl6]2- to give a Pt(IV)-alkyl species, (3) 
nucleophilic SN2 attack of water at Pt-C bond results in the formation of the alcohol product and 
regenerates the Pt(II) catalyst.   
 
Advancement of the original system has been made by Periana et al., which has replaced 
the oxidant [PtCl6]2- with sulfuric acid (15). Using an Hg2+complex in sulfuric acid, a one-pass 
yield of 40% conversion of methane to methyl hydrogensulfate was obtained at > 90% selectivity 
(14). An improved system utilizing Pt(II) chelated by 2,2’-bipyrimidine, which is more 
thermodynamically robust, resulted in a one-pass yield of greater than 73% (15). While these 
yields are the highest reported for direct partial oxidation of methane, several key disadvantages 
have prevented commercialization: low turnover frequency (16), costly methanol recovery from 
concentrated sulfuric acid, and catalyst poisoning by water and oxidation products (5). 
In contrast to the difficulties for transition metal catalysts to selectively oxidize methane, 
metalloenzymes, specifically methane monooxygenases (MMOs) with metal centers composed 
of abundantly available metals (iron and copper) are able to convert methane to methanol at 
room temperature, atmospheric pressure, in water, and using O2 as the oxidant (17). Alkane 
hydroxylases, including MMOs, are discussed in detail in the next section. As the structures of 
these metalloenzymes have become available, they have inspired chemists to make “biomimetic” 
catalysts (18) in attempts to capture the metal-centers in a functional form using a variety of 
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scaffolds. The synthesis and characterization of multiple di-iron FeIV=O complexes modeled 
after the Q intermediate of MMOs have been reported (19 – 22). To date, these complexes have 
been shown to activate C-H bonds as strong as 100 kcal/mol, however, the obtained reaction 
rates were much lower than those observed with metalloenzymes (20, 22). 
B. Alkane Oxidizing Enzymes 
B.1. Methane monooxygenases (MMOs) 
While a catalyst that supports efficient conversion of methane to methanol has so far 
eluded transition metal chemistry, Nature found a solution to utilize methane as an energy source 
long ago. Methanotrophic bacteria found in a variety of environments including methane vents in 
the deep sea, gastrointestinal tracts of cows, and landfills are unique in their ability to utilize 
methane as their sole carbon and energy source (23). Methanotrophs, comprising 13 different 
genera within the  and  protobacteria (24), are defined by their expression of a methane 
monooxygenase (MMO) that directly converts methane to methanol. The methanol product is 
further oxidized to formaldehyde by a methanol dehydrogenase and is used both for biomass 
synthesis (23) and as a source of ATP through further oxidation reactions (23). 
Most studies of MMOs have been focused on enzymes from Methyloccus capsulatus 
Bath (M. c. Bath) and Methylosinus trichorium OB3b (M. t. OB3b) (25). There are two types of 
MMOs employed by methanotrophs, soluble MMO (sMMO) (17) and membrane-bound or 
particulate MMO (pMMO) (26). All but one genus of methanotrophic bacteria express pMMO, 
and a small subset produces both MMOs (24). In methanotrophs expressing both MMO forms, 
sMMO is expressed when less than 0.8 M copper is present in the growth medium, whereas 
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with ~ 4 M copper present, pMMO is expressed along with the developments of extensive, 
intracytoplasmic membranes (27 – 28).  
B.2. pMMO 
Particulate MMOs are integral membrane metalloenzymes produced in nearly all 
methanotrophs and are composed of the three subunits pmoA, pmoB, and pmoC (26). The three 
protomers are arranged in an 3.3.3 trimeric complex, Figure 1.1 (25). The soluble region of 
the enzyme complex extends ~ 45 Å from the membrane and is composed of six -barrels. A 
significant opening spans the length of the pMMO trimer at its center; this pore is ~ 11 Å wide in 
the soluble portion and expands to ~ 22 Å within the membrane. Despite decades of research and 
the availability of two crystal structures (29), only recently has the location of the copper active 
site been identified (30). Balasubramanian et al. demonstrated that expression of only the soluble 
domain of pMMO, pmoB, from M.t.OB3b (31) was sufficient for methane oxidation (30). This 
study conclusively identified the active site to be a dicopper center with a Cu-Cu distance of 2.5 
– 2.7 Å coordinated by three highly conserved His residues (32). In light of this discovery, it is 
puzzling why Nature chose such a large enzyme complex for this reaction, when a soluble sub-
domain of pMMO is fully capable of the transformation. One theory forwarded by the authors 
suggests that the membrane portions may play an important role in increasing the local methane 
concentration as methane preferentially partitions between the aqueous solution and the 




Figure 1.1: The pMMO (M. c. Bath) structure (pdb: 1YEW); (a) the full structure with one protomer 
highlighted, reproduced from ref 29; (b) the soluble domain pmoB; (c) the first coordination sphere of the 
dicopper metal center 
Although pMMO is much more prevalent than sMMO in methanotrophs, difficulties in 
its characterization due to the fact that it is an integral membrane enzyme have resulted in far 
less understanding of its biochemistry as compared to sMMO. In fact, the conditions for isolating 
catalytically active pMMO have been the subject of extensive research, and the optimal 
conditions still remain unclear. Copper concentration in the growth medium, anaerobicity of the 
growth condition, and the detergent-protein ratio are among the many conditions that have been 
shown to affect the measured enzyme activity (33 – 34). The in vitro characterization of pMMO 
is further complicated by the absence of a known physiological reductant. Typically, purified 
pMMO is assayed for propylene oxidation activity using either NADH or duroquinol as the 
reductant (35). Activities ranging from 0.002 to 0.126 U/mg (1 U = 1 µmol propylene oxidized 
per min) have been reported from various preparations (32 – 33, 36 – 37).  
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pMMO has been shown to oxidize only alkanes and alkenes up to five carbons in length 
(38 – 39). Interestingly, for these multi-carbon substrates, sub-terminal oxidation at the C-2 
position is preferred (40). Studies using chiral alkanes have given evidence to suggest the 
pMMO mechanism for oxygen insertion occurs in a concerted fashion rather than involving 
radical or cationic intermediates, as with sMMO or cytochrome P450s (41 – 42). In addition, an 
absence of a carbon kinetic isotope effect in the oxidation of propane also suggests little or no 
structural rearrangement occurs at the carbon center during the rate-limiting step (43). 
Unfortunately, attempts to determine the pMMO mechanism have been sparser compared to 
similar efforts with sMMO, and much of the mechanism is still not well understood. 
B.3. sMMO 
Due to both its unique ability to oxidize methane as well as its high substrate promiscuity, 
i.e., the ability to hydroxylate more than 50 different compounds including aromatics (17, 35), 
sMMO has been a favored target for research (39). sMMO has been purified from M. t. OB3b 
(44), M. c. Bath (45), and several other strains of methanotrophs (46). It belongs to the family of 
bacterial multi-component monooxygenases (BMMs) (EC.1.14.13.25), which includes toluene 
monooxygenase, phenol hydroxylase, and alkene monooxygenase (47), that enable their hosts to 
utilize a variety of hydrocarbons as their sole carbon and energy source (47 – 48). Using a 
common carboxylate-bridged di-iron center in their hydroxylase, BMMs are able to activate 
oxygen for formal insertion into the substrate C-H bond, which initiates the metabolism of these 
hydrocarbons. 
Typical of BMM family members, sMMO is comprised of three components; a 
hydroxylase (MMOH), which houses the di-iron active site, a reductase (MMOR), which 
contains a flavin adenine dinucleotide (FAD), and a [2Fe-2S]-ferredoxin (Fd) cofactor that 
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shuttles electrons from the NADH cofactor to the MMOH active site, and a regulatory protein 
(MMOB), which is required for methane oxidation (17). The MMOH subunit consist of three 
polypeptides arranged as an 222 dimer, Figure 1.2 (a). The di-iron active site is embedded in 
a four-helix bundle and coordinated by four carboxylates and two imidazoles from two 
E(D/H)XXH binding motifs.  
The resting state of the hydroxylase (Hox) active site is a di(-hydroxo)-(-
carboxylato)diiron (III) species. The catalytic cycle (Figure 1.2 (b)) is initiated by a two-electron 
reduction to the di-iron (II) form (Hred). The reduction occurs simultaneously with a carboxylate 
shift of the terminally coordinated glutamate (E243), which results in protonation and 
displacement of both bridging hydroxyl ligands. Rapid reaction of Hred with O2 in the presence of 
MMOB results in a peroxodiiron (III) intermediate (Hperoxo). In the absence of electron-rich 
substrates, Hperoxo rapidly decays into the intermediate Q, a diiron(IV) oxo intermediate with a 
short Fe-Fe distance of 2.5 Å (49). The Q intermediate has been shown to be responsible for the 
oxidation of a variety of substrates (50 – 54) including methane. In the absence of substrate, Q 
decays slowly to Hox by acquiring two electrons and two protons through a still unknown 
process. Both Hperoxo and Q intermediates have well-defined Mossbauer and optical spectroscopic 
properties (53, 55). The conversion of Hperoxo to Q has been shown to be both pH-dependent and 
exhibiting a solvent kinetic isotope effect (KIE), which indicates that the O-O bond cleavage 




Figure 1.2: The sMMO structure and mechanism. (a) The structure of MMOH (pdb: 1MTY), MMOB 
(pdb: 1CKV), and MMOR (pdb: 1JQ4) with the cofactors highlighted, reproduced from ref 17. (b) The 
sMMO catalytic cycle, see text for details, (PCET: proton coupled electron transfer) 
Based on density functional theory (DFT) calculation with ~ 100 atoms (58 – 60), 
methane initially approaches the Q intermediate in the ~ 185 Å3 hydrophobic binding site distal 
to the histidine ligands. The bridging oxygen atom abstracts a hydrogen atom from methane in an 
outer-sphere, proton-coupled electron transfer reaction, during which one of the iron atoms is 
reduced to Fe (III). The electron is taken from a C-H -orbital, leaving behind a bound methyl 
radical. The C-O bond formation along with a second electron transfer to the other iron center 
from the methyl radical occurs either through a rebound mechanism with very short distances 
(H-O---C of 1.97 Å) or a concerted mechanism with the methyl fragment tightly bound to the 
hydroxyl group (61). These two proposed pathways have comparable activation barriers from 
DFT calculations, therefore the reaction most likely has a mixed character. The catalytic cycle is 




MMOH is only active in the presence of a protein cofactor, MMOB, which when 
complexed with MMOH changes its structure and reactivity. For example, MMOH from M. t. 
OB3b oxidizes alkanes and nitrobenzene to form secondary alcohols and m-nitrophenol products 
in the absence of MMOB (62). Upon MMOB addition, the product ratios shift such that mostly 
primary alcohols and p-nitrophenol are formed. In addition, MMOB must be present for efficient 
generation of MMOH intermediates in the reaction cycle, which suggests that binding of MMOB 
initiates the electron transfer (ET) and O2 binding steps (63 – 64). The presence of MMOB has 
been generally reported to enhance ET between MMOH and MMOR (63), but when chemically 
reduced MMOR was added to premixed solutions of MMOH and MMOB the same ET between 
MMOH and MMOR was inhibited (65). These apparently conflicting results have led 
investigators to suggest that slow structural changes associated with MMOB and MMOR binding 
to MMOH may result in hysteresis in MMOH activity (62). A current hypothesis is that the 
interaction of one hydroxylase component of MMOH with MMOR or MMOB could be 
dependent on the presence of MMOR or MMOB bound to the other component of MMOH (66). 
As a consequence of this dependence, the oxidative phase of the catalytic cycle may only occur 
at one of the two active sites at a time. This hypothesis has been experimentally verified by 
observing a ~ 50% maximal conversion of the initial di-iron (II) protein during reactions of 
MMOH with oxygen (53).  
The complexity of the interactions between these three enzyme components could be 
necessary to facilitate and coordinate the transport of the four substrates, hydrocarbon, oxygen, 
electrons, and protons of the sMMO reaction. The selective trafficking of these substrates to the 
diiron active site of the hydroxylase is also aided by the presence of biologically well-engineered 
substrate tunnels and pockets (67). Co-crystallization of MMOH with halogenated alkanes, Xe 
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(68), and -halogenated primary alcohols (69) has revealed the presence of multiple 
hydrophobic substrate binding pockets that trace a contiguous pathway from the protein surface 
to the di-iron center. The entry of the substrate appears to pass through several such cavities in its 
path from aqueous solution to the enzyme’s active site (69). Finally, as many as eleven binding 
sites have been identified with Xe, which has similar polarity, water solubility, and van der 
Waals radius as methane. The binding of these surrogate substrates of methane did not induce 
significant side-chain displacement in the enzyme; therefore it appears that methane and other 
sMMO substrates are bound in pre-formed hydrophobic pockets. 
Kinetic studies of the oxidation of hydrocarbon substrates by intermediate Q monitored 
through stopped-flow spectroscopy have shown three distinct substrate classes. The first class of 
substrates, including ethane, methanol, ethanol, and some ethers, displays a linear dependence of 
reaction rate on substrate concentration. In addition, a kinetic isotope effect (KIE) of near unity 
was observed, which suggests that the breaking of the substrate C-H bond is not the rate-
determining step. The second class of substrates, including methane and diethyl ether, also 
displays a linear dependence of reaction rate with substrate concentration but display a KIE > 1, 
suggesting that C-H bond activation reaction is rate-determining. Finally, the last class of 
substrates includes nitromethane, acetonitrile, and acetaldehyde, and displays normal Michaelis-
Menten kinetics with hyperbolic dependence of reaction rate with substrate concentration and a 
KIE > 1. For many of the hydrocarbon substrates discussed above, with the exception of 
methane, the Hperoxo intermediate is also a viable oxidant. However, when the Hperoxo intermediate 
is used as the oxidant rather than Q, only class II and III kinetic behavior is observed. This has 
led some investigators to conclude that reactions with Hperoxo proceed through a classical 
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hydrogen atom transfer mechanism, whereas those of Q are extensively non-classical and 
involve hydrogen atom tunneling.  
This difference could be particularly important for methane oxidation, as methane is 
kinetically stable with a large barrier height for its oxidation. For the reaction with the Q 
intermediate, tunneling across this barrier could lead to progression along the reaction 
coordinate, whereas the reaction with the Hperoxo intermediate may not proceed due to absence of 
tunneling. While this explanation could resolve why sMMO homologs cannot activate methane 
while possessing nearly the same di-iron active site, unfortunately, KIE studies for the sMMO 
methane reaction which would determine if tunnel effects were present have yielded varied 
results. Under single-turnover conditions, KIE values of 23 to 50 have been reported (50, 70), 
which indicates proton tunneling in the transition state. However, under steady-state conditions, 
a KIE of only 1.7 was observed, when comparing Vmax (or kcat) values (70 – 71), which suggests 
an absence of tunneling.  
Further complicating the sMMO reaction mechanism is the fact that, while the rate-
determining step is thought to be the hydrogen atom transfer, multiple studies have revealed that 
there is no correlation between the reaction rate of a given substrate with the Q intermediate and 
its homolytic bond dissociation energy (BDE). For example, the oxidation rates of sMMO for 
methane and ethane are nearly identical despite a BDE difference of ~ 4 kcal/mol. Another 
example would be a comparison between acetonitrile and nitromethane, which have similar 
homolytic and heterolytic BDEs, but display a 62-fold difference in reaction rates at 4 oC (72). 
Reconciliation of the KIE results that indicate the hydrogen abstraction to be rate limiting and 




B.4. Using methanotrophs/MMOs for methanol synthesis   
While methanotrophs and MMOs have been focus of extensive research over the past 
decades, successful attempts to use either the organisms or enzymes for methanol synthesis have 
been sparse. The inability to express either pMMO or sMMO in a heterologous host severely 
limits their utilization in industrially relevant organisms as well as the ability to use standard 
molecular biology methods to engineer desired protein properties. In addition, the multi-
component nature of MMOs is also a hindrance to evolving more active or more stable variants. 
One successful strategy for methanol biosynthesis using methanotrophs is to inhibit the 
downstream enzyme in methanol metabolism, methanol dehydrogenase (MDH). Using NaCl as a 
MDH inhibitor, 7.7 mM of methanol were accumulated in M. t. OB3b cultures after 20 hours 
(73). Optimization of the growth conditions as well as the addition of ethylene diamine tetra-
acetic acid to further inhibit MDH resulted in 13.2 mM methanol accumulation after 12 h batch 
fermentations with an overall activity of 0.036 U/mg cell mass (1 U = 1 mol methanol/min). 
While this strategy is successful in producing methanol, significant yield improvements and 
reduction of the product loss to the natural methanol metabolism of the methanotroph host are 
hard to envision.   
Studies of the sMMO mechanism as well as its crystal structure have also inspired 
researchers to make biomimetic catalysts replicating the same carboxylate bridged di-iron core as 
sMMO stabilized with a variety of ligands (19, 74). While advances in ligand design have led to 
catalysts which can reach the equivalent Hperoxo and Q intermediate states in the sMMO catalytic 
cycle, the obtained reactivity with alkane substrates has been modest, with no reported methane 
activity (19, 74). A key obstacle in reaching methane oxidation activity for these biomimetics 
could be an intrinsic inaccuracy in the structural model they are attempting to emulate. As all 
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available crystal structures of MMOH have been solved in the absence of MMOB, which 
modulates the MMOH tertiary structure directly affecting both substrate access and the first 
coordination sphere of the diiron center. It is therefore questionable if the observed active site 
configurations reflect that of the active configuration during methane oxidation.  
B.5. AlkB and non-heme di-iron alkane monooxygenases 
Expanding the search for potential methane biocatalysts beyond MMOs, two other class 
of enzymes, non-heme di-iron alkane monooxygenases and cytochrome P450s, are also able to 
activate oxygen and perform O-atom insertion into inert alkane C-H bonds. The family of non-
heme di-iron alkane hydroxylases has been identified in bacteria and fungi utilizing C5 – C16 n-
alkanes as their sole carbon source (75). Exemplified by the most studied alkane hydroxylase 
isolated from Pseudomonas putida GPo1, the non-heme di-iron alkane hydroxylase is a three-
component system consisting of (1) a soluble NADH-rubredoxin reductase (AlkT) (76), (2) a 
soluble rubredoxin (AlkG) (77), and (3) the integral membrane oxygenase (AlkB) (78 – 79). 
Although AlkB can be functionally expressed in Escherichia coli as lipoprotein vesicles, 
purification and maintenance of activity in the purified state is difficult, which has limited its 
mechanistic and structural analysis (80). 
Through alanine scanning mutagenesis, an eight-histidine motif has been shown to be 
necessary for AlkB function and presumably is responsible for coordination the di-iron core (81). 
This motif represents a class of di-iron centers that is shared with desaturases, epoxidases, 
decarbonylases, and methyl oxidases, and differs from the carboxylate bridged di-iron center of 
sMMO (81). However, Mossbauer studies of the AlkB metal center revealed similar features as 
sMMO, with characteristics of an antiferromagnetically coupled pair of Fe (III) ions in its resting 
state (82). The di-iron cluster also becomes high-spin diferrous following reduction and can be 
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quantitatively oxidized back to its resting state by enzymatic turnover in the presence of substrate 
and oxygen (82). Further evidence for the similarities between the AlkB and sMMO mechanisms 
has been provided through studies with the use of norcarane as a chemical probe (83). From 
these studies, the AlkB reaction has been shown to be consistent with an oxygen-rebound 
mechanism via a substrate-centered radical, analogous to the proposed P450 and sMMO 
mechanisms, exhibiting limited rearranged products (83). 
The ability to functionally express AlkB heterologously in E. coli certainly makes it a 
potentially better industrial biocatalyst compared to MMOs and also more amenable to enzyme 
engineering. However, the integral membrane nature of AlkB limits the enzyme’s expression to 
the available membrane surface area. In addition, the lack of a crystal structure and knowledge of 
both the second coordination sphere of the diiron center and the component interactions are 
significant hindrances to directed evolution efforts to shift the AlkB substrate range from C5-C16 
alkanes to methane.   
B.6. Cytochome P450s 
Cytochrome P450s, which utilize a thiolate-ligated heme (iron protoporphyrin IX) 
prosthetic group in their active sites (84), represent an entirely different solution to diiron centers 
for catalytic oxygen insertion into C-H bonds. Unlike MMOs and non-heme diiron alkane 
hydroxylases, which are only found in methanotrophs and alkanotrophs, the superfamily of 
cytochrome P450s is one of the most prevalent enzyme families found across all three domains 
of life. To date, over 10,000 P450 enzymes have been identified (data source: 
http://drnelson.utmem.edu/CytochromeP450.html). P450s are involved in the metabolism of 
xenobiotics and the biosynthesis of signaling molecules. In the first role, P450s serve as a 
protective mechanism for the degradation of exogenous compounds by introducing polar 
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functional groups to facilitate further metabolism or excretion. This defense mechanism is 
particularly prominent in plants, which require P450s to break down herbicides due to their 
immobile nature (85 – 86). This is exemplified by the presence of over 400 P450 genes in rice 
(87). In their other role, P450s are responsible for synthesis of a variety of steroid hormones and 
the conversion of polyunsaturated fatty acids to biologically active molecules implicated in 
development and homeostasis.  
The defining reaction P450s is the reductive activation of molecular oxygen as it is one of 
the few oxygenases possessing the requisite “FeIV=O.+” state for alkane C-H bond activation. In 
this reaction, one oxygen atom is inserted into the substrate while the other is reduced to water. 
The overall equation for the reaction is RH + NAD(P)H + O2 + H+  ROH +  NAD(P)+ + H2O, 
where RH is the substrate. In addition to this canonical reactivity, due to the existence of 
multiple oxidants in the P450 catalytic cycle, P450s can also catalyze epoxidation, dealkylation, 
sulfoxidations, desaturation, carbon-carbon bond scission, and carbon-carbon bond formation 
among other known reactivities (88 – 89). 
Most P450s are membrane bound just as MMOs and alkane hydroxylases and thus are 
relatively difficult to manipulate. Fortunately, many bacterial P450s are soluble, monomeric 
proteins, and as a result, they have been the focus of early research. In particular, the prototypical 
enzymes CYP101 (P450cam) from Pseudomonas putida (90 – 91) and CYP102A1 (BM3), a 
natural fusion enzyme from Bacillus megaterium in which the flavoproteins required for electron 
transfer and the hemeprotein are on a single polypeptide chain (92), provided much of the 
structural and mechanistic information of P450s. Recent interest in developing industrially useful 
P450 catalysts has also focused on enzymes from thermophilic organisms, including CYP119 
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(93), CYP174A1 (94), and CYP231A2 (95) as well as BM3 for its unique self-sufficiency and 
high catalytic rates (96 – 100). 
B.7. P450 structure 
The overall P450 fold (Figure 1.3 (a)) is retained across the enzyme superfamily even 
though members can share less than 20% sequence identity (101). The core four-helix bundle 
composed of three parallel helices (D, L, and I) and the antiparallel E helix are conserved in all 
P450s (102). The prosthetic heme group is ligated to the absolutely conserved cysteine located 
on a loop containing a highly conserved FxxFx(H/R)xCxG binding motif. This thiolate ligation 
gives rise to the 450 nm Soret absorbance maximum for the ferrous-CO complex for which 
P450s were named (103). The other common feature among P450s is a kink at the center of the I 
helix, which contains the amino acid sequence (A/G)Gx(E/D)T that has been implicated in 
oxygen binding and protonation (104 – 105). 
Although the P450 fold is highly conserved, there is sufficient structural diversity to 
accommodate the binding of significantly different substrates ranging from ethanol in CYP2E1 
(106) to large peptide antibiotics in CYP165C1 (107). In addition, since as few as one mutation 
can alter enzyme reactivity and selectivity, P450 family members (sharing at least 60% sequence 
identity) can have very different reactivities (108). P450 substrate binding occurs in an induced-
fit mechanism accompanied with large (~ 10 Å) shifts in the flexible protein regions (109). As 
the substrate is embedded in the protein core, it interacts with various protein regions, which 
results in a large set of substrate recognition sites (SRS). Six SRSs have been found to be 
common to P450s (110): the B’ helix region (SRS1), parts of the F and G helices (SRS2 and 




B.8. P450 catalytic mechanism 
The P450 hydroxylation mechanism is well understood and can be described as depicted 
in Figure 1.3 (b). The P450 catalytic cycle is initiated by substrate binding, which displaces the 
distal water ligand of the resting low-spin (LS) state of the Fe (III) heme (1) resulting in a high-
spin (HS) substrate bound complex (2). The HS Fe (III) has a more positive reduction potential, 
which triggers electron transfer from the P450 reductase producing a ferrous intermediate (3) 
(111). Oxygen readily binds to the ferrous iron center leading to the formation of an oxy-P450 
complex (4), which is the last stable intermediate in this cycle. A second electron transfer, 
usually the rate-limiting step of the catalytic cycle, results in a ferric hydroperoxo anion (5), 
which after protonation yields a ferric hydroperoxo complex (6). A second protonation at the 
distal oxygen followed by heterolytic cleavage of the O-O bond leads to the release of water and 
the formation of the oxo-ferryl porphyrin radical intermediate referred to as “Compound I” 
(CMP I) (7). CMP I then transfers an oxygen atom to the substrate, following a hydrogen 
abstraction-radical rebound mechanism (112) generating the alcohol product and returning to the 
Fe (III) resting state. The intermediates of this catalytic cycle have common features with 




Figure 1.3: Cytochrome P450 structure and catalytic cycle; (a) the structure of the hydroxylase domain of 
CYP102A1 (BM3) with the heme shown in red and the substrate N-palmitoyl glycine substrate shown in 
green (pdb: 1JPZ); (b) the P450 catalytic cycle (see text for details)  
In addition to having multiple distinct intermediates, many of which are also viable 
electrophilic and nucleophilic oxidants (113), the P450 catalytic cycle contains three branch 
points (114). These three abortive reactions are (i) autooxidation of the oxy-ferrous intermediate 
(4) with the release of a superoxide anion and returning the enzyme to its resting state (2), (ii) a 
peroxide shunt, where the coordinated hydroperoxide anion (6) dissociates, completing an 
unproductive two-electron reduction of oxygen, and (iii) oxidase uncoupling, where the CMP I 
(7) is oxidized to water instead of product formation, which results in a four-electron reduction 
of oxygen with the formation of two water molecules. These processes are generally referred to 
as uncoupling, which often occurs in reaction with non-natural substrates that are bound 
insufficienly to properly regulate solvent/proton access to the active site (89 – 90). These 
pathways are also prominent in eukaryotic P450s involved in host defense responses to 
xenobiotics through reactive oxygen species generation.   
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The electrons for the reduction step of the P450 catalytic cycle are provided by either (a) 
cytochrome P450 reductase (CPR), a soluble flavoprotein with FAD and FMN prosthetic groups, 
or (b) an iron-sulfur protein that shuttles electrons from a flavoprotein with a single FMN 
prosthetic group, or (c) a P450 reductase-like domain fused to the P450 heme domain. In each 
case, the electron donor uncouples the two electrons provided by NAD(P)H and transfers them 
singly to the P450 enzyme. Since the final reducing agent for the catalytic cycle is NAD(P)H, 
which has a midpoint potential of -320 mV (115), the resting state of the heme iron with a 
midpoint potential of ca. -300 mV (116 – 117) is reduced slowly in the absence of substrate. The 
substrate binding event triggers a change in the spin state of the heme iron from LS to HS, which 
induces a positive shift of 100 to 300 mV in the heme reduction potential allowing for rapid 
electron transfer (118). This mechanism clearly acts as a safeguard against the unproductive 
consumption of NAD(P)H and the formation of superoxide and peroxides. This substrate-
induced initiation of electron transfer represents a specific P450 regulatory mechanism and is a 
clear departure from the initiation of the MMO catalytic cycle through binding of MMOB. 
The P450 proton relay mechanism composed of several water molecules stabilized in the 
P450 active site as well as an acid-alcohol pair of amino acids (CYP101:Thr252, Glu366 
CYP102: T268, Glu409) is equally important to P450 catalysis. This relay along with the 
electron transfer mechanism regulates the production of reactive intermediates and controls the 
flux of species into the branching points between productive and nonproductive pathways (119). 
For example, mutation of the conserved threonine in P450cam to a hydrophobic residue resulted 
in near normal rates of cofactor oxidation, but was accompanied only by the release of hydrogen 
peroxide as the mutant could not effectively cleave the O-O bond without proper protonation 
(120). Coupling of product formation with cofactor consumption was restored by mutating this 
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position to amino acids capable of hydrogen-bonding interactions. The function of this proton 
delivery network is also dependent on substrate binding. For non-natural, poorly fitting 
substrates, their binding is insufficient to expel excess water from the active site, and protonation 
of the hydroperoxide anion (6) can occur at the proximal position, resulting in peroxide release. 
In fact, the uncoupling of proton and electron transfer does not even require a poorly fitting 
substrate; simply blocking the site of hydroxylation with fluoro-groups is sufficient to result in 
normal cofactor consumption with only water or peroxide production (121). 
B.9. P450 substrate binding and substrate specificity   
As mentioned previously, P450 substrate binding occurs by an “induced fit” model as 
proposed by Koshland (122) in which the enzyme accommodates different substrates in its active 
site by virtue of having a high level of flexibility to undergo appropriate conformational changes. 
Comparison of the X-ray structures of cytochrome P450s crystallized in substrate-free and 
substrate-bound forms (109) shows large structural rearrangements induced by substrate binding, 
which suggests that the SRSs are quite flexible and can provide a variety of substrates access to 
the heme. The absence of charged and hydrogen-bonding groups in the typical P450 substrate, as 
well as in the active sites of most P450 enzymes, requires such binding mechanisms as an 
alternative means to stabilize the substrate-enzyme complex. In many cases, different substrate 
analogues bind tightly to P450 enzymes simply due to their poor solubility in water rather than 
the presence of specific interactions with active site residues (123). 
Given this general mode of substrate binding, it is unsurprising to find that the P450 
specificity for substrate hydroxylation can be readily determined by three factors: (a) the affinity 
of the substrate for the P450 active site, which is largely determined by the substrate 
lipophilicity, (b) the intrinsic reactivity of the individual C-H bond in the substrate as determined 
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by the C-H bond strength, and (c) steric constraints imposed by the active site geometry. While 
the compatibility of a substrate within a P450 active site and steric constraints of binding modes 
are case specific, lipophilicity has been shown to be directly correlating to KM or Kd for sets of 
similarity structured compounds (124 – 125). The general preference of P450 oxidation occurs 
with the following order of C-H bonds: tertiary>secondary>primary, which was determined 
using several small molecular probes that minimized the effect of the P450 active site structure 
in controlling the site of oxidation (126). This preference is reinforced by DFT calculations for 
the activation barriers for hydrogen abstraction, which predict a similar reactivity preference: 
benzylic or allylic>tertiary >secondary>primary (127 – 128).  
B.10. P450 reactions using terminal oxidants  
In addition to the normal P450 “turnover” conditions utilizing oxygen and NAD(P)H,  the 
P450 catalytic cycle can also be accessed through the branching/shunt pathways using a variety 
of terminal oxidants including hydrogen peroxide, alkyl peroxides, acyl peroxides, and 
iodosobenzene.  Early studies with alkylperoxides provided evidence for the formation of a ferric 
alkylperoxo complex (FeIII-OOR) (129) as well as a compound II-like ferryl (FeIV=O) species, 
which is one oxidation equivalent higher than the resting ferric state (130 – 131) but little 
evidence for the formation of a CMP I-like ferryl porphyrin radical. However, recent works have 
confirmed the formation of both a compound-II – like and a compound-I – like species as 
transient intermediates (132 – 133). 
The obvious advantage between reactions utilizing O2/NAD(P)H vs. peroxide is oxygen 
binding to a Fe2+ heme center vs. peroxide binding to Fe3+ heme center. The difference in the 
redox state between oxygen and peroxide eliminates the need for two reduction steps in the 
peroxide-driven pathway. However, the efficiency of this mode of reaction is generally poor due 
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to the intrinsically destructive nature of peroxides as well as the lack of acid-base catalytic 
residues in the P450 structure, with the exception of P450s which naturally utilize peroxides as 
their oxidant (134). In natural peroxidases, such as chloroperoxidase, the formation of the ferryl-
oxo intermediate involves proton transfer from the proximal to the distal oxygen atom of the 
bound hydrogen peroxide, which is aided by a conserved His-Arg or His-Asp amino acid pair 
(135). P450s have highly hydrophobic active sites that lack these acid-base catalytic residues in 
close proximity to the oxygen binding pockets.  
The peroxide-driven P450 reactions proceed through the formation of CMP 0, which 
after protonation and heterolytic O-O cleavage generates CMP I. In contrast, P450 reactions 
driven with iodosobenzene (PhIO) produce only CMP I as an oxidant without any potential 
involvement of peroxo-iron species, since PhIO is a single oxygen donor (136). The initial 
finding of solvent oxygen incorporation through experiments with 18O-labeled water in reactions 
supported by PhIO led researchers to question if the oxidation proceeded via a ferryl 
intermediate (137 – 138). However, subsequent work has shown that the oxygen of PhIO readily 
exchanges with the medium through a porphyrin-oxidant complex, [(Porp)FeIII-OIPh]+ (139). 
Nevertheless, whether PhIO-meditated reaction is a faithful mimic of the P450 reaction remains 
contentious due to differences observed in regio- and chemoselectivities (136) and kinetic 
isotope effects (140) between reactions supported by PhIO and NAD(P)H/O2 (141). 
B.11. H-abstraction and mechanistic comparisons with MMOs 
Similarities between the mechanisms of P450s, di-iron non-heme alkane hydroxylases, 
and sMMO have long been recognized (142 – 144), as the active oxidants of these enzymes, a -
oxo-diiron (IV) intermediate called compound Q for sMMO and an oxo-iron (IV) porphyrin -
cation-radical called CMP I for P450s, share the same net oxidation state. This is unsurprising 
25 
 
considering the energy requirements for breaking the inert alkane C-H bonds. In the consensus 
radical rebound mechanism for the O-atom insertion step, the ferryl oxygen initially abstracts a 
hydrogen from the substrate, leaving a carbon radical, which in turn recombines with the oxo 
radical coordinated to the iron atom (145). This mechanism is supported by observed large 
intramolecular isotope effects as well as the partial loss of stereo-chemistry at the carbon center 
for reactions with chemical probes (146 – 148). 
Complexities in the radical rebound mechanisms arising from the mixed-spin nature of 
the transition state during the H-atom abstraction by the ferryl-oxo intermediate have been 
explained by DFT calculations (149). For the P450 mechanism, the reaction can proceed through 
a the low (doublet)-spin state, where the unpaired electron residing on the substrate after H-atom 
abstraction has an opposite spin to the electron in the iron-hydroxyl orbital. In contrast, the 
oxidant can also be in a high (quartet)-spin state, such that the substrate-based radical has the 
same spin as the P450 iron-hydroxyl species. As the collapse of the low-spin pathway lacks the 
spin-inversion barrier of the high-spin state, it proceeds without a barrier, and H-atom abstraction 
and the radical rebound can be considered to proceed in a concerted fashion. This mixed-spin 
transition state model with two distinct pathways for the H-atom abstraction-rebound mechanism 
has been able to reconcile seemingly contradictory radical lifetime experiments as well as 
differences in reaction KIEs (149). In addition to having a LS triplet state and a HS quintet state, 
the reaction with diiron metal centers (i.e., sMMO, AlkB) is further complicated by two possible 
angles of approach of the substrate C-H bond. In contrast to P450s, where the presence of the 
porphyrin prevents side-on or equatorial approaches, both end-on and side-on approaches are 
possible with di-iron ferryl-oxo species. As a consequence, both linear and bent Fe-O-H 
geometries are possible for the transition state (so that electrons can be transferred to both  and 
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 orbitals), which results in four distinct reaction pathways with intermediates: 3TS, 3TS, 5TS 
and 5TS. 
Regardless of the spin-state of the reaction pathway, the transition state for the H-
abstraction step presents the largest barrier in the reactions involving CMP I, or Q (58, 127). For 
methane, this barrier height is 26.7 kcal/mol for P450 CMP I, which is significantly higher than 
the ca.19 kcal/mol barrier for known P450 substrate camphor. The barrier heights for other small 
gaseous alkanes, ethane (21.6 – 21.8 kcal/mol) and propane (terminal: 21.6 kcal/mol, 
subterminal: 19 kcal/mol) are also much lower than methane (127, 149 – 151). As a comparison, 
this transition state barrier for H-abstraction from a methane C-H bond has been calculated to be 
as low as 13.8 kcal/mol  (60) and as high as 23.2 kcal/mol (152) for sMMO. While these 
calculations show the barrier heights for P450 hydroxylation of known substrates and sMMO 
hydroxylation of methane are comparable, it is difficult to draw meaningful conclusions for the 
potential of P450s to oxidize methane.  
C. Cytochrome P450 Enzyme Engineering 
Due to their involvement in drug metabolism and their ability for regio- and 
stereoselective hydroxylation on a variety of substrates, numerous potential applications have 
been suggested for P450s (153 – 155). While, undoubtedly many industrial whole-organism 
biosyntheses involve P450s in their pathway (156), direct/explicit use of P450s for 
biotechnology applications has been scarce. The most publicized example of incorporation of 
P450s into practical products is the generation of transgenic “blue” carnations from petunias 
(157) and for enhanced production of  “blue” roses (158). Examples for the use of P450s in the 
synthesis of high value pharmatheutical therapeutics include the production of hydrocortisone 
(159), cortisone (160), Pravastatin (161), and Artemisinin (162). 
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The limiting factors toward broader utilization of wild-type P450s as biocatalysts include 
poor expression, being membrane-bound, and lacking known redox partner proteins. For these 
reasons, protein engineering efforts have been focused on expanding the substrate range of well-
expressed bacterial P450s with known redox partners to accept desired target compounds. Much 
of this work has been focused on P450cam and BM3 (163). P450cam is a type I P450 requiring a 
putidaredoxin containing a [2Fe-2S] cluster and an FAD-containing putidaredoxin reductase for 
the highly stereoselective hydroxylation of its physiological substrate (1R)-camphor to (1R)-5-
exo-hydroxycamphor. BM3, as mentioned previously, is a type II P450 with its FAD and FMN 
containing reductase fused to its heme domain as a single polypeptide chain  (92).  BM3’s native 
function is believed to be the detoxification of polyunsaturated fatty acids (164 – 165). Its unique 
domain architecture has been credited for its high hydroxylation and epoxidation rates (~ 17,000 
min-1 (166)) on long-chain fatty acid substrates (92, 166). In addition, these two proteins were 
also the first P450s of which crystal structures in the presence (167 – 168) and absence of 
substrates (169 – 173) were solved, which has also aided protein engineering efforts.  
C.1. P450cam 
Protein engineering of P450cam has been successful in switching its substrate specificity 
(174 – 179) through the introduction of point mutations to the active site. This strategy has been 
particularly successful because the enzyme backbone remains relatively fixed during catalysis 
(119). With just one to three active site mutations, P450cam variants have been generated to 
hydroxylate (+)-R-pinene, a structural relative to (+)-camphor (174), aromatic compounds such 
as ethylbenzene (179), diphenylmethane, phenylcyclohexane, naphthalene, pyrenes (175, 178, 
180 – 182), phenanthrene, fluoranthene, (183), polychlorinated benzenes (184), and indole to 
form indigo (185). Although improving the promiscuous activity of P450cam for non-natural 
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substrates has proved to be relatively easy, i.e., requiring just a few mutations, the resulting 
variants generally exhibited poor coupling between cofactor consumption and product formation, 
typically ranging from 5% to 32%. 
Far fewer examples exist for P450cam variants with nearly wild-type coupling efficiency 
for non-native substrates, as these variants require multiple rounds of mutagenesis. For example, 
simply introducing a Y96F mutation will increase P450cam’s ability to epoxidize styrene 25-fold, 
with 32% coupling compared to only 7% coupling for the wild-type (186). Placing an additional 
V247L mutation in the active site increases the coupling efficiency to 60% (175).  The best 
example for the ability of P450cam to be engineered to accept new substrates with high coupling 
efficiency was provided by Xu et al. (187) with the engineering of P450cam to hydroxylate short-
chain alkanes. Over the course of multiple studies (176, 187 – 188), the authors gradually 
decreased the active site volume by incrementally introducing bulky, hydrophobic residues.  A 
P450cam quadruple mutant, F87W/Y96F/T101L/V247L, was able to oxidize butane at 750 min-1 
with 95% coupling compared to 4% for wild type (176). To achieve 85% coupling of product 
formation with NADH consumption for propane oxidation, five additional mutations, 
L244M/L294M/T185M/L1358P/G248A, were required (187). This variant with nine active site 
mutations was also able to oxidize ethane at 78.2 min-1 with 10.5 % coupling (187). 
Finally, multiple attempts have been made to fuse the electron transfer components of 
P450cam to its hydroxylase domain to increase enzyme activity (189 – 190). In addition, fusion of 
the P450cam hydroxylase domain with reductases from naturally occurring self-sufficient P450s 
such as P450RhF isolated from Rhodococcus sp. NCIMPB 9784 (190) has also resulted in self-
sufficient enzymes. However, while these constructs are often superior to free enzymes at a 1:1:1 
ratio (hydroxylase: putidaredoxin reductase: putidaredoxin) in rates of electron transfer and 
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product formation, they fall short of the optimal free enzyme activity obtained at higher ratios of 
electron transfer components, i.e., 1: > 4 : > 12 (121).  
C.2. CYP102A1 (P450BM3) 
BM3 is one of the most studied and frequently engineered P450s, as it has the fastest 
known catalytic rate for a P450 and is a natural fusion protein with a type II reductase and its 
hydroxylase found on a single polypeptide (134). Its high rate of catalysis has been shown to be 
the result of BM3 domain architecture: when the heme and reductase domains are expressed 
independently and mixed together, the resulting activity is severely diminished (191). In addition 
to the self-sufficiency, BM3 can also be easily manipulated genetically and expressed at levels 
up to 1 g/L in laboratory strains of Escherichia coli (192). In contrast to P450cam, the BM3 
protein backbone undergoes large structural changes (> 10 Å) during catalysis as revealed by 
differences between the substrate-free crystal structure (168) and structures of BM3 complexed 
with known substrates (168 – 169). The large active site volume reflects the poor regioselectivity 
with which BM3 hydroxylates its preferred C12-C20 fatty acids substrates (193). All these factors 
make BM3 well suited for directed evolution experiments and potential use as a biocatalyst. 
Much like P450cam, BM3 has been engineered to accept a variety of substrates. Most 
rational engineering efforts of BM3 targeted hydrophobic residues lining the substrate-binding 
channel as well as active site residues immediate to the heme center. By mutating the two 
residues (R47, Y51) located at the opening of the substrate pocket that stabilizes the carboxylic 
acid moiety of the preferred fatty acid substrate, BM3 variants were isolated with increased 
activity for oxidation of alkyltrimethyl ammonium compounds (194), hydroxylation of shorter 
chain fatty acids (195), and epoxidation of the anti-malarial drug-precursor amorphadiene (196). 
Introducing additional active site mutations to these variants yielded a variant (R47L/Y51F 
30 
 
/A264G) with activity toward fluoranthrene (177) and alkoxyresorufins (197) and a variant 
(R47L/Y51F/F87A/A264G) with activity toward pyrene (177). Screening with a simple NADPH 
consumption assay to monitor cofactor consumption in the presence of a substrate, directed 
evolution of BM3 yielded a highly promiscuous variant F87V/L188Q/A74G with enhanced 
activity for a variety of substrates such as indole, alkanes, arene, and polycyclic, aromatic 
hydrocarbons (198 – 200). Similar engineering efforts generated variants with activity for -
ionone, a carotenoid intermediate (201), and valencene for (+)-nootkatone production (202). 
From these rational engineering efforts, general structural function relationships have 
emerged, which have aided further engineering efforts. For example, active site residue F87, 
which is positioned directly between the bound substrate and the heme center, has been shown to 
affect both the substrate specificity and regioselectivity of fatty acid hydroxylation (203). 
Introduction of the F87V mutation converted BM3 into a regio- and stereoselective arachidonic 
acid epoxygenase (203). This mutation along with F87A also increases the oxidation activity for 
a variety of aromatic compounds (204). This improved affinity for aromatic compounds is 
consistent with the removal of the F87 phenyl side chain directly adjacent to the heme center. 
Building on these studies, Pleiss and coworkers constructed a focused library targeting residues 
F87 and A328, allowing for a restricted set of non-polar amino acids (A,V, F, L, I). From this 
library, variants with activity for the oxidation of linear terpenes, cyclic monoterpenes, cyclic 
sesquiterpenes (99), cyclo-octane, cyclodecane, and cyclododecane (205) were found. 
Work in our group has been focused on evolving BM3 to accept small alkanes as 
substrates with the ultimate target of methane hydroxylation. Starting from wild-type BM3, we 
enhanced its promiscuous activity for octane hydroxylation by applying a colorimetric screen for 
the hydroxylation of p-nitrophenoxy octane to evaluate enzyme libraries generated by random 
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mutagenesis (206). After multiple rounds of random mutagenesis, variant 139-3 was obtained, 
supporting 1,000 turnover number (TON) on octane, a 6.7-fold increase compared to wild type 
and measurable activity for propane oxidation (500 TON) (207). Selection pressure was then 
shifted toward propane hydroxylation through the use of a colorimetric screen based on dimethyl 
ether demethylation (DME) (208). Subsequent rounds of mutagenesis yielded variant 35E11, 
with 17 total amino acid mutations, supporting 6,000 propane TON and 250 ethane TON (209). 
In addition to small alkane hydroxylation activity, other BM3 variants generated in the 35E11 
lineage were found with (1) regioselectivity for terminal hydroxylation of octane (210), (2) 
stereoselective secondary hydroxylation of linear alkanes (208), and (3) stereoselective 
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New functions have been engineered in a variety of pre-existing enzymes using directed 
evolution, however, examples in which the engineered variants exhibit comparable catalytic 
properties with the non-natural substrate as the wildtype enzyme with its preferred substrates are 
rare. Here, we describe the in vitro evolution of a proficient P450 propane monooxygenase, 
P450PMO, starting from a fatty acid hydroxylase CYP102A1 (BM3). Applying only positive 
selection pressure in combination with a domain engineering mutagenesis strategy, which 
targeted the heme and reductase domains independently and in combination, re-specialization of 
BM3 for the non-natural substrate propane was achieved after several rounds of directed 
evolution. P450PMO supports up to 45,800 propane turnovers with 98.2% coupling of substrate 
oxidation and cofactor consumption, rivaling those of natural P450s with their preferred 
substrates. In addition, we were able to demonstrate in vivo propane hydroxylation using these 
BM3 variants in resting Escherichia coli cells reaching activities up to 176 U g-1 cdw, which 






Cytochrome P450 enzymes (P450s) are exceptional oxygenating catalysts (1 – 2) with 
enormous potential in drug discovery, chemical synthesis, bioremediation, and biotechnology (3 
– 4). Compared to their natural counterparts, however, engineered P450s often exhibit poor 
catalytic and cofactor coupling efficiencies (3). Obtaining native-like catalytic proficiencies is a 
mandatory first step towards utilizing the power of these versatile oxygenases in chemical 
synthesis. 
Cytochrome P450 BM3 (BM3) isolated from B. megaterium catalyzes the subterminal 
hydroxylation of long-chain (C12–C20) fatty acids (5). Its high activity and catalytic self-
sufficiency (heme and diflavin reductase domains are fused in a single polypeptide chain) (4-6) 
makes BM3 an excellent platform for biocatalysis. However, despite numerous reports of the 
heme domain being engineered to accept nonnative substrates, including short-chain fatty acids, 
aromatic compounds, alkanes, and alkenes (7 – 15), reports of preparative-scale applications of 
BM3 remain scarce (16 – 19).  
The native BM3 function is finely regulated through conformational rearrangements in 
the heme and reductase domains and possibly also through hinged domain motions (5, 20 – 21). 
Hydroxylation of fatty acids occurs almost fully coupled to cofactor (NADPH) utilization, 93–
96% depending on the substrate (22 – 23). In the presence of nonnative substrates or variants 
containing amino acid substitutions, the mechanisms controlling efficient catalysis in P450s are 
disrupted (24 – 25), leading to the formation of reactive oxygen species and rapid enzyme 
inactivation (5). High coupling efficiencies on substrates whose physicochemical properties are 
substantially different from the native substrates have not been achieved, and typical coupling 
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efficiencies range from less than 1% to 40% (8, 11, 14). Strategies for addressing this “coupling 
problem” are needed in order to take engineered P450s to larger-scale applications.  
Selective hydroxylation of small alkanes is a long-standing problem, for which no 
practical catalysts are available (26 – 28). In an effort to produce BM3-based biocatalysts for 
selective hydroxylation of small alkanes, we previously engineered an enzyme variant 35E11, 
which accepts propane and ethane as substrates (29). However, despite greater than 5,000 total 
turnover supported in vitro, the utility of this catalyst remained limited because of its poor in vivo 
performance (see below), which was mostly due to low coupling efficiencies between product 
formation to cofactor consumption (17.4% for propane and 0.01% for ethane oxidation). The 
goal of our work was to engineer a BM3 variant with native-like activity and coupling efficiency 
toward a structurally challenging, non-native substrate, propane, and evaluate the impact of these 












C. Results and Discussion 
C.1. Complete mutagenesis of BM3 through a domain engineering strategy 
We used a domain-based protein-engineering strategy, in which the heme, flavin 
mononucleotide (FMN), and flavin adenine dinucleotide (FAD) domains of variant 35E11 were 
evolved separately but evaluated in the context of the holoenzymes. As a final step, beneficial 
mutations identified in each sub-domain were recombined (Figure 2.1). Most previous 
engineering efforts have focused mutagenesis to the heme (hydoxylase) domain of BM3(7, 9, 11 
– 12, 14), although mutations in the reductase and linker regions have been shown to also affect 
catalytic properties, specifically coupling of co-factor consumption with substrate hydroxylation 
(29 – 31). However, no systematic engineering efforts had been undertaken to engineer the 
complete 1,048 amino acid holoenzyme.  
 
Figure 2.1: Outline of the domain engineering strategy used to improve cytochrome P450 BM3 
heme and reductase domain (HL = heme domain library, RL = reductase domain libraries) 
Holoenzyme libraries outlined in Figure 2.1 were created using random, saturation, and 
site-directed mutagenesis and screened for activity on a propane surrogate, dimethyl ether (14). 
Variants with improved dimethyl ether demethylation activity were confirmed by a rescreen, 
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purified, and characterized for propane hydroxylation activity using sealed head-space vials in 
the presence of a cofactor regeneration system. As a cumulative measure of both catalytic and 
coupling efficiency, improvement in total turnover number (TON), i.e., moles of propanol 
produced per mole of enzyme, was used as the sole selection criterion.  
Measurement of the half-denaturation temperature (T50), the temperature at which the 
enzyme retains 50% of its activity after a 15 minute incubation, of variant 35E11 heme domain 
demonstrated a considerable reduction in its thermostability as a consequence of the 15 
accumulated mutations (T50=43.4 oC vs. 55.0 oC for wild-type BM3). We therefore subjected 
variant 35E11 to an initial thermostabilization step (HL1), in which known stabilizing mutations 
from a thermostablized BM3 peroxygenase (32) were tested singly and in combination in the 
35E11 background (see Table 2.1). Variant ETS8 (35E11-L52I-I366V), which showed the best 
combination of increased stability, T50=+5.1 oC, with only a small decrease in propane TON, 
TONpropane=  -1,250, was selected for further directed evolution.  








TON[b] L52 L234 V340 I366 E442
35E11 - - - - - 43.4 n/a n/a 
ETS1 I - - - - 44.5 1.1 -510 
ETS3 - I - - - 43.2 -0.3 -1,450 
ETS4 - - M - - 46.0 2.6 -1,290 
ETS5 - - - V - 47.1 3.7 -850 
ETS6 - - - - K 45.0 1.6 +170 
ETS8 I - - V - 48.5 5.1 -1,250 
ETS9 I - - - K 46.8 3.4 -2,950 
ETS10 - - M - K 44.2 0.8 -3,180 
ETS11 - - - V K 46.6 3.2 -1750 
[a] T50 calculated based on a two-state denaturation model using the percentage of 450 nm CO-binding 
peak of P450 variants remaining after 15-min incubations at varying temperatures 
[b] TON determined as nmol product/nmol enzyme. Propane reactions contained 25 – 100 nM protein, 
potassium phosphate buffer saturated with propane, and an NADPH regeneration system containing 100 
μM NADP+, 2 U/mL isocitrate dehydrogenase, and 10 mM isocitrate. Errors are at most 10%. 
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Using ETS8 as parent, heme-domain random mutagenesis libraries were generated by 
error-prone PCR (HL2). Variant 19A12, ETS8-L188P, was identified from this library with more 
than a twofold increase in propane TON (Table 2.2). Using 19A12 as the parent, a pool of active-
site libraries (HL3) were constructed in which 17 positions along the substrate channel and near 
the active site (74, 75, 82, 87, 88, 181, 184, 188, 260, 264, 265, 268, 328, 401, 437, and 438) 
were subjected individually to saturation mutagenesis. From these site-saturation libraries, 
further improvements in propane-hydroxylating activity were achieved in multiple variants, 
including 11-3 (19A12-A74S) which supported 13,200 propane TONs. Recombination of the 
beneficial mutations identified in these active-site variants (HL4, HL5) led to variant 1-3 
(19A12-A74S-V184A) and variant 7-7 (19A12-A74E-S82G), supporting 19,200 and 20,500 
propane TONs, respectively. 
In parallel to the mutagenesis efforts targeting the BM3 heme domain, two libraries were 
constructed in which random mutations were targeted to the FMN and FAD binding domains of 
35E11, RL1 and RL2, respectively. Screening of more than 5,000 members from each library for 
dimethyl ether demethylation led to the identification of eight beneficial mutations (G443D, 
V445M, T480M, T515M, P654Q, T664M, D698G, and E1037G). Of these eight mutations, 
G443D and V445M are actually located in the C-terminus4 sheet of the heme domain, as RL1 
included not only FMN domain but also the last 32 amino acids of the heme domain due to 
library construction. These eight positions were further optimized through saturation 
mutagenesis in a holoenzyme construct having the 11-3 heme domain (RL3, RL4). By swapping 
the heme domains, we aimed to remove mutations whose beneficial effect is solely dependent on 
the presence of the 35E11 heme domain. With the 11-3 heme domain, improved variants were 
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found to contain G443A, V445R, P654K, T664G, D698G, and E1037G mutations and supported 
propane TON between 16,000 and 20,000.  
In the final step, a library containing the beneficial reductase domain mutations was fused 
to the heme domain of variant 7-7 (L9). The most active variant isolated from this library, 
P450PMOR2, supported more than 45,800 turnovers and produced 2- and 1-propanol in a 9:1 
ratio. As we expected, the increase in productivity strongly correlated with the increase in 
coupling efficiency, which in the best variant P450PMOR2, 98.2% reaches levels comparable to 
those measured for wild-type BM3 in the hydroxylation of fatty acids, 88% for myristate, 93% 
for palmitate, and 95% for laurate (22 – 23).  
Table 2.2: In vitro propane oxidation activities of most representative P450 BM3 variants[a] 
Variant Library 





TON Heme  domain 
Reductase 
domain 
35E11 - - - 210 17.4 5,650 
19A12 HL2 L52I, L188P, I366V - 420 44.2 10,550 
11-3 HL3 L52I, A74S, L188P, I366V - 390 55.3 13,200 
1-3 HL4 L52I, A74S, V184A, L188P, I366V - 320 72.1 19,200 
7-7 HL5 L52I, A74E, S82G, L188P, I366V - 150 90.9 20,500 
P450PMOR1 L9 




E1027G 455 94.4 35,600 
P450PMOR2 L9 
L52I, A74E, S82G, 
L188P, I366V, 
G443A 
D698G 370 98.2 45,800 
[a] Mean values from at least three replicates + 10 % error 
[b] Mutations in 35E11 are R47C, V78F, A82S, K94I, P142S, T175I, A184V, F205C, S226R, H236Q, 
E252G, R255S, A290V, A328F, E464G, I710T.  
[c] Over the first 20 s 
[d] Ratio between propanol formation rate and NADPH oxidation rate in propane-saturated buffer 
The sequence of mutational events leading to P450PMO generation reveals a continuous 
rearrangement of substrate channel and active-site residues (Table 2.2). The mutation of L188P 
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resulted in the single largest increase in propane hydroxylation activity, 2.4-fold relative to its 
parent, ETS8. Leu 188 is a helix capping residue located at the C-terminus of the F helix, which 
along with the G-helix forms a lid that undergoes a conformational change during catalysis. In a 
hinged motion, these two helices move from an “open” state in the absence of a substrates to a 
“closed” confirmation when substrate is bound (33). Accurately assessing the effect of this 
mutation, which removes the interstrand hydrogen bond provided by the Leu188 amid NH 
group, is difficult in the absence of an X-ray crystal structure. However, one likely outcome of 
this mutation could result in an enzyme resting state with the F and B’ helix being in closer 
proximity, mimicking the substrate-bound confirmation. In the subsequent rounds of active site 
optimization, two different active site configurations, 19A12-A74S-V184A and 19A12-A74E-
A82G were found to supported nearly the same number of propane TONs. However, the 
coupling of substrate oxidation with cofactor consumption differed significantly between these 
two variants, 72.1% vs. 90.9%. This 18.8% difference in coupling resulted in only a 6.7% 
difference in propane TON, which suggests that the benefit of higher coupling efficiency for 
improving enzyme activity diminishes at higher coupling.  
Interestingly, the activity-enhancing substitutions in the reductase domain are clustered in 
the same region in the FAD domain (T664G, D698G, E1037G) and nearby linker to the FMN 
domain (P654K) (see Figure 2.2). Perturbation of electrostatic charge distribution appears to be a 
prevailing trend, suggesting a more important role of these forces in BM3 function than 
previously proposed (34). In contrast, no beneficial mutations were identified in FMN domain. 
This may reflect its higher sensitivity to mutagenesis, as judged by the significantly lower 
fraction of functional variants in the FMN libraries compared to the FAD libraries. In addition, 
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chemical and thermal denaturation studies have shown that, among the three cofactors, FMN is 
the most weakly bound to the enzyme (35).  
 
Figure 2.2: Map of the activity-enhancing reductase domain mutations on a homology model of 
P450BM3 FAD-binding domain prepared on the basis of the rat cytochrome P450 reductase structure 
(PDB: 1AMO (36)). Structural similarity between the two is supported by a preview of the solved but not 
yet published structure of P450BM3 FAD-binding domain (6). Heme domain and FMN domain are 
represented as in PDB: 1BVY (37). A 30 -residue linker connects the C-terminus of the FMN-binding 
with the N-terminus of the FAD-binding domain (dotted line). 
 
C.2. Whole-cell bioconversion of alkane by BM3 variant with resting cells  
A common strategy to reduce the prohibitive costs of NADPH-driven biotransformations 
is the use of cofactor regeneration systems (16, 38 – 39). For bulk chemical transformations such 
as alkane hydroxylation, these in vitro approaches are not economically viable (40). The 
propane-hydroxylating P450 variants were therefore evaluated in whole-cell biotransformations 
using resting E. coli cells. The expression levels of these variants in minimal medium were 
initially less than 0.5% of total cell mass. After optimization of growth and expression condition, 
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we were able to achieve expression of soluble P450s at 6–11% of total cell mass. The whole-cell 
biotransformations were conducted in 100 -mL fermenters using cell suspensions in nitrogen-
free M9 minimal medium supplemented with glucose. The cell culture was continuously aerated 
with a 1:1 propane/air mixture to supply the substrate and oxidant. Under these conditions, cell 
densities of 0.5 – 0.9 g cdw L-1 were used to avoid oxygen-transfer limitations. Activities of 80–
120 U g-1cdw (where 1 U = 1 mol propanol min-1) were measured for P450PMO-R1 and-R2 
using various E. coli strains (Figure 2.3). 
 
Figure 2.3: Whole-cell biotransformations of propane. Initial activities of selected P450 BM3 variants in 
different E. coli strains using air/propane (1:1) feed (pH 7.2, 25oC) measured after 1 h 
 
 The experiment was repeated in a larger fermenter (0.3 L, pH and dissolved oxygen 
control) with a suspension of P450-expressing DH5 cells, as DH5 was previously shown to be 
the most productive strain. The cell cultures were fed with a 1:1 mixture of pure oxygen and 
propane, and propanol formation was monitored for up to 9 h (Figure 2.4(a)). Under these 
conditions, very high activities (up to 176 U g-1 cdw) were obtained (Table 2.3). In comparison, 
the maximal activities of 30 U g-1cdw on n-nonene were reported for the natural AlkB alkane 













g-1 P450 h-1) 0.5 h 3 h 
35E11 air (1:1) 9 2 12 
19A12 air (1:1) 41 9 44 
7-7 air (1:1) 74 n.d. 88 
P450PMOR1 air (1:1) 118 73 119 
P450PMOR2 air (1:1) 104 68 106 
P450PMOR1 O2 (1:1) 176 63 96 
P450PMOR2 O2 (1:1) 119 39 94 
[a] Mean values from two biological replicates +15% error. n.d. = not determined 
[b] At 0.5–0.9 g cdw L-1 cell density 
[c] Calculated from the first hour of biotransformation 
At higher cell densities (ca. 4 g cdw L-1), propanol accumulated to a concentration of 
more than 15 mM over 4 hours (Figure 2.4 (b)). The improved coupling efficiencies resulted in 
considerably extended periods of whole-cell activity, 6 vs. 0.5 h (Figure 2.4 (a – b)) comparing 
P450PMO vs. 35E11. To investigate the possible causes for the decrease in productivity over time, 
we monitored the biocatalyst concentration over the course of the biotransformation (Figure 2.4 
(c)). At the end of the experiment, approximately 52% of the initial P450PMOR2 was still 
correctly folded. Control experiments using P450PMOR2-expressing cells and propanol 
concentrations up to 30 mM showed no product inhibition or over-oxidation, suggesting that host 
related factors, rather than biocatalyst-dependent factors, are limiting. Indeed, 40–60% of the 
initially measured activity could be restored by resuspending cells from the plateau phase (i.e., 
after 4–6 h reaction) in fresh medium. In addition, the rate of biocatalyst inactivation could be 
reduced by varying the relative concentration of oxygen in the gas feed, with more extended 
whole-cell activity periods obtained at a propane/oxygen ratio of 4:1 compared to 1:1 (Table 
2.3). Optimization of this parameter as well as the availability of more robust host strains (40) is 




Figure 2.4: (a) Time course of propane biotransformation using recombinant DH5 cells using 
oxygen/propane (1:1) feed (pH 7.2, 25oC). Product amount is given per gram cell dry weight to facilitate 
comparison among variants. Control: no propane in the gas feed. (b) Concentration of propanol during 
biotransformation of propane with DH5 cells expressing P450PMOR1 () and P450PMOR2 (□) at 
medium cell density (4g cdw L-1). (b) Relative P450 concentration as determined from CO-binding 
difference spectra on cell lysate; OD = optical density 
 
D. Conclusion 
Overall, a domain-based directed evolution strategy has enabled us to engineer a finely-
tuned, multicofactor, multidomain enzyme to exhibit native-like catalytic properties on a 
substrate significantly different from the native substrate. With this approach, we could use 
relatively small and targeted libraries to identify beneficial mutations throughout the enzyme, 
which were recombined to yield the most efficiently engineered P450 reported to date. This 
strategy should prove useful for engineering other enzymes with multiple, interacting functional 
domains. With high activity and coupling efficiency for propane oxidation, P450PMOs could be 
used in whole-cell biohydroxylation of propane at room temperature and pressure with air as 
oxidant. Total activities and product formation rates exceeding those obtained with naturally 
occurring alkane monooxygenases on their native substrates (41 – 45) were achieved in this first 
report of whole-cell bioconversion of propane to propanol in E. coli. These results open the door 
to considering P450-based oxidations of short-chain alkanes, with promise for green conversion 
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To compare the functional richness of mutagenesis libraries generated by error-prone 
PCR, site-saturation mutagenesis, combinatorial active site saturation with a reduced set of 
amino acids and structure-based computational library design, seventeen mutagenesis libraries of 
cytochrome P450 BM3 were designed and constructed. Each library was evaluated for the 
fraction of variants that had acquired activity for demethylation of dimethyl ether and selected 
variants were also characterized for propane and ethane hydroxylation. Among these libraries, 
the ones generated by combinatorial active site saturation with a reduced set of amino acids 
displayed both a higher fraction of functional variants and variants with higher activity than both 
an error-prone PCR library with a similar mutation rate (2.1 mutation/protein) and site-saturation 
mutagenesis libraries targeting the same three residues. The most effective library design for 
generating variants for both dimethyl ether demethylation and small alkane hydroxylation was 
the CRAM algorithm developed and described here. While none of the isolated variants of this 
study achieved the level of specialization for propane hydroxylation previously obtained through 
multiple rounds of mutagenesis and selection, the levels of activity achieved by these variants 
show that jumps in sequence space from a specialized enzyme to generalist variants with desired 





Over the past decades, directed protein evolution has become a versatile tool for both the 
engineering of protein properties to meet industrial demands (1 – 2) and the exploration of 
structure-function relationships of biocatalysts (3 – 4). Using iterative cycles of sequence 
diversification and functional selection, enzyme variants have been reported with a variety of 
improved protein functions such as binding, enantioselectivity, thermostability, and altered 
substrate specificity (5 – 8). Recent advances in computational modeling (9), combined with the 
increased availability of structural and sequence information, have resulted in an expansion in 
the number of mutagenesis techniques and methods employed in directed protein evolution, such 
as SCOPE (10), CASTing (11), ISM (12), ISOR (13), and other structure-based computational 
library designs (14 – 16).  
These semi-rational mutagenesis approaches aim to generate functionally enriched 
libraries by targeting mutations to specific regions of a protein such as an enzyme’s active site or  
a protein-ligand interface determined to be important by structural or sequence analysis (17). 
While the viability of all these methods has been demonstrated by successful examples of their 
implementation, there have been very few attempts at comparing them with more traditional 
mutagenesis techniques such as error-prone PCR (EP-PCR) (18) or site-saturation mutagenesis 
(19). Part of the difficulty in comparing mutagenesis approaches is the inherent stochastic 
element of the directed evolution experiment. Since the outcome of such experiments relies on 
the specific choice of variants selected as parent for the subsequent round of evolution, repeating 
the same directed evolution experiment can lead to different sequence solutions. Therefore, 
comparing only the best variants generated through different mutagenesis techniques provides 
only anecdotal evidence for a method’s efficacy. A more informative comparison of mutagenesis 
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techniques would be to evaluate the range of acquired activities and fraction of functional 
variants generated by each method in a single round of mutagenesis and screening for a defined 
function, using an identical starting point. 
Here, we evaluate four mutagenesis approaches, (1) random mutagenesis by EP-PCR, (2) 
site-saturation mutagenesis (SSM), (3) Combinatorial Active Site saturation Test with a reduced 
set of amino acids (reduced CASTing) (20), and (4) two-structure-based computational library 
design approaches (16), for their ability to generate cytochrome P450 BM3 (BM3) (21) variants 
with activity for demethylation of dimethyl ether (DME) and hydroxylation of propane and 
ethane. BM3 is a self-sufficient fusion protein composed of a P450 monooxygenase and an 
NADPH diflavin reductase that hydroxylates C12-C20 fatty acids as its preferred substrates (22) 
and does not have any detectable activity on these three substrates. Previous efforts in our lab 
generated variant P450PMO (PMO) (23) through 16 rounds of mutagenesis with 23 mutations with 
activity on all three substrates. In addition, PMO accepts propane as its preferred alkane 
substrate. The evolutionary strategy of enhancing the promiscuous alkane hydroxylation activity 
of BM3 and subsequent variants used to obtain PMO mimicked a natural evolution pathway and 
demonstrated that these functions can be acquired upon iterative rounds of mutagenesis and 
screening. The existing evolutionary lineage from BM3 to PMO allows us to compare the 
variants generated by these different mutagenesis approaches to determine the degree of 




C. Results  
C.1. Library design and composition  
We designed and constructed 17 mutagenesis libraries of BM3 using EP-PCR (1), SSM 
(10), reduced CASTing (4) and structure-based computational methods (2), with library 
compositions listed in Table 3.1 and as described in Chapter 8.D. The residues targeted for SSM, 
reduced CASTing, and computationally-guided libraries were determined using the crystal 
structure of the BM3 heme domain bound with N-palmitoyl glycine, PDB:1JPZ (24). We 
identified ten residues (A74, L75, V78, A82, F87, L181, A184, L188, A328, and A330) as 
mutagenesis targets for both SSM and structure-based computational library design. These 
residues fall within various substrate recognition sites (SRS) identified for class II P450s (25), 
see Figure 3.1, and were selected over adjacent candidates because their side chains are oriented 
directly toward the active site. In addition, six of these ten residues (A74, V78, A82, A184, 
L188, and A328) were previously mutated in the evolutionary path from BM3 to PMO (23) and 
thus were known sites of beneficial mutations.  
For the reduced CASTing libraries, mutations were targeted to three residues, V78, A82, 
and A328, as they were previously found to shift BM3’s substrate specificity toward smaller 
substrates (26 – 27). The allowed amino acid cassette was restricted to L, I, M, V, F, A, and W 
with the use of degenerate codons following the intuition that introducing amino acids with large 
hydrophobic side chains should improve activity for smaller substrates. Four libraries were 
constructed, three of which mutated two of the three residues pairwise, and one library which 
mutated all three targets together. This library will be referred to as the three-site reduced 
CASTing library.  
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Instead of constructing a structural model of the BM3 transition state with small alkanes, 
we elected to use computational tools to find sequences that would maintain the substrate-bound 
conformation in the absence of substrate for the structure-based computational library design. 
This choice was made because a structure of the BM3 substrate-enzyme complex in a reactive 
conformation is not available (28 – 29), and the small alkane substrates lack functional groups 
that would aid the computational design in stabilizing potential transition states. The two 
designed libraries, Corbit and CRAM, mutated the same ten residues as the site-saturation 
libraries, but only allowed for two possible amino acids at each position as determined by each 
algorithm (see Table 3.1). The Corbit algorithm, which has previously been successful in creating 
diverse libraries of green fluorescent protein (16), models protein stability as a surrogate for 
protein function. In this approach, the selected mutations appeared more frequently in sequences 
predicted to support the desired enzyme fold. The second approach, which we termed the CRAM 
algorithm, aggressively packed the active site by computationally determining the largest 
tolerated amino acid substitutions at each of the ten target positions. 
 
Figure 3.1: (a) The ten residues targeted for site-saturation mutagenesis and structure-based 
computational library design chosen based on their proximity to the bound N-palmitoyl glycine substrate 
in the 1JPZ structure of BM3 (24); (b) Close-up of SRS 1, 2, and 4 (25), heme shown in red. N-palmitoyl 










V78  A82  A328  A330  Remaining residues  V78/A82  V78/A328  A82/A328 
V78/A82/
A328  CRAM  Corbit 
A74  ‐  ‐  ‐ ‐ ‐ ‐ ‐  ‐ ‐ ‐ LW AV 
L75  ‐  ‐  ‐ ‐ ‐ ‐ ‐  ‐ ‐ ‐ LF LF 
V78  ‐  ALLa ‐ ‐ ‐ ‐ LIVMFAW  LIVMFAW ‐ LIVMFAW IF VL 
A82  ‐  ‐  ALL ‐ ‐ ‐ LIVMFAW  ‐ LIVMFAW LIVMFAW VL AS 
F87  ‐  ‐  ‐ ‐ ‐ ‐ ‐  ‐ ‐ ‐ FA FA 
L181  ‐  ‐  ‐ ‐ ‐ ‐ ‐  ‐ ‐ ‐ LW LF 
A184  ‐  ‐  ‐ ‐ ‐ ‐ ‐  ‐ ‐ ‐ AV AT 
L188  ‐  ‐  ‐ ‐ ‐ ‐ ‐  ‐ ‐ ‐ LW LW 
A328  ‐  ‐  ‐ ALL ‐ ‐ ‐  LIVMFAW LIVMFAW LIVMFAW VF AF 
A330  ‐  ‐  ‐ ‐ ALL ‐ ‐  ‐ ‐ ‐ LW AV 
<MAA>b  2.1  0.9 0.9 0.9 0.9 0.9 1.7  1.7 1.7 2.6 7.5 5 
Library size (number 
of unique sequences)  1,166
c  32  32  32  32  192  49  49  49  343  1,024  1,024 
Clones screened  1,408  91  91 91 91 546 176  176 176 1,056 2,548 2,548 
Library coverage (%)d  N/A  94  94 94 94 94 97  97 97 95 92 92 
Fraction of folded 
variantse  0.52  0.9  0.96  0.62  0.96  0.95  0.91  0.95  0.97  0.94  0.75  0.84 
Fraction of active 
variantsf  0.36  0.26  0.21  0.36  0.12  0.01  0.22  0.71  0.74  0.54  0.34  0.31 
Average DME activity  0.03  0.01 0.02 0.04 0.01 0.00 0.09  0.24 0.28 0.17 0.19 0.12 
Standard deviation of 
DME activity  0.05  0.03  0.05  0.06  0.05  0.00  0.09  0.23  0.23  0.18  0.38  0.21 
a All: 20 amino acids as encoded by the NNK codon used in the site-saturation mutagenesis. b <MAA>: average mutation rate. c Estimation for the 
number of unique sequences sampled from 1,408 clones of the EP-PCR library was determined using PEDEL (30).dLibrary coverage was 
determined using GLUE (30). e Fraction of folded variants were determined by CO-binding spectroscopy, corrected for stop codon presence.  
f Fraction of variants active for DME (of all variants) were determined in cell-free extract, corrected for background Purpald ® oxidation.  
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C.2. Library characterization for DME demethylation and protein folding 
All 17 libraries were characterized for both DME demethylation activity and protein 
folding using high throughput assays; the results are summarized in Table 3.1. DME 
demethylation activity was quantified colorimetrically through the use of a dye, Purpald®, which 
reacts with the formaldehyde product of the P450 reaction to form a purple adduct with a UV/Vis 
peak maximum at 550 nm (27). The protein folding of each variant was determined by CO-binding 
difference spectra of the cell-free extract (31).  
We screened 1,408 variants from a Taq polymerase generated EP-PCR library with an 
error rate of 2.1 amino acid substitutions/protein, which corresponds to sampling ~ 1,166 unique 
sequences, as calculated by the PEDEL algorithm for estimating the diversity of EP-PCR 
libraries (30). We found 52% of the variants to be folded (CO binding difference > 0.01) and 
36% of the variants active for DME (Abs 550 > 0.13, corresponding to background Purpald® 
oxidation). The ten site-saturation libraries constructed with NNK codons, which encode for all 
20 unique single-mutants, were screened to 94% library coverage (91 clones). Nine of the ten 
libraries contained a high fraction of folded variants, > 90%, with the library at A328 containing 
only 62% of folded variants. Variants that acquired DME activity were found in libraries 
targeting residues V78 (15%), A82 (9%), A328 (34%), and A330 (20%). 
 Given the high mutational tolerance of these active site residues for protein folding, it 
was unsurprising to find that the reduced CASTing libraries also contained a high fraction of 
folded variants, > 91%. The pairwise libraries, each having 49 unique members, were screened to 
97% library coverage (176 clones), and the three-site library with 343 unique members was 
screened to 95% library coverage (1,056 clones). The fraction of functional variants varied from 
22% for the library mutating V78/A82 to 71% and 74% for libraries mutating V78/A328 and 
73 
 
A82/A328, respectively. The three-site reduced CASTing library had only 54% of variants active 
for DME demethylation.  
Finally, the two structure-based computationally designed libraries Corbit and CRAM, 
each containing 1,024 unique members, were screened to 92% library coverage (2,548 clones),  
with 84% and 75% of folded variants, respectively. The fraction of variants with DME 
demethylation activity was similar between these two libraries, with 34% of CRAM variants and 
31% of Corbit variants being functional.  
While all four mutagenesis strategies were able to generate variants with DME 
demethylation activity, the distribution of activity levels varied. The library profiles, i.e., 
activities of variants plotted in ranked order, for all libraries are shown in Figure 3.2. For 
simplicity and easier library comparisons, the variants from all ten SSM libraries were grouped 
and treated as single libraries for this analysis. Likewise, the three pairwise reduced CASTing 
libraries were also grouped.  
Figure 3.2 (a) shows that both the EP-PCR library and the combined SSM libraries 
generated variants with DME activities up to 0.5 A550nm, after correcting for background Purpald 
oxidation, with library averages of 0.026 + 0.050 and 0.010 + 0.039, respectively. These 
averages reflect the overall low functional richness of these libraries with a majority of both 
variant populations being inactive. In contrast, the variants of the reduced CASTing libraries 
exhibit DME activities up to 0.97 A550nm, with library averages of 0.12 + 0.19 and 0.17 + 0.18 for 
the pairwise and three-site reduced CASTing libraries, respectively. A comparison of the library 
profiles of SSM libraries at these three residues, the pairwise, and three-site reduced CASTing 
libraries, Figure 3.2 (b), shows an increase in number of active variants with higher mutation rate 
and library size. However, the range of obtained DME activities only increased for the pairwise 
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reduced CASTing libraries compared to SSM libraries. The library profiles of the Corbit and 
CRAM libraries show even higher DME activity: A550nm of 2.6 was reached. However, as only ~ 
30% of the variants are functional, the library averages of 0.18 + 0.38 and 0.12 + 0.21 are similar 
to the reduced CASTing libraries.  
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Figure 3.2: Profile of DME activity obtained by mutagenesis libraries with the activity of each variant plotted in ranked order. (a) Variants from 
the ten site saturation libraries and the top 910 variants of the EP-PCR library. (b) Variants from the site saturation, pairwise, and the complete 



























































C.3. Propane and ethane hydroxylation 
After the DME demethylation screen was repeated for selected variants from each library 
in at least duplicate, top-performing variants were purified and characterized for propane and 
ethane hydroxylation activity (see Appendix A for complete sequence and activity information). 
Figure 3.3 (a) shows the histogram of propane and ethane turnover number (TON) of variants 
isolated from these libraries. From the ten SSM libraries, twelve variants were identified 
supporting propane TON ranging from 120 to 2,200. Mutations at V78 (T, C, S) and A82 (E,Q) 
located in the B’ helix of SRS1 yielded variants with moderate propane activity, 120 to 370 
TON. More active variants, > 1,000 propane TON, were obtained with mutations at residues 
A328 (I, P, L, V) and A330 (L, P, V), which are located in the loop between the J and K helices. 
The best single active-site variant, A328V, supports 2,200 propane TON with a product 
formation rate of 7.1 min-1 and 8.1% coupling of cofactor consumption.  
Six variants were identified from the Taq EP-PCR library, supporting 130 to 3,300 
propane TON. The best variant, 4F9 (F162L) supports 3,300 propane TON with a product 
formation rate of 19 min-1 and 15% coupling of cofactor consumption. The F162L mutation 
occurs in the linker between the E and F helices, located outside of the active site. While this 
residue was not mutated in variants of the PMO lineage, several residues in the adjacent F-helix 
were mutated, which may suggest the importance of this region for altering substrate specificity.  
From the reduced CASTing libraries, nine variants were identified supporting 380 to 
4,200 propane TON with only four of the nine variants containing mutations at all three targeted 
residues. The best variant, WT-A82L-A328V, supports 4,200 propane TON with a product 
formation rate of 40 min-1 and 44% coupling of cofactor consumption. In addition, two of these 
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nine variants, WT-A82L-A328L and WT-A82L-A328V, were also able to hydroxylate ethane, 
supporting 140 and 200 TON, respectively.  
As far more variants from the CRAM and Corbit libraries exhibited high DME 
demethylation activity compared to the other libraries, we selected the 88 most active variants 
from each library and screened them for propane and ethane hydroxylation directly as cell-free 
extracts using the assay outlined in Chapter 5.1. From this screen, 37 variants supporting at least 
2,000 propane TON and 100 ethane TON as crude extracts were purified and characterized. All 
37 variants were found to support at least 3,500 propane TON with 16 of the variants supporting 
at least 300 ethane TON as purified enzymes. A much higher number of active variants for 
propane and ethane hydroxylation was found in the CRAM library, 25 and 13, respectively, 
compared to the Corbit library, which only produced twelve variants with activity on propane and 
three variants with ethane activity. The most active CRAM variant was E32 with mutations 
A74W, V78I, A82L, A184V, L188W, A328F, and A330W. E32 supported 16,800 propane TON 
and 1,200 ethane TON. The most active Corbit variant, OD2, with mutations A74V, L181F, and 
A328F, supported 11,600 propane TON and 660 ethane TON. The coupling of cofactor 
consumption with propanol formation was also determined for a selection of these variants. Most 






Figure 3.3: (a) Histogram of propane (a.1) and ethane (a.2) hydroxylating variants identified from various libraries. (b) Scatter plots of 































































































Figure 3.3 (b) shows the scatter plot of propane and ethane hydroxylation activities of all 
characterized variants vs. their DME demethylation activity. The data scatter of DME activity vs. 
propane TON, Figure 3.3 (b.1), appears to be normally distributed with a coefficient of 
determination (r2) of 0.51 for linear regression of the data. In comparison, the data scatter of 
DME activity vs. ethane TON plot, Figure 3.3 (b.2), is not normally distributed, and a strong data 
bias exists representing variants with DME activity but unable to hydroxylate ethane. An r2 of 
0.30 is obtained for the linear correlation of DME activity and ethane TON. From these plots, we 
can conclude that both propane and ethane hydroxylation activity is positively correlated with 
DME demethylation since the p-values for the null hypothesis, i.e., random data scatter, are 1.5 x 
10-11 and 1.26 x 10-6, respectively. In addition, since very few variants with high DME activity 
were inactive for propane hydroxylation, DME demethylation is a good predictor for propane 
activity. However, more quantitative conclusions for the differences in predictability of DME 
demethylation for propane hydroxylation vs. ethane hydroxylation are difficult to determine. 
By far the best source of variants with activity for propane and ethane hydroxylation is 
the designed library generated by the CRAM algorithm. The 25 propane hydroxylation variants 
with mutations at the same ten targeted residues form a concise and convenient data set for 
sequence analysis. The distribution of amino acids for all 25 variants, shown in Figure 3.4 (a), 
displays strong biases at seven of the ten targeted positions. Tryptophan appears at residue 74 
and 188 in more than 72% of the sequences, likewise, strong preferences exist for L at positions 
75 (84%), 82 (76%), and 181 (88%), I at 78 (76%), and F at 87 (96%). Of the remaining targeted 
positions, a weaker preference existed for W at 330 (68%), and V at 184 (60%), and nearly equal 
representations of both allowed amino acids were observed at position 328. Further sequence 
analysis of these variants accounting for their propane TON, Figure 3.4 (c – e), shows a fine-
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tuning of amino acid preference and reduction of the sequence space with increased activity. For 
variants supporting less than 7,500 propane TON, a higher fraction of the less preferred amino 
acids are found at positions 74, 75, 78, 82, and 188. Proceeding to variants supporting higher 
propane TON, the occurrences of the less preferred amino acids decrease, culminating in nearly 
absolute preference for W at position 74, L at positions 75, 82, and 181, I at position 78, and F at 
position 87 for variants supporting more than 10,000 propane TONs. These results indicate that 
the screening process was able to find a narrow section of the total allowed sequence space 
containing the best solutions for propane hydroxylation. Comparing the amino acid preference of 
CRAM library variants, W74/L75/I78/L82/F87/L181, with the residues found in PMO, 
E74/L75/F78/G82/F87/L181, the positions with a preference for the wild-type amino acid (75, 
87, 181) are not mutated in either of the CRAM variants or PMO, while mutations at the other 
positions (74, 78, 82) differ between the CRAM variants and PMO. The CRAM variants 
preferred larger hydrophobic residues at these locations, whereas PMO introduced both a 
charged and a hydrophilic amino acid. Although the choices of amino acids may differ, both sets 
of mutations may result in a similar constriction of the substrate channel. Due to both the close 
range of obtained activity and the low number of active variants produced by the other 
mutagenesis libraries, similar sequence analysis did not yield significant trends. 
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Figure 3.4: Amino acid distribution at each of 
the ten targeted positions of propane 
hydroxylating CRAM library variants: (a) all 
active variants, (b) identity of PMO’s amino 
acid for these residues, (c) variants supporting 
less than 7,500 TON, (d) variants supporting 
7,500 – 10,000 TON, (e) variants supporting  > 










Since variants with activity for DME demethylation and propane hydroxylation were 
identified from all the mutagenesis approaches we investigated, with as few as one mutation, it 
appears that finding variants with these two functions was much easier than we anticipated based 
on previous studies (26, 32). As a substrate, propane shares many similarities with hexane, the 
smallest known alkane hydroxylated by BM3. They are both hydrophobic with poor water 
solubility and possess sub-terminal alkane C-H bonds of comparable bond strength as BM3’s 
preferred fatty acid substrates (99–100 kcal/mol). The only difference between propane and other 
known BM3 substrates is its smaller molecular size, which should result in a lower binding 
affinity. The major impact of poorly bound substrates on the P450 reaction mechanism is a 
weaker activation of the catalytic cycle, as the poorly bound substrates cannot displace the distal 
water-ligand to initiate catalysis (33).  
For wild-type BM3, the propane binding event needs to be the sole trigger for the 
activation of catalysis, as the enzyme exhibits low resting state oxidase activity (~ 10 min-1), 
which indicates that substrate-independent activation of the catalytic cycle occurs rarely. 
However, variants of BM3 can exhibit much higher resting state oxidase activity, thereby 
reducing the requirement of propane binding to induce catalysis. In fact, variants generated in the 
P450PMO lineage and many of the variants found in this study have substrate-free cofactor 
consumption up to an order of magnitude higher than that of the wild-type enzyme. The 
existence of this alternative pathway for propane hydroxylation activity, which can be achieved 
without appreciable propane-induced activation of the catalytic cycle (34), could explain the high 
number of identified propane-hydroxylating variants. The accessibility of this alternative 
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pathway for substrate hydroxylation still requires some degree of substrate binding affinity and 
should diminish for substrates with lower affinity, such as ethane. 
Unlike the high number of variants isolated with activity for propane hydroxylation and 
DME demethylation, far fewer isolated variants exhibited ethane hydroxylation activity. One 
possible explanation for this result is the poor correlation between DME demethylation and 
ethane hydroxylation, as shown in Figure 3.3 (b.2). Since DME demethylation was the criterion 
used to filter variants for ethane hydroxylation characterization, a poor correlation between the 
activities would result in the elimination of ethane-hydroxylating variants with poor DME 
demethylation activity. Another potential explanation for this result is that variants with ethane 
hydroxylation activity are simply rarer in the sequence space that we investigated than variants 
with activity for propane hydroxylation and DME demethylation. This possibility is quite 
understandable since ethane is both smaller than propane and lacks the energetically favorable 
sub-terminal alkane C-H bond that is common to propane and BM3’s preferred fatty acid 
substrates. Therefore, ethane hydroxylation presents challenges to not only the activation of the 
P450 catalytic cycle due to its smaller size, but also the ability of the P450 to break a ~ 1 
kcal/mol stronger C-H bond. 
Another finding from these mutagenesis libraries is the extremely high mutational 
tolerance of the BM3 active site. The high fraction of tolerated mutations observed with BM3 
active site residues appears to contradict the general observation that mutations in the core of a 
protein are on average more destabilizing than mutations of solvent-exposed residues (35). 
Residues in the packed protein core generally have more interactions with neighboring amino 
acids than solvent-exposed residues. As a result, they have lower site entropy, which has been 
hypothesized to reflect decreased tolerance for mutation (36). However, the BM3 active site 
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residues inherently have a higher degree of flexibility compared to typical core residues, since 
the active site of BM3 undergoes significant motion between the “closed” substrate-bound state 
and its “open” resting state (37). The active site environment between these two states also 
differs significantly in terms of solvent accessibility (33), which may allow these positions to 
tolerate polar or even charged amino acid substitutions. Therefore, the flexible nature of the BM3 
active site, which is atypical of packed protein core structures, may be responsible for the higher 
mutations tolerance of these residues.   
In comparing the functional richness between the libraries generated by the various 
mutagenesis methods we investigated, it was surprising to find that the EP-PCR library appears 
to generate more active variants than the combined efforts of the SSM libraries (see Figure 3.2 
(a)). Comparing the functional richness of EP-PCR mutagenesis with SSM is inherently 
subjective since a poor choice of mutagenesis sites or selection criteria can easily skew the 
efficacy of the site-saturation libraries. However, since comparable screening effort was required 
to evaluate the ten site-saturation libraries (910 clones) and the EP-PCR library (1,408 clones), 
this comparison is reasonable from a practical standpoint. Although the number of clones 
sampled from these libraries is similar, the actual sequence diversity is quite different: 200 
unique variants for the combined NNK libraries vs. 1,166 expected unique variants for the EP-
PCR library. This sixfold increase in number of unique sequences could account for the higher 
number of DME demethylating variants identified in the EP-PCR library. The screening efficacy 
of the site-saturation libraries can be improved with the use of more efficient codons such as 
NDT1 (20) or a combination of codons to better match the number of unique nucleotide 
                                                 




sequences with the number of unique amino acid substitutions of the libraries. However, even 
with the best possible codon selection, to generate a set of site-saturation libraries with the same 
number of unique sequences as the EP-PCR library generated in this study would require nearly 
60 site-saturation libraries. Clearly, EP-PCR is better than SSM at generating sequence diversity 
quickly and cheaply, at the cost of not controlling or knowing the sites of mutagenesis. Based on 
this inherent trade-off, EP-PCR should be superior to SSM in generating diversity for functions 
that are affected by mutations across protein structure, such as thermostability, solubility, or 
modulating promiscuous activity. Conversely, for functions that require specific changes in the 
enzyme’s active site, such as altering regio- and enantio-selectivity, the easily generated 
sequence diversity of the EP-PCR library is wasted, since the majority of the mutations is not 
created at the necessary locations. Therefore, for these functions, SSM at active site residues has 
the potential to be more effective. 
Comparing functional richness of the site-saturation libraries at V78, A82, and A328 with 
the reduced CASTing libraries mutating the same residues pairwise, Fig 3.2 (b), shows that the 
reduced-CASTing libraries are far better in both the range of activities obtained and the number 
of active variants. In terms of the sequence diversity in this comparison, the pairwise reduced 
CASTing libraries combine to have 147 unique variants, whereas the three SSM libraries 
combine to have only 60 possible variants, which should account for some of the differences in 
the observed functional richness. However, since the mutations found to support DME 
demethylation and propane hydroxylation at V78 (C, T, S) and A82 (E, Q) were not included in 
the allowed amino acids of the reduced CASTing libraries (L, I, V, F, M, A, and W), the 
pairwise reduced CASTing libraries found active variants that would not have been found 
through recombination of the beneficial point mutations. One obvious question is whether the 
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variants found from the reduced CASTing library are better than those that could have been 
isolated from either the recombination of the beneficial point mutants identified from site-
saturation libraries or iterative rounds of SSM. We cannot answer this question directly, as 
neither approach was attempted. However, such comparisons would only be anecdotal and 
cannot determine which method is superior. Ultimately, all three approaches are flawed, as each 
makes a fallible assumption about the interaction of mutations. In the reduced CASTing library, 
the initial reduction of the allowed amino acids assumes that better solutions do not exist in the 
excluded amino acids. Likewise, the strategies of recombining beneficial single mutations or 
iterative site-saturation assumes that synergistic effects between mutations are minimal, and the 
best combination of mutations contains mutations found to be beneficial individually. How these 
assumptions accurately reflect the interaction of mutations for a particular protein will ultimately 
determine the efficacy of their application. 
While the pairwise reduced CASTing libraries displayed both a higher range of obtained 
activities and a higher number of active variants than SSM libraries mutating the same residues, 
the range of DME demethylation activity obtained by the three-site reduced CASTing library did 
not increase compared to that of the pairwise reduced CASTing libraries. In addition, the fraction 
of functional variants for the three-site reduced CASTing library, 54%, was lower than the 
pairwise reduced CASTing library involving A328, 71% and 74%. This indicates that with the 
expanded sequence space, 343 vs. 49 library members, the larger library had more unique active 
sequences, but a larger fraction of the sequence space was occupied by inactive variants. One 
explanation for this result is that mutations at V78 and A82, which are located in close 
proximity, reduce the volume of the active site in the same region. Therefore, adding an 
additional mutation to the existing mutations at V78 and A328 or A82 and A328, which are 
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already sufficient for function, has only neutral or deleterious effects. Beyond this structure 
based argument, the reduced benefit of increasing the mutation rate of the CASTing library may 
be an inherent dilution effect analogous to that observed for random mutagenesis, where 
increasing the mutation rate beyond 1 – 2 amino acid substitutions results in lower quality 
libraries (38).  
The single point mutations at V78, A82, A328, and A330 that resulted in variants with 
DME demethylation activity and propane hydroxylation activity generally introduced amino 
acids with bulkier side chains into the active site, which follows the intuition that reducing active 
site volume would promote activity for a smaller substrate. Since none of the PMO mutations, 
V78F, A82G, or A328F, were found at these positions, they are not beneficial individually. The 
presence of proline mutations at A328 and A330 suggests that altering the orientation of the loop 
containing these residues can result in improved activity in addition to mutations that simply 
reducing the active site volume. The best mutation, A328V, has been reported to affect fatty acid 
binding and cause a shift in regioselectivity of the hydroxylation reaction (39). A crystal 
structure of WT-A328V has been solved with N-palmitoyl glycine bound in the active site (PDB: 
1ZOA) (39). A structure alignment of WT-A328V and wild-type BM3 (Figure 3.5) shows little 
structural deviation, with an overall RMDS of the -carbons of only 0.23 Å. The largest 
deviation between the two structures occurs near the 13o kink in the I-helix, the proposed site of 
oxygen binding (40). However, similar deviations can be observed between different structures 
in wild-type BM3 in this region, which could reflect the general flexibility rather than the result 
of this mutation. The methyl group of the valine side chain induces a slight twist in the bound 
substrate, N-palmitoyl glycine, at the C-5 carbon; otherwise the active site packing is identical. 
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The lack of gross changes in the active site packing between these two structures illustrates that 
propane hydroxylation activity is obtainable without significant structural deviations. 
  
Figure 3.5: Structural alignment of BM3 (1JPZ (24)), shown in green, with BM3-A328V (1ZOA (39)), 
shown in cyan, heme shown in red. Close-up of the active site showing a shift of the bound N-palmitoyl 
glycine due to the presence of V328 side chain electron density 
Of the seven mutations found through random mutagenesis, only I260V, located on the I-
helix, is near the active site. The mutations F162L and I153V found in the more active variants 
are clustered in the region between the E and F helices. The remaining mutations E4D, T235M, 
D232V and Q359R, are at surface-exposed residues, which are typical of mutations found using 
random mutagenesis (41), whose effects are difficult to rationalize.  
Across all nine variants isolated from the reduced CASTing libraries, V78L was the only 
mutation found at position 78, whereas more substitutions were beneficial at A82 (L, W, M, and 
V) and A328 (L, V, and F). Since the allowed amino acid set excluded glycine, only two PMO 
mutations, V78F and A328F, could have been found by these variants. Of these two mutations, 
only A328F was found in the isolated variants. Since this mutation was not found to be 
beneficial individually, its presence in PMO and these reduced CASTing variants suggests there 
are synergistic effects between this residue and neighboring amino acids. The effect of the V78L 
mutation on propane TON was also showed a dependence on the surrounding mutations: when 
V78L was introduced to WT-A328L or WT-A82L-A328L, the resulting variants lost 48% of the 
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parental propane activity. However, when V78L was mutated in WT-A82W-A328F, the 
resulting variant had sixfold improved propane activity. This illustrates the ruggedness of active 
site landscape, in which the effects of mutations are highly dependent on the identity of 
neighboring amino acids. While the effects of an amino acid substitution are heavily dependent 
on existing mutations, different amino acid substitutions at a given residue can result in nearly 
identical activities, for example, mutating A82 to either M and V produced nearly equal 
increases in propane TON, 3.8-and 3.3-fold in the same parental background of WT-V78L-
A328L. These results suggest that reducing the allowed set of amino acids is a good trade-off for 
mutating more residues simultaneously, as different amino acid substitutions can achieve similar 
effects, a result which supports the structure-based computationally designed approach we 
pursued. 
The most effective libraries we generated in this investigation for acquiring DME 
demethylation and propane hydroxylation activity are the CRAM and Corbit structure-based 
computationally designed libraries. These two libraries mutated all ten targeted active site 
residues allowing for two possible amino acids at each position. By redesigning the active site in 
such a global fashion, we obtained variants with propane and ethane activity rivaling those 
achieved by variants of the P450PMO lineage (34). The best variant from the CRAM library, E32, 
supported 16,800 propane TON and 1,200 ethane TON, which are ~ 50% of PMO’s activity on 
these substrates. The best variant from the Corbit library, OD2, supported 11,600 propane TON 
and 660 ethane TON, which are 34% and 27% of PMO’s activity on these substrates. As a 
comparison, these activity levels were obtained by variants of P450PMO lineage after 10 – 12 
rounds of mutagenesis and screening.  
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Of the 37 variants we isolated from these two designed libraries, all allowed amino acids 
were found at least once. While all mutations were represented, there are clear biases in amino 
acid preference (see Figure 3.4). The consensus sequence of the active CRAM variants, W74, 
L75, I78, L82, F87, L181, V184, W188, F328, and W330, is actually the sequence of variant 
E32, the most active variant, which suggests that the screening process was able to find an 
optimal solution within the allowed sequence space (210).  Of the six positions–75, 78, 87, 181, 
184, and 328–where the PMO residue was an allowed choice by the library design, five positions 
converged on the PMO amino acid. This convergence on mutations found in PMO is not 
surprising since the PMO active site is a good solution for the selected activities. However, 
assigning significance to these amino acid preferences in the context of the total possible 
sequence space of these ten residues (1020) is problematic, as each mutation was compared 
against only one other amino acid within a limited set of surrounding mutations. Therefore, the 
best solution obtained from the designed libraries is certainly not the optimal solution for the 
total sequence space. All we can ascertain from the CRAM library results is that, within the 
chosen subsection of the sequence space, multiple solutions for propane and ethane 
hydroxylation exist, and a locally optimal solution is obtainable.  
These designed libraries also demonstrate that jumps in sequence space from BM3 to 
variants with moderate propane hydroxylation activity (~ 10,000 TON) are achievable. None of 
the obtained variants, however, reached the level of specialization that was previously obtained 
with P450PMO, in either propane TON or coupling of cofactor consumption. In the evolution of 
BM3 to PMO, the specialization for propane hydroxylation did not occur evenly through the 16 
rounds of mutagenesis. In fact, the variants of the lineage can be categorized into three distinct 
groups by their substrate specificity for linear alkanes as (1) preferring longer chain alkanes, (2) 
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having equal preference for alkanes of chain lengths C3 – C10, and (3) preferring shorter chains 
alkanes with the length of propane (34). These three groups of variants represent a transition 
from a specialized fatty acid hydroxylase to generalist P450s with broad alkane substrate 
acceptance followed by second transition to a specialized propane monooxygenase. This last 
transition occurs in the final four rounds of mutagenesis where the largest improvements in 
cofactor coupling (44% to 93%) and propane TON (10,550 to 33,400) occur. In addition, 
mutations acquired in these final rounds of mutagenesis are located not only in the P450 heme 
domain but also in the reductase domain. This suggests that mutations outside the active site or 
even the heme domain in general, may be necessary for functional optimization. The range of 
obtained propane TON (3,500 – 16,800) and coupling of co-factor consumption (36% – 68%) for 
variants identified by the designed libraries correspond to those values of the generalist 
intermediates found preceding the propane specialization phase of the PMO evolution. This 
suggests semi-rational library design can be an effective strategy to move away from a 
specialized enzyme toward generalist variants, but functional specialization still requires 
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Enzymes of the AlkB and CYP153 families catalyze the first step in the metabolism of 
medium chain-length alkanes, selective oxidation of alkanes to the 1-alkanols, and enable their 
host organisms to utilize alkanes as carbon sources. Small gaseous alkanes, however, are 
converted to alkanols by members of the evolutionarily unrelated methane monooxygenase 
(MMO) family. Propane and butane can be oxidized by CYP enzymes engineered in the 
laboratory, but these produce predominantly the 2-alkanols. Here we report the in vivo directed 
evolution of two medium chain-length terminal alkane hydroxylases, the integral-membrane di-
iron enzyme AlkB from Pseudomonas putida GPo1 and the class I soluble CYP153A6 from 
Mycobacterium sp. HXN-1500, for enhanced activity on small alkanes. We established a P. 
putida evolution system that enables selection for terminal alkane hydroxylase activity and used 
it to select propane- and butane-oxidizing enzymes based on enhanced growth complementation 
of an adapted P. putida GPo12 (pGEc47B) strain. The resulting enzymes exhibited higher rates 
of 1-butanol production from butane and maintained their preference for terminal hydroxylation. 
This in vivo evolution system could be generally useful for directed evolution of enzymes that 






Microbial utilization and degradation of alkanes was discovered almost a century ago (1). 
Since then, several enzyme families capable of hydroxylating alkanes to alkanols, the first step in 
alkane degradation, have been identified and categorized based on their preferred substrates (2). 
The soluble and particulate methane monooxygenases (sMMO and pMMO) and the related 
propane monooxygenase and butane monooxygenase (BMO) are specialized on gaseous small-
chain alkanes (C1 to C4), while medium-chain (C5 to C16) alkane hydroxylation seems to be the 
domain of the CYP153 and AlkB enzyme families.  
Conversion of C1 to C4 alkanes to alkanols is of particular interest for producing liquid 
fuels or chemical precursors from natural gas. The MMO-like enzymes that catalyze this reaction 
in nature, however, exhibit limited stability or poor heterologous expression (2) and have not 
been suitable for use in a recombinant host that can be engineered to optimize substrate or 
cofactor delivery. Alkane monooxygenases often co-metabolize a wider range of alkanes than 
those which support growth (3). We wished to determine whether it is possible to engineer a 
medium-chain alkane monooxygenase to hydroxylate small alkanes, thereby circumventing 
difficulties associated with engineering MMO-like enzymes as well as investigating the 
fundamental question of whether enzymes unrelated to MMO can support growth on small 
alkanes.  
The most intensively studied medium-chain alkane hydroxylases are the AlkB enzymes 
(4 – 6), especially AlkB from Pseudomonas putida GPo1 (7 – 10). While most members of the 
AlkB family act on C10 or longer alkanes, some accept alkanes as small as C5 (2). A recent study 




assimilation. AlkB selectively oxidizes at the terminal carbon to produce 1-alkanols. No 
systematic protein engineering studies have been conducted on this diiron integral membrane 
enzyme, although selection and site-directed mutagenesis efforts identified one amino acid 
residue that sterically determines long-chain alkane degradation (9). 
The most recent addition to the biological alkane-hydroxylating repertoire is the CYP153 
family of heme-containing cytochrome P450 monooxygenases. Although their activity was 
detected as early as 1981 (11), the first CYP153 was characterized only in 2001 (12). Additional 
CYP153 enzymes were identified and studied more recently (13 – 15). These soluble, class I-
type three-component P450 enzymes and the AlkB enzymes are the main actors in medium-
chain-length alkane hydroxylation by the cultivated bacteria analyzed to date (15). CYP153 
monooxygenases have been the subject of biochemical studies (12 – 13, 16), and their substrate 
range has been explored (14, 17). Known substrates include C5-C11 alkanes. The best 
characterized member, CYP153A6, hydroxylates its preferred substrate octane predominantly (> 
95%) at the terminal position (13).  
Recent studies have shown that high activities on small alkanes can be obtained by 
engineering other bacterial P450 enzymes such as P450cam (CYP101, camphor hydroxylase) 
and P450 BM3 (CYP102A1, a fatty acid hydroxylase) (18 – 19). The resulting enzymes, 
however, hydroxylate propane and higher alkanes predominantly at the more energetically 
favorable subterminal position; highly selective terminal hydroxylation is difficult to achieve by 
engineering a subterminal hydroxylase (20). We wished to determine whether a small-alkane 
terminal hydroxylase could be obtained by directed evolution of a longer-chain alkane 




AlkB from P. putida GPo1 and CYP153A6 from Mycobacterium sp. HXN-1500 (13, 21) to 
enhance their activity on butane. Because terminal alkane hydroxylation is the first step of alkane 
metabolism, we reasoned that it should be possible to establish an in vivo evolution system that 
uses growth on small alkanes to select for enzyme variants exhibiting the desired activities.  
The recombinant host Pseudomonas putida GPo12 (pGEc47B) was engineered 
specifically for complementation studies with terminal alkane hydroxylases and was used 
previously to characterize members of the AlkB and CYP153 families (15, 22). This strain is a 
derivative of the natural isolate P. putida GPo1 lacking its endogenous OCT-plasmid (octane 
assimilation) (23), but containing cosmid pGEc47B, which carries all genes comprising the alk 
machinery necessary for alkane utilization, with the exception of a deleted alkB gene (24). We 
show that this host can be complemented by a plasmid-encoded library of alkane hydroxylases 
and that growth of the mixed culture on butane leads to enrichment of novel butane-oxidizing 





C. Results  
C.1. P. putida GPo12 (pGEc47B) growth on short-chain 1-alkanols  
P. putida GPo12 (pGEc47B) was shown in previous studies to grow on medium chain-
length alkanols like 1-octanol and on the corresponding alkane only when complemented by a 
terminal alkane hydroxylase (15, 22). To determine whether this strain could be used to select or 
screen for improved terminal alkane hydroxylation activity, we tested its ability to grow with the 
primary and secondary C1-C8 alkanols as sole carbon sources (Figure 4.1). No growth was 
observed on any of the secondary alcohols or on methanol during the 18 -day period. Ethanol, 1-
propanol and 1-butanol supported relatively strong growth, comparable to that of the positive 
control grown on glucose. Slow growth was observed on 1-pentanol, 1-hexanol, and 1-octanol.  
 
Figure 4.1: Growth of P. putida GPo12(pGEc47B) with primary and secondary linear short and medium 
chain-length alkanols. The OD600 of the cultures was measured after 18 days of growth in liquid M9 
minimal medium with 0.5% (vol/vol) primary (CX-1ol; X  =  number of carbon atoms) or secondary (CX-
2ol) alcohols as carbon source dissolved in a 5% (vol/vol) organic layer of heptamethylnonane. Alcohols 
smaller than five carbon atoms were added without organic solvent. Cultures with 0.5% (wt/vol) glucose 
or no added nutrient served as controls. 
The results indicated that the terminal hydroxylation products of all the short-chain n-
alkanes except methane are readily utilized as carbon sources, while subterminal oxidation 




screening and selection for terminal hydroxylation of long, medium, and short chain-length 
alkanes.   
C.2. Creation of gene libraries through random plasmid mutation  
It was not efficient to use error-prone PCR to randomly mutate the target genes, as 
cloning of PCR products into the pCom vector yielded fewer than 2,000 transformants, much 
less than the hundreds of millions of mutants that can be used for evolution with a growth 
selection. Mutant libraries were therefore constructed by complementing P. putida GPo12 
(pGEc47B) strains with randomly mutated plasmids encoding AlkB or CYP153A6. The 
drawbacks of including mutations that affect the vector (antibiotic resistance and origin of 
replication) rather than just the inserted genes were compensated by the large library size and 
ease of library construction. Mutator strains were used to generate the plasmid libraries, and to 
increase diversity both available mutator strains were used, Escherichia coli XL1Red 
(Stratagene) and E. coli JS200 pEP Pol I (25). E. coli XL1Red has deficiencies in the DNA 
repair mechanism that lead to a 5,000-fold increase in the general mutation rate (26) (Stratagene 
manual).  E. coli JS200 pEP Pol I expresses an engineered mutator DNA polymerase I, which 
mainly amplifies plasmid DNA with lower reliability, thus introducing mutations in the plasmid 
DNA (25). The nucleotide mutation level in XL1Red after two weeks of continuous culturing 
was approximately 0.1/kb, while four rounds of mutation in JS200 pEP Pol I yielded up to 
0.4/kb. Cultures of both mutator strains were combined, and the mutated plasmids were 
transformed into P. putida GPo12 (pGEc47B) through triparental mating with the helper strain 




strain library in minimal medium with an alkane as sole carbon source for up to three weeks, as 
described in Chapter 8.E.6. 
C.3. P. putida growth on butane through complementation with AlkB and CYP153A6 variants 
A mixed culture containing alkane hydroxylase variants will become enriched in strains 
best adapted to use alkanes as their sole carbon source. However, not only can beneficial 
mutations in the hydroxylase gene lead to improved growth, but adaptations of the host and 
vector will do so as well. For P. putida GPo12 (pGEc47B) complemented by CYP153 genes, it 
had been observed that the host had to be adapted through prolonged cultivation on alkanes to 
obtain significant growth on these substrates (15) without any mutations occurring in the cyp153 
genes themselves. To test whether host adaptation was also occurring in our experiments, 21 
single colonies obtained from the first round of enrichment cultures were compared to the parent 
strain by plate growth tests (data not shown). Solid media growth tests were chosen over liquid 
media due to the growth instability of liquid minimal media cultures of P. putida GPo12 
(pGEc47B), which often showed different growth rates between replicates or, occasionally, 
failure to grow at all. The host, vector, and operons of the best mutants were analyzed 
individually by comparing them in growth tests to their wild-type counterparts. To identify and 
analyze potentially adapted hosts, the adapted recombinant strain was cured of the plasmid and 
transformed with the appropriate wild-type plasmid. Adapted vectors were isolated from the 
strains and the alkB gene or cyp153A6 fdrA6 fdxA6 operon was replaced by the wild-type 
sequence by cloning, before being mated into the wild-type host. Furthermore, potentially 
improved hydroxylase genes were recloned into a wild-type vector and transferred into a wild-




Comparison of all the resulting strains in growth assays led to the identification of several 
improved hosts and vectors. Strain Pcyp1, an adapted P. putida GPo12 (pGEc47B) strain, 
showed faster growth on pentane than its parent when complemented by the wild-type 
pCom8_cyp153A6 plasmid. Further adaptation of Pcyp1 led to Pcyp2, which again grew faster 
on pentane. Similarly, strain Palk1 showed improved growth on propane and butane when 
transformed with wild-type pCom10_alkB. For the CYP153A6 system, adapted plasmid 
pCom8* enabled faster growth of P. putida GPo12 (pGEc47B) on pentane, even when it 
contained the wild-type operon. Sequencing showed no mutation of the CYP operon in 
pCom8*_cyp153A6 or in the sequence 500 nucleotides up- and downstream from the operon. 
For the AlkB system, no improved vectors were obtained. The adapted host and vector 
components were specific for the particular system used, i.e., strain Palk1 did not show improved 
growth on short chain-length alkanes compared to the wild-type host when complemented with 
CYP153A6. Likewise, Pcyp1, Pcyp2, and pCom8* were only adapted for their specific systems. 
The nature of the mutations and how they benefit growth on short-chain alkanes is unknown.  
In addition to creating these adapted hosts and plasmids, the first rounds of in vivo 
directed evolution generated enzyme mutants AlkB-BMO1 (butane monooxygenase) and 
CYP153A6-BMO1, both of which conferred improved growth on butane. Sequencing revealed a 
single nucleotide mutation in each: mutation of the codon CTA to GTA led to single amino acid 
substitutions L132V in AlkB-BMO1 and, through a GCA to GTA change, the substitution A94V 
in CYP153A6-BMO1 (A97V in the published sequence reported in reference 13). All the 





Table 4.1: Relative growth of adapted P. putida GPo12 (pGEc47B) strains, expressing 
CYP153A6 and AlkB variants, on minimal media plates with alkanes as the sole carbon source 
Complementing alkane 
monooxygenase 
Days required for growth to a full lawn with  
selected carbon source 
Ethane Propane Butane Pentane Octane 
AlkB wild-type    NG[a] 5 5 3 2 
AlkB-BMO1 NG 5 3 6 7 
AlkB-BMO2 NG 5 2 4 8 
CYP153A6 wild-type NG NG NG 2 2 
CYP153A6-BMO1 NG NG 5 1.5 5 
[a]NG: No growth detected during 3 -week observation
 
 
Figure 4.2: Growth of P. putida GPo12 (pGEc47B) strains on alkanes. (A) Strains of adapted P. putida 
GPo12 (pGEc47B) complemented by an empty plasmid, or expressing CYP153A6 wild type or 
CYP153A6-BMO1 (left, middle, and right section) were grown for 5 days with butane as sole carbon 
source. (B) Growth of adapted P. putida GPo12 (pGEc47B) strains complemented by an empty 
plasmid, expressing the AlkB wild type, or its mutants BMO1 and BMO2, on butane after 2 days 
Palk1 expressing AlkB-BMO1 showed a significant increase in rate of growth on butane 
compared to Palk1 expressing wild-type AlkB. In contrast, growth rates on pentane and octane 
were reduced. No significant growth improvement on propane was observed, and neither enzyme 
supported growth on ethane. These results suggest that the L132V mutation in AlkB-BMO1 
specifically improves activity toward butane. A similar result was found for Pcyp2 
(pCom8*_cyp153A6-BMO1), which grew more slowly on octane than Pcyp2 
(pCom8*_cyp153A6) but faster on pentane. The CYP153A6-BMO1 variant also supported 
growth on butane, which wild-type CYP153A6 did not. Thus the A94V mutation appears to 




Plasmids pCom8*_cyp153A6-BMO1 and pCom10_alkB-BMO1 were subjected to a 
second round of mutagenesis and mated into Pcyp2 and Palk1, respectively. A further-improved 
AlkB monooxygenase, AlkB-BMO2, was obtained after enrichment and screening. Sequencing 
revealed a total of three nucleotide mutations, all resulting in amino acid substitutions in AlkB-
BMO2: V129M (GTG to ATG), L132V (CTA to GTA), and I233V (ATC to GTC). To ensure 
comparison in identical genetic backgrounds, the mutated gene was recloned into a wild-type 
pCom10 vector, mated into fresh Palk1, and compared in growth tests to Palk1 expressing AlkB 
wild-type and AlkB-BMO1 (Table 4.1, Figure 4.2). Compared to its parent AlkB-BMO1, AlkB-
BMO2 performed even better in growth complementation studies with butane. Growth on 
pentane and octane was also improved, but was still inferior to that obtained with the wild-type 
enzyme. Thus, the mutations V129M and I233V improved the overall activity of AlkB-BMO2 
compared to its parent, AlkB-BMO1. Enrichment and screening yielded no additional 
improvement in the CYP153A6 system. 
C.4. Whole-cell butane bioconversions of AlkB-BMO1, -BMO2, and CYP153A6-BMO1  
In order to quantify the effects of the mutations on enzyme performance, whole-cell 
bioconversions were performed using growth-arrested E. coli BL21(DE3) cells containing the 
CYP153A6 variants expressed from pCom8*. Although pCom plasmids are not efficient 
expression platforms, we nonetheless observed functional CYP153A6 expression in E. coli, as 
indicated by the CO difference spectral peak at 450 nm (Figure 4.3). In contrast, no 450 nm 
signal was observed for cells harboring the empty pCom8* plasmid. Cytochrome P450s are 
notoriously difficult to express, and it has been reported that the CO binding activity of 




isolated from its native host (21). However, we found CYP153A6 to express well in E. coli 
DH5 and showed a stable CO difference spectrum for hours at room temperature, if protease 
inhibitor was added before cell disruption. Using E. coli BL21(DE3) cells, which are deficient in 
the Lon and OmpT proteases, eliminated the need to add protease inhibitor for stable CYP153A6 
expression. Cell extract from these cultures, expressing CYP153A6 or CYP153A6-BMO1, 
retained full CO-binding capacity for 24 h when stored at 25 °C. At 45 °C, CO-binding capacity 
decreased with time, showing a half-life of 638 + 68 min for cell extract containing CYP153A6-
BMO1 and 367 + 58 min with CYP153A6. 
 
Figure 4.3: CO difference spectra of lysed E. coli BL21(DE3) cell suspensions. E. coli BL21(DE3) 
cultures expressing the CYP153A6 variant were concentrated 5:1 in phosphate buffer, and UV-VIS 
spectra were obtained from the cell-free extracts after CO saturation. The peaks correspond to 0.21 mM 
and 0.17 mM folded P450 for the CYP153A6 and CYP153A6-BMO1 samples, respectively. Cells 
carrying the empty vector treated in the same way served as the negative control.  
The typical concentration of folded CYP153A6 in the cell suspensions used for 
bioconversions was 0.1 – 0.2 M, with CYP153A6-BMO1 usually expressing ~ 20% less than 




concentration after the 60 -min bioconversion reactions. Bioconversion studies showed 
significantly altered activity and selectivity for CYP153A6-BMO1 that closely followed its 
growth complementation performance (Figure 4.4 (A)). Control bioconversions performed under 
the same conditions but using transformants of empty pCom8 vector did not produce alkanols. 
Butane bioconversions yielded an average total of 393 µM 1-butanol in the aqueous phase after 
60 minutes with CYP153A6-BMO1, versus 277 µM with wild-type CYP153A6. From the 
concentration of product formed divided by the concentration of folded P450, the average 
turnover rate of CYP153A6-BMO1 in 1-butanol production was 49 min-1, a 75% increase 
compared to 28 min-1 for CYP153A6. Interestingly, the selectivity for terminal hydroxylation 
also increased with the mutant, from 78% to 89% of total alkanol product. The A94V mutation 
also improved activity and selectivity for conversion of pentane to 1-pentanol, but had the 
opposite effect with propane and octane. 
 
Figure 4.4: Whole-cell bioconversions were carried out with at least two replicates using resting E. coli 
BL21(DE3) cells expressing CYP153A6 (A) and AlkB (B) variants. Relative enzymatic activities in the 
aqueous cell suspension were calculated from the alcohol product formed per minute and the enzyme 
concentration (A) or total cell dry weight (B). The lower graphs represent relative activities for 1-alkanol, 
and the upper part shows 2-alkanol production (if detected). Solely added carbon sources were propane 
(C3), butane (C4), pentane (C5), and octane (C8). White graphs depict wild-type activity, light gray 





Since E. coli cells expressing only AlkB showed no product formation, bioconversions 
were performed using cells transformed with pCom8_alkBFG. Minak-Bernero et al. (27) 
demonstrated that the AlkBFG system including the monooxygenase AlkB and the non-essential 
and essential rubredoxins AlkF and AlkG is functional in E. coli, without the need for the 
rubredoxin reductase AlkT. Results of bioconversions using AlkB, AlkB-BMO1, and AlkB-
BMO2 (Figure 4.4 (B)) showed that the activity of the mutants was greater than that of wild type 
on butane, the substrate used for in vivo evolution, as well as on propane. As with CYP153A6, 
performance on pentane and octane decreased. The evolved mutants also showed increased 
activity on propane, the only change in activity that was not reflected in a similar observable 
change in growth complementation performance. This could reflect an activity that is too low or 
sub-optimal growth conditions during enrichment, such as insufficient substrate concentration or 
toxicity of the substrate.  
In 30 minutes, butane bioconversions utilizing AlkB, AlkB-BMO1, or AlkB-BMO2 
produced on average 630 µM, 1030 µM, and 1580 µM 1-butanol in the aqueous phase, 
respectively. The dry cell weights of the cell suspension used for the bioconversions ranged from 
3.0 to 4.0 g/L. The activities (in µmol 1-butanol min-1 g [cell dry weight] -1) thus increased from 
6.1 to 9.5 and 15.7 units, respectively. Bioconversions with AlkB variants were highly 
regioselective, producing no detectable 2-alkanol from propane and pentane and very little 2-






D.1. Advantages and drawbacks of in vivo evolution of terminal alkane hydroxylases  
An in vivo directed evolution system with selection for terminal alkane hydroxylase 
activity has been developed and applied to engineering enzymes from the AlkB and CYP153 
families. The goal of this work was to increase hydroxylase activity on short-chain alkanes while 
maintaining these enzymes’ remarkable preference for the thermodynamically disfavored 
terminal position, thereby taking a first step toward engineering small-alkane hydroxylases that 
can be expressed in a recombinant bacterial host amenable to further engineering. 
Evolution in vivo using a growth selection enables searches through libraries as many as 
108 mutants in a simple flask culture while exerting selection pressure for many useful enzyme 
characteristics simultaneously (e.g., substrate specificity, regioselectivity, specific activity, 
coupling of cofactor utilization to product formation, and expression level). In this particular 
case, the Pseudomonas host used for the directed evolution only utilizes primary alcohols, 
allowing selection directly for terminal hydroxylation. This is the only method we know of for 
efficient, high throughput selection or screening of this important activity. Previous efforts to 
engineer P450 BM3 or P450cam for alkane hydroxylation resulted in enzyme variants mainly 
targeting energetically favored subterminal positions (18 – 19). The present system promises to 
be useful for the directed evolution of a range of alkane hydroxylases, since P. putida GPo12 
(pGEc47B) can be complemented for growth on alkanes by many different AlkB and CYP153 
genes (15, 22). Furthermore, growth tests showed that the host can utilize a range of 1-alkanols 




This powerful growth selection system could handle a mutation rate perhaps ten times 
greater than the 0.1 to 0.4 nucleotide changes per kb obtained using the mutator strains. The P. 
putida GPo12 organism and the components used in this study, however, are somewhat difficult 
to handle with regards to growth stability, expression, mutation rates, cloning, and 
transformation efficiency. Furthermore, in vivo evolution also has limits for identifying 
moderately improved mutants, since enrichment to pure culture may require weeks or months of 
continuous culturing, depending on the actual doubling time on a given substrate and the level of 
improvement over the parent. This makes the stepwise accumulation of small improvements 
more challenging.  
D.2. Selection for growth on propane and butane improves hydroxylase function  
Our results prove that propane and butane are substrates of AlkB from P. putida GPo1, 
verifying earlier assumptions (3). No growth complementation was observed on ethane, and the 
E. coli system utilized in the bioconversion reactions could not be used to determine whether 
ethane is converted to ethanol by AlkB variants, because the glycerol added to allow NADH 
regeneration was fermented to ethanol by the E. coli BL21(DE3) host. Quantification of AlkB 
activity on ethane would require purification and reconstitution of AlkB and its electron transport 
system or genetic modification of the strain used for whole-cell bioconversions. 
Second-generation variant AlkB-BMO2 supported significantly better growth and butane 
bioconversion, more than double that of wild-type AlkB. Although specific activity (mol 
product/mol enzyme/minute) could not be deteremined for the AlkB variant, absolute 1-butanol 
production rates in bioconversion reactions were significantly higher (up to 1.6 mM in 30 min) 




formation with the AlkB system was surprising, in view of the fact that it relied on a non-native 
E. coli host reductase, while the CYP153A6 system contained the complete native electron 
transfer chain composed by its ferredoxin and ferredoxin reductase. In earlier studies, AlkB 
activity in E. coli cells increased from 3 U to 20 U, when the specific reductase, encoded by 
alkT, was present (6). However, the significantly higher E. coli whole-cell bioconversion rates 
with AlkB variants did not translate into better growth complementation of adapted P. putida 
GPo12 (pGEc47B) strains. It is known that AlkB expresses two-to tenfold better in E. coli than 
P. putida. On the other hand, AlkB has a five- to sixfold-higher specific activity in P. putida (8). 
Thus, a possible explanation for the growth complementation is that CYP153 variants express 
better or have a higher specific activity in P. putida compared to AlkB variants. Futhermore, the 
twice-adapted host Pcyp2 might contain chromosomal improvements that are able to compensate 
for the lower apparent butane oxidation activity of CYP153A6-BMO1 and thus achieve the same 
growth rate on butane as Palk1 expressing AlkB. 
Although no crystal structures are available for any enzyme of the AlkB family, a 
topology model for AlkB (9, 28) has been published. Mapping of the evolved AlkB variant 
mutations onto that model (Figure 4.5 (A)) shows that two of the three mutations generated in 
AlkB-BMO2, V129M and L132V, are close to the histidine-containing sequence motif A 
(H138EXXHK143), which is one of four highly conserved histidine-containing motifs in AlkB 
believed to coordinate the iron ions and presumed to be part of or close to the active site (9, 29). 
Thus, a direct effect of V129M and L132V on the active site of AlkB seems possible. The third 
amino acid substitution, I233V, is located close to the periplasm in the sixth predicted 





Figure 4.5: Models for (A) AlkB and (B) CYP153A6. (A) Topology model of AlkB, taken from van 
Beilen et al. (34). Variants AlkB-BMO1 and AlkB-BMO2 with increased activity on butane carry L132V 
and V129M+L132V+I233V mutations (marked by white circles), respectively. Amino acids 129 and 132 
are close to the first of four histidine-containing sequence motifs (A – D) that contribute to coordinating 
the Fe ions. Position 233 is located in the periplasmic end of the sixth transmembrane domain (numbers 1 
– 6). (B) CYP153A6 structural model with bound substrate octane (spheric object), modified from 
Funhoff et al. (8). CYP153A6-BMO1 carries a mutation corresponding to A97V in the model.  
Evolved CYP153A6-BMO1 is the first CYP153 shown to hydroxylate butane and enable 
its host to grow on this short chain-length alkane. The gaseous alkanes are usually processed by 
distinct, specialized enzymes, like the di-iron methane and butane monooxygenases (2) that are 
unrelated to the cytochrome P450s. Complementation of P. putida GPo12 (pGEc47B) with 
various CYP153 wild-type enzymes resulted in growth on alkanes ranging from pentane to 
decane (15), but never on butane. And, until now, biotransformations using CYP153 enzymes 
have only demonstrated activity for hexane and longer alkanes (13 – 14, 17). Here, we 
demonstrate that CYP153A6 wild type and CYP153A6–BMO1 act on butane and even propane, 
but only the BMO1 variant was able to complement growth of Pcyp2 on butane. The activity for 
1-butanol formation of 49 min-1 (0.8s-1) measured in CYP153A6-BMO1 assay is still less than 
that reported for the methane monooxygenase from Methylosinus trichosporium OB3b (8.8 s-1) 




does CYP153-BMO1 exhibit increased total activity on butane compared to its wild-type parent, 
but its preference for terminal hydroxylation also increased, resulting in only 11% 2-butanol 
formation compared to 22% for the wild-type enzyme. CYP153A6-BMO1 was converted into a 
genuine butane monooxygenase by in vivo-directed evolution. 
CYP153A6-BMO1 contains a single amino acid substitution, which corresponds to 
A97V in the published structure model (13). This mutation, which has a slightly negative effect 
on expression level (the CYP153A6-BMO1 variant usually showed ~ 80% of the CO-binding 
activity of the wild type) stabilized CYP153A6 and nearly doubled its half-life at 45 °C. 
However, this effect is unlikely to explain the higher observed bioconversion rates, since both 
enzymes were stable at 25 °C, and no loss of folded P450 was observed at the end of the 
bioconversions. These findings argue for a direct positive effect of the A97V substitution on the 
butane hydroxylation activity. Based on a proposed model of CYP153 (13), however, A97 is 
predicted to be located in a loop distant from the active site, pointing toward the protein surface 
and not the substrate channel (Figure 4.5 (B)). Why the activity of CYP153A6 and CYP153A6-
BMO1 on propane, as observed in the E. coli bioconversion experiments, is not accompanied by 
growth complementation of Pcyp2 on propane remains unknown. A minimum activity required 
for growth may not have yet been reached. It is also possible that the substrate is not available at 
a sufficient concentration or is toxic.  
The appearance of improved variants of AlkB and CYP153A6 demonstrated that in vivo 
evolution in adapted P. putida GPo12 (pGEc47B) can be applied to very different 
monooxygenase enzymes. Despite the higher absolute activity and better regioselectivity of 




important advantages for further engineering. CYP153 enzymes are soluble, and accurate 
determination of functional expression and concentration is easier due to observable CO binding. 
Furthermore, CYP153 proteins have been shown to function in whole-cell bioconversions as 
single-component, self-sufficient fusion proteins with the P450RhF reductase domain (17, 31). 
Further directed evolution of terminal alkane hydroxylases like AlkB or CYP153A6 should help 
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In continuing directed evolution of P450 BM3 for small alkane hydroxylation, we 
developed a high-throughput screen to directly assay for P450 alkane hydroxylation activity. 
With the use of a pressurizable 96-well reactor, the P450 alkane hydroxylation reaction was 
conducted in high throughput and the alcohol product was quantified spectroscopically by a 
coupled enzyme assay utilizing 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) as a 
horseradish peroxidase (E.C. 1.11.1.7) substrate to detect hydrogen peroxide generated by 
alcohol oxidase (E.C. 1.1.3.13) oxidation of the product alcohol. Applying this screen to 370 
P450 variants generated in our laboratory, we identified variant E31 (WT-A74L-V78I-A82L-
A184V-L188W-A328F-A330W) as the best candidate for further engineering. Through 
subsequent rounds of site-saturation and random mutagenesis, multiple variants supporting 1,700 
– 4,000 ethane TONs were identified. Recombination of the identified mutations generated 
variant E31-D140E-L215P-T436R supporting 5,800 ethane TON. However, none of the BM3 
variants were able to produce ethanol or methanol in whole-cell alkane bioconversions using 
growth-arrested E. coli BL21 (DE3) cells. In contrast, CYP153A6, a natural terminal alkane 
hydroxylase, was able to produce ethanol in whole-cell alkane bioconversions. The inability of 
BM3 variants to produce ethanol in vivo reflects their poor affinity for ethane and indicates they 






Selective hydroxylation of small alkanes is a long-standing problem for which few 
practical catalysts are available (1 – 3).  The lack of such catalysts that can convert gaseous 
alkanes into transportable liquid commodities has been a barrier to broader utilization of these 
resources (4). While this transformation has been achieved only by a limited set of transition-
metal – based catalyst systems (5 – 7), a variety of alkane hydroxylases found in alkanotrophic 
microorganisms support this reaction at ambient conditions using oxygen as the oxidant (8). 
Unfortunately, since most of these hydroxylases function as a part of a larger enzyme complex 
and are membrane associated, their potential for industrial applications is limited. For these 
reasons, we have been engineering well-expressed, soluble, bacterial cytochrome P450 
monooxygenases for small gaseous alkane hydroxylation. 
Our previous protein engineering efforts have been focused on shifting the substrate 
specificity of both a self-sufficient P450 fatty acid hydroxylase from Bacillus megaterium 
CYP102A1 (BM3) (9) and a natural P450 medium-chain alkane hydroxylase from 
Mycobacterium sp. HXN-1500 CYP153A6 (A6) (10) to accept smaller alkane substrates. Using 
a variety of mutagenesis techniques and screening for activity on surrogate substrates such as 
dimethyl ether (DME) (11), BM3 variants with propane and ethane hydroxylation activity have 
been generated (12 – 14). Similarly, a variant with improved butane hydroxylation activity was 
obtained from A6 using random mutagenesis and a growth-based selection (15). While rapid 
improvements for the activities directly under selection pressure, DME demethylation and 
terminal butane hydroxylation, were observed in the isolated variants, activity improvements for 




demethylation activity with propane hydroxylation activity as measured by turnover number 
(TON) (r = 0.74) was much better than that with ethane hydroxylation activity (r = 0.52). 
Because of this difference in the correlation of activities, only relatively small improvements for 
ethane hydroxylation were obtained, while a complete shift in substrate specificity from fatty 
acids to propane was achieved through the application of the DME demethylation screen. 
Similarly, the growth-based selection used in the in vivo directed evolution of A6 also showed a 
poor predictability for substrates not under selection (15). For example, the isolated variant 
CYP153A6-BMO1 with improved activity for terminal hydroxylation of butane actually 
displayed diminished activity for propane hydroxylation.  
The importance of the screen or selection to apply the desired selection pressure in 
directed evolution experiments has been well documented (16 – 18). Therefore, to continue 
protein engineering of P450s for hydroxylation of even smaller substrates ethane and methane a 
more suitable screen or selection is necessary. In this chapter, we describe the development of a 
high-throughput screen for terminal alkane hydroxylation activity using a pressurizable 96-well 
reactor to conduct the P450 reaction in high throughput and a coupled enzyme assay for 
colorimetric quantification of the alcohol product. Applying this screen to 370 BM3-derived 
variants generated in our laboratory, including variants from the alkane hydroxylation lineage 
(11 – 14), SCHEMA-guided chimeragenesis (19 – 21), and variants evolved for various drug 
compounds (22 – 23), we identified variant E31 (WT-A74L-V78I-A82L-A184V-L188W-
A328F-A330W) as the best candidate for further engineering. Subsequent rounds of random and 
site saturation mutagenesis with screening for ethane hydroxylation generated variants with 1.5 




C. Results and Discussion 
C.1. High-throughput ethane hydroxylation assay development 
To apply selection pressure for ethane and methane hydroxylation in our laboratory 
evolution of P450s, a variety of small molecules was evaluated as surrogate substrates. High 
throughput screens were developed based on P450 oxidation of dichloromethane, chloromethane, 
and methanol (see Appendix C). In each instance, activity for these compounds was not a better 
predictor for ethane hydroxylation activity than DME demethylation. Ultimately, we pursued 
screening for ethane and methane hydroxylation directly using a pressurizable 96-well reactor 
system from Symyx (Santa Clara, CA) to conduct the P450 alkane reaction in high throughput. 
To quantify the alcohol product colorimetrically, the P450 reaction was first coupled to an 
alcohol oxidase (AO) reaction that converts the alcohol product to one equivalent of hydrogen 
peroxide and one equivalent of an aldehyde. In a second reaction, horseradish peroxidase (HRP) 
oxidizes 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) to its green radical cation 
using the hydrogen peroxide generated by the AO reaction. Thus, quantification of the alcohol 
product can be achieved spectroscopically with UV/Vis absorbance at 420 nm (24). The 
substrate scope of this assay is limited by the substrate affinity of AO, which accepts terminal 
linear alcohols with methanol as its preferred substrate (25). 
Figure 5.1 summarizes the reactions of the screen and illustrates the sensitivity of the 
screen with both ethanol and methanol standards. Following the screening conditions detailed in 
Chapter 8.E.4, the spectroscopic (A420nm) responses to methanol and ethanol are 0.011 A420nm/µM 




difference in alcohol sensitivity reflects the twofold higher substrate affinity (KM) of AO for 
methanol compared to ethanol (26). 
 
 
Figure 5.1: The high throughput alkane hydroxylation assay: (a) The coupled enzyme reaction scheme of 
the assay. (b) Assay sensitivity with methanol and ethanol standards 
To validate the assay’s ability to accurately quantify P450 ethane hydroxylation 
reactions, we selected twelve BM3 variants with various ethane activities and tested each variant 
for ethane hydroxylation as both cell-free extract and purified enzyme. To generate even more 
variety in ethanol yields, each variant was assayed at three different enzyme concentrations. The 
resulting ethanol product was quantified by both GC-FID as detailed in Chapter 8.H.2 and the 
coupled enzymatic assay. Ethanol quantifications were in good agreement between the two 
methods, with an R2 of 0.96 based on linear regression of the data, see Figure 5.2. The slope of 
the regression, 1.20, indicates that the ABTS assay underestimates the ethanol yield in the 






throughput colorimetric assay is as precise as GC-FID in evaluating the ethanol yield of P450 
reactions. 
 
Figure 5.2: Comparison of ethanol quantification by GC-FID with enzymatic colorimetric assay 
C.2. BM3 variants ethane hydroxylation evaluation 
We applied this screen to evaluate BM3 variants that have accumulated in our lab from 
various projects for ethane and terminal propane hydroxylation activity. Previously, each variant 
needed to be purified and evaluated individually using GC-FID, which severely limited the 
number of variants that could be characterized. With the colorimetric assay, hundreds of variants 
can be evaluated in parallel as cell-free extracts. To this end, we selected 194 BM3 variants from 
the P450PMO alkane hydroxylation lineage (11 – 14), including a thermostabilized derivative 
AB2 (P450PMO-C47R-I94K), thermostable chimeras of BM3 with its homologues (20), BM3-
derived chimeras displaying a wide range of substrate activities (19, 21), and variants generated 
during evolution of BM3 for terminal alkane hydroxylation (27). In addition, 88 variants from 
each of the CRAM and Corbit libraries (Chapter 3) were also selected based on their DME 




A total of 370 variants were tested as cell-free extracts in at least duplicate for both 
ethane hydroxylation and terminal propane hydroxylation. None of the selected variants 
supported significant 1-propanol production in the assay (> 50 M product), while 26 variants 
were identified to be active for ethane hydroxylation, producing at least 45 M ethanol (see 
Table 5.1). None of the 55 chimeras of BM3 were found to hydroxylate ethane, which was not 
surprising, since these enzymes were never selected for this activity. Of the 26 active variants, 
six were from the PMO lineage: PMO, 7-7, 1-3, 53-5H, 35E11, and AB2, supporting ethane 
TON ranging from 440 to 1,260 in cell-free extracts. Two ethane-hydroxylating variants isolated 
from the reduced CASTing library detailed in Chapter 3, WT-A82L-A328V and WT-A82L-
A328L, were also identified by the screen.   
In addition to these known ethane-hydroxylating variants, WT-V78F-A82S-A328F and 
WT-V78T-A82G-A328L, which were generated by grafting only the active site mutations of 
variants 53-5H (14) and 77-H9 (14) onto wild-type BM3, were also found to support 180 and 
210 ethane TONs, respectively. Although 53-5H shows a threefold increase in ethane TON as 
compared to WT-V78F-A82S-A328F, both variants produce the same amount of ethanol,  since 
the improvement in activity was offset by a decrease in protein expression. The remaining 16 






Table 5.1: Ethane hydroxylating BM3 variants identified by the high-throughput screen 











PMO lineage 1-3 0.64 81 1,070 150 
PMO lineage 7-7 1.31 229 1,260 50 
PMO lineage AB2 0.93 154 1,110 180 
PMO lineage PMO 1.00 155 940 60 
PMO lineage 53-5H 0.46 50 530 20 
PMO lineage 35-E11 0.41 45 440 70 
Reduced CASTing 
Library WT-A82L-A328V 0.76 109 390 50 
Reduced CASTing 
Library WT- A82L-A328L 0.72 73 220 20 
WT-779H WT-V78T-A82G-A328L 0.58 52 210 60 
WT-53-5H WT-V78F-A82L-A328V 0.47 45 180 40 
CRAM library CB8 0.52 49 300 20 
CRAM library CD7 0.55 54 410 60 
CRAM library CG2 0.74 92 610 100 
CRAM library CE4 0.58 61 630 20 
CRAM library CA3 0.60 64 670 100 
CRAM library CA4 0.55 54 760 110 
CRAM library E78 0.84 111 930 40 
CRAM library E41 0.73 90 960 140 
CRAM library E30 0.86 114 980 90 
CRAM library E66 0.94 131 1,020 70 
CRAM library CF2 1.27 195 1,070 140 
CRAM library E32 1.00 142 1,350 20 
CRAM library E31 1.28 198 1,860 30 
Corbit library OD7 0.67 77 670 70 
Corbit library OD2 0.55 55 500 80 
Corbit library OE5 0.45 45 250 40 
a Ethane reactions contained ca. 100 nM protein, alkane saturated potassium phosphate buffer, and an 
NADPH regeneration system containing 100 μM NADP+, 2 U/mL isocitrate dehydrogenase, and 10 mM 






 From these 26 variants, we selected variant E31 (WT-A74L-V78I-A82L-A184V-
L188W-A328F-A330W) as the parent for further directed evolution for ethane hydroxylation. It 
not only displayed the highest ethane TON in the cell-free extract assay, but also had a higher 
thermostability than wild-type BM3 with a  half-denaturation temperature (T50), the temperature 
at which the enzyme retains 50% of its activity after a 15 minute incubation, of 56.2 oC 
compared to 54.5 oC for wild-type BM3. In comparison, the thermostabilities of other candidates 
from the PMO lineage with comparable A420nm such as 7-7 (T50 = 44.2 oC) or AB2 (T50 = 48.9 
oC) were much lower.  
To further validate the high-throughput ethane hydroxylation screen, we applied the assay 
across a 96-well plate containing E. coli cultures expressing variant E31. Using 20 µL of cell-
free extract in the P450 reaction, which corresponds to ca. 120 nM of enzyme, an average TON 
of 1,830 was obtained with a coefficient of variance (CV) of 33% (see Figure 5.3 (a)). Increasing 
the enzyme loading of the reaction by using 40 µL of cell-free extract marginally increased the 
amount of ethanol product (from 230 µM to 310 µM) and resulted in 1,230 TON (CV of 24%). 
This decrease in TON with increased enzyme loading indicates that the P450 reaction with 40 µL 
cell-free extract is no longer limited by enzyme activity but rather by the depletion of a reactant, 
most likely oxygen (11). Therefore, the improvement in CV is merely an artifact of the reaction 
reaching a saturating limit rather than a systematic improvement of assay precision. Based on 
these results, 20 µL of cell-free extract were used in P450 reactions for the screening of E31 and 





Figure 5.3: Ethane hydroxylation validation with monoclonal E31 plate: (a) 20 L cell-free extract in 500 
L reaction (ca. 120 nM P450), (b) 40 L cell-free extract in 500 L reaction (ca. 240 nM P450) 
C.3. Random mutagenesis of variant E31 for ethane hydroxylation 
Following validation of the high-throughput ethane hydroxylation screen with the 
monoclonal 96-well plate of variant E31, both random mutagenesis and active site saturation 
mutagenesis were pursued to improve ethane hydroxylation activity. For random mutagenesis, an 
error-prone PCR library using the gene encoding variant E31 as template was constructed with a 
commercial mutagenic polymerase, Mutazyme II ®. Following the supplied protocols, a library 
with an average nucleotide substitution rate of 3.7/protein was obtained using 100 ng of template 
DNA. From screening 2,640 variants of this library for ethane hydroxylation activity, we 
obtained two variants, 24F8 (E31-E140D, L215P, P454S) and 22H11 (E31-D222E, A289E) with 
1.6- and 1.5-fold increased ethane TON, respectively.  
Surprisingly, the ethane TON of the purified enzymes was found to be significantly lower 
than the observed TON in the cell-free extract screening (see Table 5.2). This decrease in 
enzyme activity with purification contradicts our previous experience, in which propane TON is 
generally higher with purified enzymes compared to cell-free extracts (11). The most likely 




cell-free extract as compared to purified enzymes. To expedite the CO-binding assay on a 96-
well plate scale, the reducing agent, sodium hydrosulfite, is added to the enzyme solution before 
exposure to carbon monoxide (28). Since sodium hydrosulfite is unstable and reacts with oxygen 
to generate superoxide and hydrogen peroxide, which are deleterious to both the P450 and its 
heme prosthetic group (29), the inevitable protein/heme degradation may result in 
underestimation of the actual amount of P450 used in the screening reactions. 
Table 5.2: Ethane TON of select variants as cell-free extract and purified enzyme 
Variant Ethane TON Cell-free extract a CV (%) b Purified enzyme a  CV (%) b 
E31 1,830 32.8 1,200 15.4 
22H11 2,200 27.3 1,800 14.9 
24F8 3,400 24.2 1,900 13.2 
a TON determined as nmol product/nmol enzyme. Ethane reactions contained ~ 100 nM protein, alkane saturated 
potassium phosphate buffer, and an NADPH regeneration system containing 100 μM NADP+, 2 U/mL isocitrate 
dehydrogenase, and 10 mM isocitrate (see Chapter 8.E.4 for experimental details). 
 b CV determined as the ratio of the standard error over the mean determined from four replicate reactions. 
All five mutations found in these two variants occur at surface-exposed residues outside 
of the active site. Mutations L215P and D222E are located in the G helix, adjacent to residues 
that are part of substrate recognition site three of type II P450s (30). However, the side chains of 
these two residues are oriented away from the active site and do not appear to interact with the 
residues known to alter P450 substrate specificity. While the L215P mutation should disrupt the 
packing of this helix, rationalizing of how such an effect would lead to improved activity is 
difficult.  
Due to the high mutation rate of the error-prone PCR library, these variants are carrying 
multiple mutations, which are unlikely to all be beneficial. To eliminate potential neutral and 
deleterious mutations, a recombination library allowing all five mutations and the corresponding 




polymerase chain reaction (SOE-PCR) (31). From screening 90 clones of this library with 32 
unique members (94% completeness), we found two variants with improved ethane 
hydroxylation activity compared to variant 24F8. These two variants, RA1 (E31-D140E-L215P-
D222E) and RD2 (E31-D140E-L215P), supported 2,100 and 2,200 ethane TON, respectively. 
Variant RD2 is variant 24F8 without the P454S mutation, which appears to be deleterious for 
ethane hydroxylation activity.  Variant RA1 recombined the two mutations of RD2 with D222E 
from 22H11, this latter mutation also appears to be deleterious since the activity of RA1 is 
diminished compared to RD2. The thermostabilities of variants 24F8, RA1, and RD2 were 
determined to select a parent for the next library. Surprisingly, the T50s of all three variants, 49 – 
51 oC, were significantly lower than that of the parent, variant E31 (56 oC). This large decrease 
in thermostability was reminiscent of the introduction of the L188P mutation in the PMO 
evolutionary lineage (T50 = -3 oC), which also replaced a leucine in a -helix with a proline.  
Without significant differences in thermostability between these variants, we constructed 
a second error-prone PCR library with the gene encoding RD2 as the template using Taq 
polymerase (32). From screening 2,640 members of this library with an average nucleotide 
substitution rate of 4.3/protein, variant 20D4 (RD2-D432G) was found with a 1.8-fold 
improvement in ethane hydroxylation activity. The D432G mutation occurs in the 4 sheet, close 
to G443A mutation identified in the PMO evolutionary lineage (33). This mutation would disrupt 
existing hydrogen bonds of D432 with Y429, E430, and E442, which could destabilize the 
folding of the beta-sheet. The importance of this beta-sheet structure for P450 function lies in 




transport chain (34). In these two rounds of random mutagenesis, an overall 3.3-fold increase in 
ethane TON was achieved from variant E31 (1,200 TON) to variant 20D4 (4,000 TON).  
C.4. Active site site-saturation mutagenesis of variant E31 for ethane hydroxylation 
In addition to the random mutagenesis, ten active site residues of variant E31 were also 
targeted for site-saturation mutagenesis. Because variant E31 was isolated from the CRAM 
computationally designed library, which mutated ten active site residues allowing two amino 
acids at each position, it already contained seven active site mutations: A74L, V78I, A82L, 
A184V, L188W, A328F, and A330W. Instead of mutating many of these previously targeted 
residues again, we selected the targets for mutagenesis accounting for the sequence consensus of 
the ethane hydroxylation variants of the CRAM library. The ethane-hydroxylating CRAM 
variants displayed significant amino acid preference (> 70% representation) for F at position 87, 
L at position 75, W at position 188, and W at position 330. Therefore, these four positions were 
not mutated. Thus the ten residues targeted for saturation mutagenesis were composed of the six 
remaining targets from the computationally-guided libraries, A74, L75, V78, A82, A184, and 
A328, and residues in regions of the active site not mutated in E31, A263, I264, T436, and L437. 
Residues A263 and I264 are located in the I helix which constitutes the surface of the active site 
opposite to the B’ helix that contains residues 74, 75, 78, and 82. T436 and L437 are in the 4 
sheet, which contains mutations previously found to be beneficial for small alkane hydroxylation 
in the PMO evolutionary lineage (33).  
These ten site-saturation libraries were constructed with SOE-PCR and screened to 94% 
completeness for ethane hydroxylation. Differences between the fraction of folded variants of 




mutational tolerance at these residues of E31 compared to wild-type BM3. Of the six libraries 
constructed with both enzymes (A74, L75, V78, A184, and A328), the fraction of folded variants 
decreased from an average of 0.95 with wild-type BM3 to 0.67 with variant E31. The single 
largest decrease occurred at position A82, for which the wild-type BM3 tolerated all possible 
mutations, but the equivalent E31 library contained only 36% of folded variants. Since both 
enzymes have similar thermostabilities, this decrease in mutational tolerance indicates that the 
active site of E31 is much smaller or more rigid than wild-type BM3, such that many more 
mutations result in steric clashes with neighboring residues.  
From these site-saturation libraries, we identified four variants with mutations L74R, 
I78W, T436L, and T436R, supporting 1,700 – 2,600 ethane TON. Of the libraries targeting the 
six residues that were previously subjected to mutagenesis, only two (L74R and I78W) of the 
120 total possible mutations were found to be beneficial. The lack of beneficial mutations at 
residues L82, V184, and F328 implies that these amino acids are the best solutions for ethane 
hydroxylation activity in the context of the remaining E31 mutations. Two of the four beneficial 
mutations introduced a positively charged arginine into the active site. The introduction of amino 
acids with charged side-chains into the active site also occurred in the PMO lineage and has been 
hypothesized to separate the active site volume into distinct pockets (33). The other two 
beneficial mutations, I78W and T436L, introduced bulkier amino acids, continuing the trend of 
volume-reducing mutations. 
C.5. Recombination of active site mutations with mutations from error-prone PCR libraries 
Using variant RD2 as the parent, the beneficial mutations for ethane hydroxylation 




recombined. Variant RD2 was selected as the parent, since its mutations have already been 
shown to be beneficial through a prior round of recombination. In addition, its mutations E140D 
and L215P are distant from the active site, which should reduce the probability of the mutations 
interacting during recombination. In contrast, the mutation identified in the second round of 
random mutagenesis, D432G, lies in close proximity to active site residue T436. By including 
this mutation in the recombination library, this residue was allowed to revert to the wild-type 
amino acid, which would avoid potential conflicts with mutations at T436. Starting with RD2, a 
recombination library allowing mutations L74R, I78W, T436L, T436R, D432G, and the 
corresponding wild-type amino acid at each position was constructed using SOE-PCR and  
screened for ethane hydroxylation to 94% completeness. From this library, we identified variant 
RD2-T436R (E31-D140E-L215P-T436R), supporting 5,800 ethane TON, as the most active 
variant.  
C.6. Whole-cell alkane bioconversions  
Having increased the ethane TON nearly fivefold from E31 to E31-D140E-L215P-
T436R, we next tested these variants for their ability to produce methanol in in vitro methane 
hydroxylation reactions. None of variants generated from E31 were able to produce detectable 
amounts of methanol (> 2 M) in these reactions. From our previous work with P450PMO 
(Chapter 2) and CYP153A6 (Chapter 4), we demonstrated that the alcohol yield of P450 whole-
cell bioconversions supported with a continuous supply of alkane and oxygen can reach up to 15 
mM of alcohols (12). Since the product yields of these whole-cell bioconversions are generally 




the ethane hydroxylation variants in whole-cell bioconversions for small alkane hydroxylation, 
including methane. 
Using growth and expression conditions outlined in Chapter 8.K.1, propane 
bioconversions were first conducted with selected variants with PMO and CYP153A6 as controls 
to verify their viability in whole-cell bioconversions and to monitor the background ethanol 
fermentation under reaction conditions (see Figure 5.4). All six variants were able to produce 
propanol with activities ranging from 19 to 120 U/mol P450, where 1 U = 1 mol product/min. 
While we did not explicitly evolve variants RD2, 20D4, and RD2-T436R for improved propane 
hydroxylation activity, their in vivo propane hydroxylation activities are correlated with their in 
vitro ethane hydroxylation activities. The best ethane-hydroxylating variant RD2-T436R was 
nearly sixfold more productive than PMO for in vivo propane hydroxylation. GC-FID analysis of 
these propane bioconversions showed only an average of 52 + 10 M of ethanol was produced, 
which indicates minimal background ethanol fermentation. 
 





When the alkane source of the bioconversions was switched from propane to ethane with 
all other conditions unchanged, none of the cells containing BM3-derived variants were found to 
produce ethanol above background levels. The only P450 with in vivo ethane hydroxylation 
activity was CYP153A6, with a yield of 340 + 80 M ethanol after 30 minutes, corresponding to 
an activity of 8.7 U/µmol P450. None of the P450s were able to produce detectable amounts of 
methanol in methane bioconversions.  
The lack of in vivo ethane hydroxylation activity of BM3 variants with in vitro ethane 
hydroxylation activity is perplexing considering that the same variants were able to produce 
propanol under identical conditions. This discrepancy may be due to the presence of other P450 
substrates such as indole (35 – 36) or endogenous fatty acids that compete with the alkane during 
the whole-cell reactions but are absent during the in vitro reactions. The presence of the indole 
reaction is readily apparent by the visible formation of indigo over the course of the whole-cell 
reactions and the presence of other endogenous substrates is suggested by an increased rate of 
cofactor consumption when purified enzymes are assayed in the presence of cell lysate (data not 
shown). 
 
D. Conclusion and Future Directions 
Using a high throughput screen for P450 ethane hydroxylation, we have found variants 
with improved in vitro ethane hydroxylation through both random and site-saturation 
mutagenesis. However, the inability of even the most active variant, RD2-T436R, to hydroxylate 
ethane in whole-cell bioconversions reflects a poor affinity for ethane and highlights the gap 




Although the lack of in vivo ethane hydroxylation is a discouraging outcome in measuring the 
progress of BM3 evolution, it does not eliminate the possibility that a BM3-derived variant can 
support in vivo ethane or methane hydroxylation. Iterative rounds of random and target 
mutagenesis that were applied in this chapter can be continued to further improve the in vitro 
ethane hydroxylation activity. However, CYP153A6, which already hydroxylates ethane as a 
natural, promiscuous function and supports ethane whole-cell bioconversion may be a better 
starting point for the engineering of a P450-based methane monooxygenase.  
The drawbacks of engineering CYP153A6 are (1) it is a type I P450 with its reductase 
components expressed as separate enzymes, and (2) no crystal structure has been solved for any 
of the CYP153 family members. For these reasons, we initially pursued the in vivo selection- 
based evolution of CYP153A6 as described in Chapter 4. However, it is clear that the growth-
based selection is inefficient at applying selection pressure to improve enzyme activity, as 
plasmid and strain adaptations were obtained with equal frequency as enzyme mutations. To 
engineer CYP153A6 for ethane and methane hydroxylation activity, a suitable high throughput 
screen is necessary. One option is to apply the ethane/methane hydroxylation screen described in 
this chapter and supply the reductase components through either co-expression or addition as 
purified enzymes. Another applicable screen is the dehalogenation of iodomethane, which 
releases formaldehyde that can be quantified colorimetrically by Purpald®.  
The lack of a CYP153A6 crystal structure is perhaps a bigger barrier for protein 
engineering, since the application of the many targeted mutagenesis techniques described in 
Chapter 3 would not possible. While a homology model of CYP153A6 based on the CYP101 




largely solvent-exposed in the model. Therefore, solving the crystal structure of CYP153A6 or 
obtaining a suitable homology model should be pursued with a high priority. Until such 
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We investigated five P450s for the ability of their active heme-ferryl oxidant to hydroxylate the 
104.9 kcal/mol C-H bond of methane within their native active site configuration, using terminal 
oxidants to circumvent the substrate binding activation of dioxygen in the P450 catalytic cycle. 
We found that the soluble cytochrome P450 from Mycobacterium sp. HXN-1500, CYP153A6, 
hydroxylates methane with 0.05 turnovers using iodosylbenzene as the oxidant. The methanol 
product of the iodosylbenzene reaction was validated by isotope labeling using13CH4 and H218O. 
Attempts to demonstrate this activity under turnover conditions (NADH/O2) in reactions utilizing 
reconstituted reductase proteins were unsuccessful. We attribute this to the low methane binding 
affinity of CYP153A6, which does not exhibit a spin-shift in the presence of methane. In 
contrast, CYP153A6 was found to support both ethane hydroxylation and iodomethane 






Selective methane conversion to a liquid fuel such as methanol remains one of the great 
challenges in hydrocarbon chemistry (1). Thus far, only a few catalyst systems utilizing 
transition metals, such as platinum or gold dissolved in specialized environments such as 
concentrated acid solvents, are capable of this transformation (2 – 3). For a variety of reasons 
including catalyst cost, reaction medium toxicity, catalyst poisoning by oxidized products, and 
low activity, none of these catalysts are practical (4). Methane monooxygenases (MMOs) found 
in methanotrophic bacteria (5) appear to be ideal catalysts for this reaction, as they convert 
methane to methanol at rates up to 220 min-1 using oxygen at ambient conditions (6). However, 
despite decades of research, these enzymes have yet to be functionally expressed in heterologous 
hosts (7 – 8). For these reasons, we and others have been engineering another class of enzymes, 
cytochrome P450s (P450s), which shares a similar C-H bond activation mechanism as MMOs 
and utilizes similar high-valent iron oxygen species as the active oxidant, for small alkane 
hydroxylation with the ultimate goal of achieving methane oxidation (9 – 13). In contrast to 
MMOs, which are only found in methanotropic bacteria, P450s are ubiquitous across all 
kingdoms of life. Of the more than 11,500 known P450s (data source: 
http://drnelson.utmem.edu/CytochromeP450.html as published in August 2009), none has been 
shown to naturally hydroxylate methane.  
Using both directed evolution and rational design, propane and ethane hydroxylation 
activities have been successfully engineered with two different P450s, CYP102A1 (BM3) (14) 
and CYP101 (P450cam) (13). However, activity for methane remained elusive. Methane presents 




the initiation of the P450 catalytic cycle, which normally occurs upon the displacement of a 
distal water ligand as the result of substrate binding, and (2) the formation of the active radical 
[(Porp)+.FeIV=O]+, known as Compound I (CMP I), which requires substrate-induced water 
expulsion from the active site. These challenges are faced for any poorly fitting non-natural 
substrate, albeit magnified by the small size and apolar nature of methane. The strength of the 
methane C-H bond, however, presents a unique challenge to the oxidizing potential of CMP I.  
From density functional theory (DFT) calculations, the transition state for the H-atom 
abstraction presents the largest barrier in the oxygen insertion reaction of CMP I (15). For 
methane, this barrier height is 26.7 kcal/mol, which is significantly higher than the ca. 19 
kcal/mol barrier for substrates such as camphor or propane’s secondary C-H bond, or even the 
21.6 – 21.8 kcal/mol barriers for ethane and the terminal propane C-H bond (16 – 19). As a 
comparison, this transition state barrier has been calculated to be as low as 13.8 kcal/mol for 
sMMO acting on methane (20).  
The complete absence of methane oxidation activity in numerous BM3 variants evolved 
for propane and ethane hydroxylation activity led us to question if the P450 CMP I can overcome 
the 26.7 kcal/mol barrier needed to abstract the hydrogen of the methane C-H bond. In this 
chapter, we separated the substrate binding problem presented by the small size of  methane from 
the challenge of the higher activation barrier presented by the methane C-H bond by assaying the 
reactivity of CMP I directly through terminal oxidant-supported P450 reactions. Using 
iodosylbenzene (PhIO), 3-chloroperoxybenzoic acid (MCPBA), and hydrogen peroxide (H2O2), 




CYP153A6 BMO-1(21), to hydroxylate alkanes ranging from methane to octane was 
determined.  
BM3 and P450cam were selected because they have been engineered to hydroxylate 
alkanes as small as ethane (9, 13). PMO is a laboratory-evolved BM3 variant, which exhibits 
wild-type like coupling and catalytic efficiency for propane as its preferred substrate. A6, a 
natural P450 alkane hydroxylase which prefers medium-chain-length alkanes, and its laboratory-
evolved variant CYP153A6 BMO-1 with improved butane hydroxylation activity (21) were 
chosen for their ability to hydroxylate medium-chain-length alkanes at the terminal position. In 
PhIO-supported reactions, CMP I is formed directly, while a ferric hydroperoxo complex (CMP 
0) is formed in reactions with peroxides. The generation of CMP I from this complex requires 
protonation at the distal oxygen followed by heterolytic O-O bond cleavage (Figure 6.1).  
 
Figure 6.1: Reaction scheme for PhIO and peroxide-supported alkane hydroxylation 
From these terminal oxidant-supported P450 reactions, we found A6 and A6 BMO-1, to 
be able to break the methane C-H bond supporting 0.05 and 0.02 turnovers, respectively, using 
PhIO as the oxidant. This demonstrates both the feasibility of P450 methane oxidation and the 




P450 active sites for small alkane oxidation. By chemically generating the active radical, we 
eliminated the requirement for substrate binding to initiate P450 catalysis, which enabled us to 
determine the innate substrate range of each P450 active site.     
Recently, P450 methane hydroxylation has also been demonstrated with wild-type BM3 
through the utilization of perfluoro carboxylic acid additives (22). This “chemical tuning” 
approach apparently resolves the aforementioned challenges of methane as a P450 substrate 
through the generation of a catalytically active enzyme complex with reduced active site volume 
using an inert molecule as an external trigger to initiate catalysis. This study also demonstrates 
that the barrier for P450 methane oxidation is poor activation of the P450 catalytic cycle due to 





C. Results and Discussion 
C.1. P450s alkane hydroxylation using terminal oxidants 
Given the inherent destructive nature of the terminal-oxidant supported reaction for both 
the enzyme and heme prosthetic group and the likely low efficiency of the oxidation reaction 
with small alkane substrates, we elected to use a much larger quantity of enzyme (100 M) in 
these reactions than previous studies (1 – 2 M) (23 – 24). Only the hydroxylase domain of each 
P450 was used since terminal oxidant-supported reactions do not require heme iron reduction.  
Each enzyme was purified through a three-step purification and lyophilized prior to use (see 
Chapter 8.C for details). The reactions were initiated by the addition of oxidants to pre-incubated 
mixtures of enzymes and substrates, following previously established protocols (23 – 25).  
The results of the alkane hydroxylation reactions supported by terminal oxidants are 
summarized in Table 6.1. In general, PhIO-supported reactions resulted in higher product yields 
than peroxide-supported reactions with a few exceptions where yields were similar. This 
difference highlights uncoupling at CMP 0 as one of the difficulties in the hydroxylation of non-
natural substrates. With preferred substrates, substrate binding expels water from the active site 
such that the protonation of CMP 0 only occurs through the proton transport chain, resulting in 
CMP I formation (26). In contrast, the binding of poorly fitting, non-natural substrates, such as 
small alkanes, does not fully expel water from the active site, and protonation can occur at the 




Table 6.1: Alkane hydroxylation by P450s utilizing terminal oxidants 
 product formed, mol (mol P450)-1 a  
Substrate BM3 PMO P450cam A6 A6 BMO-1
 PhIO MCPBA H2O2 PhIO PhIO MCPBA H2O2 PhIO MCPBA H2O2 PhIO 
Methane -b - - - - - - 0.05 (0.02) - - 0.02 (0.01) 
Ethane - - - - - - - 2.5  0.34  0.23 2.1  
Propane 1.0  0.35  0.30 0.77 0.83 0.78  0.96  3.9 1.6  0.41 3.0 
Hexane 1.7  0.35  0.31 0.76 0.53 0.38 0.06  0.48 0.57  0.24 n.d.c 
Octane 1.4  0.12  0.20 0.29 0.31 0.22  0.07 (0.02) 0.51  0.15 0.30 n.d. 
aAlkanes (2.5 mM, or saturated at 20 psi) were incubated with P450 (100 M) and terminal oxidant (5 mM) at 25 oC for 10 min. The data represent the averages 
of at least two experiments and do not correct for P450 destruction; standard errors are within 20% of the reported average with exceptions given in parentheses. 
b Dash indicates a lack of detectable amounts of product. 




Wild-type BM3 and P450cam were found to hydroxylate alkanes as small as propane 
using all three oxidants producing only sub-terminal alcohols. This indicates that alkanes as 
small as propane can be properly oriented near CMP I in the native active sites for oxidation to 
occur. In the case of BM3, under turnover conditions (NADPH/O2), alkane hydroxylation has 
been observed only for hexane and nothing smaller. The lack of activity for the smaller alkanes 
under turnover conditions is solely due to poor substrate binding, which results in insufficient 
activation of the catalytic cycle and uncoupling at CMP 0. PMO exhibits the same substrate 
range as BM3 with similar TON for propane using terminal oxidants. This indicates that the 
laboratory evolution from BM3-to PMO-enabled propane binding to both activate the catalytic 
cycle and generate CMP I efficiently without changes in H-atom abstraction reaction, i.e., the 
reaction between CMP I of BM3 and PMO with propane, remain the same. The readiness of 
BM3’s CMP I to react with propane may also explain the ease with which propane hydroxylation 
activity was obtained from BM3 through various mutations (Chapter 3).  
A6 was found to hydroxylate all alkane substrates, even methane, with PhIO as the 
oxidant. This demonstrates that direct methane-to-methanol conversion by a P450 heme 
porphyrin catalyst at ambient conditions is possible and does not necessarily require the use of 
additional effectors to alter the active site geometry. With PhIO as the oxidant, A6 is able to 
hydroxylate methane with 0.05 TON. This low TON shows that although methane can be 
oxidized by A6, it is a poor substrate with minimal reactivity even in the presence of a pre-
generated CMP I.  The A6 methane TON is 50-fold lower compared to A6 ethane TON, which 
may reflect poor binding of methane in the active site compared to ethane, since the generation 
of CMP I is substrate-independent. The higher methane C-H bond strength (104.9 vs. 101.0 




and H2O2 did not yield detectable methanol product. Considering the low yield of the methane 
reaction with PhIO and the general trend of peroxide reactions being less efficient, the absence of 
methanol product in these reactions could be due to the limited ability to detect the product (2.0 
M, corresponding to a signal-to-noise ratio of 3). Surprisingly, reactions with the preferred 
substrates of A6, hexane and octane, yielded far less product as compared to reactions with 
ethane and propane. This may be the result of competition between these preferred substrates and 
PhIO for active site access. Finally, CYP153A6 BMO-1 also exhibited methane oxidation with 
PhIO, but with only 0.02 TON. Its propane TON also decreased compared to A6 from 3.9 to 3.0, 
which reflects the diminished activity observed under turnover conditions. Since CYP153A6 
BMO-1 was only selected for growth complementation on butane, this loss of activity for smaller 
alkanes is a consequence of natural drift as these activities were not under direct selection (28).  
In PhIO-supported reactions of A6 and PMO with hexane and octane, slightly different 
regioselectivities were observed compared to those obtained under turnover conditions, whereas 
reactions with BM3 and P450cam displayed similar regioselectivities to those observed under 
turnover conditions. For A6, 1-hexanol and 1-octanol were obtained with > 95% selectivity 
under turnover conditions, but in PhIO-mediated reactions, significant sub-terminal products 
were generated: 34% for hexane and 46% octane. In contrast, PMO produces 2-hexanol and 2-
octanol with > 90% selectivity in NADH/O2 supported reactions, but in PhIO-mediated reactions 
24% of 1-hexanol and 30% of 1-octanol were produced. Regioselectivity differences between 
PhIO-supported and NADPH/O2 supported reactions have been reported for several substrates 
(29) and suggest there are differences in active site packing between PhIO- and NADH/O2-
supported reactions. These differences could be the result of lingering iodoarene in the active site 




conditions, substrate binding precedes CMP I formation, which may allow the substrate to orient 
in the preferred conformation, whereas in PhIO-supported reactions, the CMP I species is 
generated in the absence of the substrate. In A6 PhIO-supported reactions with propane, 1-
propanol was produced with a similar regioselectivity (35%) as the NADH/O2 supported 
reaction (41%). Propane hydroxylation may be less sensitive to differences in active site packing 
between PhIO- and NADH/O2-supported reactions since it already occurs with low 
regioselectivity.      
13C and 18O labeling experiments were conducted to verify the carbon and oxygen 
sources of the methanol product generated in PhIO reactions with A6. Reactions with 13C 
methane produced an m/z 33 ion peak unique to 13C-methanol, which corresponds to a +1 m/z 
shift of the major 12C-methanol ion of m/z 32 (see Appendix D). This result confirms the carbon 
source of the methanol product to be the supplied methane gas. Quantification against authentic 
13C-methanol standards showed A6 produced 0.035 + 0.009 TON with 13C-methane. To confirm 
the oxygen source of the methanol product, we took advantage of the fact that CMP I generated 
with PhIO undergoes oxygen exchange with solvent water (30), such that solvent oxygen 
incorporation is a hallmark of the reaction mediated by PhIO. Reactions in the presence of 50% 
H218O also produced an m/z 33 ions peak corresponding to a +2 m/z shift of the m/z 31 ion of 
12C-methanol, unique to 18O-methanol. Quantification for 18O incorporation was not possible due 
to the low yield and the presence of a mixture of 16O- and 18O-methanol products. As a general 
comparison for the PhIO reaction with A6, ethane reactions in the presence of 50% H218O 
resulted in a 50% decrease in 16O ethanol, which suggest nearly quantitative 18O incorporation, 
which is in good accordance with literature values (25). These results confirm the obtained 




C.2. A6 alkane hydroxylation under turnover conditions  
 Convinced that the A6 CMP I can hydroxylate methane, we investigated A6 for 
oxidation of methane and other alkanes under turnover conditions utilizing reconstituted A6 
reductase proteins. For the in vitro A6 alkane hydroxylation reactions, its reductase components, 
ferredoxin reductase (fdrA6) and ferredoxin (fdxA6) were purified following literature protocols 
established for the purification of putidaredoxin and putidaredoxin reductase of P450cam (31), 
which share 44% and 43% sequence identity with the ferredoxin and ferredoxin reductase of A6. 
The isolated proteins were quantified using known extinction coefficients for their FAD and 
[Fe2-S2] cofactors (31) and characterized for electron transfer activity using cytochrome c 
reduction (32).  
An optimum ratio of reductase components of 1:1:10 for A6:fdrA6:fdxA6 was 
determined from octane hydroxylation reactions and used for subsequent experiments (see 
Appendix D). At this ratio of reductase components, the substrate-free cofactor consumption rate 
was only 3 – 5 min-1. In the presence of octane, the rate of cofactor consumption reaches ca. 80 
min-1, which is significantly lower than that of typical bacterial P450s, which often reaches 
1,000s min-1 (33), but is consistent with the rates of other natural alkane hydroxylases acting on 
their preferred substrates: sMMO ca. 220 min-1 on methane (6), AlkB ca. 150 min-1 on octane 
(34), and butane monooxygenase ca. 36 min-1 on butane (35). The rate of octanol formation was 
found to be 75 min-1, which is slightly higher than the reported value for the same activity 
determined with A6 in P. putida GPo12 cell extracts (36). Reactions with ethane at 20 -psi 
headspace pressure resulted in ethanol formation rates of 32 min-1, but reactions with both 12C-




The absence of A6 methane hydroxylation activity under turnover conditions can be 
rationalized by a lack of CMP I formation during the reaction, analogous to the lack of wild-type 
BM3 propane hydroxylation under turnover conditions. P450 catalysis is initiated by substrate 
binding, which displaces the distal water ligand inducing a spin-shift from the low spin resting 
state to a catalytically active high spin state (37). For A6, this spin-shift is indicated by UV/Vis 
difference spectra (38) and is observed for alkanes as small as ethane, but is absent for methane 
(Figure 6.2). This lack of spin-shift in the presence of methane demonstrates the absence of CMP 
I formation as a barrier for catalysis under turnover conditions.  
 
Figure 6.2: Alkane induced spin-shift of A6 as determined at saturation by absorbance difference between 
A392 and A418. The percentage of high-spin content was determined relative to the spin-shift induced by the 
preferred substrate octane. For gaseous substrates, the spin-shift was determined with 40 -psi head-space 
pressure. For liquid alkanes, the spin-shift was determined with 1 mM substrate in a 1% ethanol solution. 
To gain more insight into the differences in A6-catalyzed oxidation of a preferred 
substrate vs. a smaller, non-natural substrate, the kinetic parameters (KM and kcat) and the kinetic 
isotope effect (KIE) were determined for the oxidation of hexane, octane, and the dehalogenation 
of iodomethane (Table 6.2). Attempts to characterize ethane hydroxylation kinetics were 
unsuccessful, as saturating kinetics were not observed over the pressure range investigated (see 
























because it possesses both a molecular size and a C-H bond strength (102.9 kcal/mol) 
intermediate of those of methane (104.9 kcal/mol) and ethane (101.0 kcal/mol). The liquid form 
of iodomethane offers the additional benefit that saturating kinetics can be observed. From the 
preferred substrate octane to iodomethane, a 50-fold increase in KM from 0.32 mM to 17.7 mM 
was observed. Surprisingly, there was only a small difference in the kcat values for these two 
substrates, 75 min-1 for octane vs. 58 min-1 for iodomethane. The overall 70-fold decrease in 
catalytic efficiency from 3.9x103 M-1s-1 for octane to 55 M-1s-1 for iodomethane is thus largely 
due to the higher KM.  
The kinetic isotope effect (KIE) of a P450 reaction, determined by comparing the 
reaction rate of deuterated and non-deuterated substrates, can indicate if the C-H bond activation 
is the rate-limiting step in catalysis. Since a C-D bond has lower vibrational frequency compared 
to a C-H bond, it has a lower zero point energy. As a result of this lower ground state energy, the 
deuterated substrate has a higher activation barrier for reaction, which would produce a slower 
reaction rate if breaking of the C-H bond is rate-limiting. For the preferred A6 substrates hexane 
and octane, KIEs of near unity were observed. This indicates the reaction of CMP I with these 
substrates is not rate-limiting under turnover conditions, which is expected, as the second 
electron transfer step is generally rate-limiting for P450s acting on their preferred substrates (39). 
In contrast, a KIE of 5.8 was observed for iodomethane dehalogenation, which demonstrates that 
the H-atom abstraction reaction has become rate-limiting. A KIE of 5.8 falls within the classical 
limit and indicates an absence of hydrogen atom tunneling, which has been suggested to occur 
during sMMO oxidation of methane (40). As a comparison, a similar KIE of 6.4 has been 
observed for P450cam hydroxylation of (1R)-5,5-difluorocamphor (41). By blocking the preferred 




when the oxidation occurs under unfavorable geometries. The higher mobility of iodomethane 
within the A6 active site may have a similar effect such that the substrate C-H bond is not 
properly oriented near CMP I for reaction.  
Table 6.2: A6 alkane hydroxylation under turnover conditions 









Methane a 0 n.d.b n.d. n.d. n.d. 
Iodomethane c 58 (5.1)   17.7(1.4) 55 42 5.8 
Ethane a 61 (8.3) n.d. n.d. 74 n.d. 
Hexane c 98 (7.0) 0.78 (0.04) 2.1x103 96 1.0 
Octane c 75 (7.2) 0.32 (0.02) 3.9x103 98 1.0 
a Reactions contained 0.5 M A6, 0.5 M FdrA6, 5 M FdxA6,1 mM NADH, in 0.1 M phosphate  buffer, 
pH 8.0 under alkane atmosphere with head-space pressure ranging from 20 – 60 psi. Ethane kcat  and 
coupling were determined at 40 psi head-space pressure, corresponding to the maximum rate of ethanol 
formation observed. b n.d.–not determined. cReactions contained 0.5 M A6, 0.5 M FdrA6, 5 M 
FdxA6,1 mM NADH, the substrate in 2% ethanol and 0.1 M phosphate buffer, pH 8.0. The data represent 
the averages of three replicates; values in parentheses are the standard errors. 
In conclusion, we have demonstrated the use of terminal oxidants for evaluating the 
innate substrate specificity of P450s, independent of the requirement for substrate binding to 
initiate catalysis. Using this assay, we were able to show that CMP I of A6 can support methane 
oxidation, just as the CMP I of BM3 is poised for propane oxidation, despite the fact that neither 
activity is observed under turnover conditions. This result confirms that the methane C-H bond 
of 104.9 kcal/mol can be oxidized by a P450 and suggests that A6 can be a good starting point 
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Herein we demonstrate that a small panel of variants derived from cytochrome P450 
BM3 from Bacillus megaterium covers the breadth of reactivity of human P450s by producing 
12 of 13 mammalian metabolites for two marketed drugs, verapamil and astemizole, and one 
research compound. The most active enzymes support preparation of individual metabolites for 
preclinical bioactivity and toxicology evaluations. Underscoring their potential utility in drug 
lead diversification, engineered P450 BM3 variants also produce novel metabolites by catalyzing 
reactions at carbon centers beyond those targeted by animal and human P450s. Production of a 
specific metabolite can be improved by directed evolution of the enzyme catalyst. Some variants 
are more active on the more hydrophobic parent drug than on its metabolites, which limits 
production of multiple-hydroxylated species, a preference that appears to depend on the 






Selective C-H oxidation represents one of the great challenges for which synthetic 
chemists find only substrate-specific solutions (1 – 4). Breakthroughs in selective C-H oxidation 
methodology could benefit drug discovery, among other fields, by enabling rapid and parallel 
analog construction for a specific molecular scaffold. Such improvements in efficiency would 
greatly increase the number and variety of compounds that could be produced and raise the 
likelihood of identifying effective therapeutic agents.  
Many synthetic strategies for C-H oxidation rely on a reactive intermediate that plays 
upon subtle differences in C-H bond strength (1–5 kcal mol-1) to achieve regioselectivity (5). 
Owing to the large number of C-H bonds in most bioactive chemicals, identifying a reagent that 
can react at one C-H bond in preference to all others can be difficult, or even impossible. Nature 
solves the selectivity problem by incorporating discrete molecular recognition elements into 
enzyme catalysts so that they can use specific enzyme–substrate interactions to impart reactivity 
to a specific C-H bond. 
Cytochromes P450 (CYPs) are a large superfamily of heme-containing C-H oxidation 
enzymes. In humans, CYPs play key roles in drug metabolism and clearance. An ability to 
predict how potential pharmaceuticals will be metabolized will better equip us to identify 
derivatives with improved biological activity, solubility, toxicity, stability, or bioavailability (6). 
In fact, FDA guidelines indicate that uniquely human metabolites and metabolites present at 
disproportionately higher levels in humans as compared to the animal species used during 
standard toxicology testing may require safety assessment before beginning large-scale clinical 




Preparation of these metabolites at sufficient scale for evaluation is not trivial and often 
requires a de novo synthesis for each metabolite. Biosynthetic methods that employ purified 
human CYPs or crude liver microsomes are not much better, because human CYPs are poorly 
stable, membrane-bound, multi-component protein systems that generally exhibit low reaction 
rates. As an alternative to using human CYPs as biocatalysts for metabolite production, we and 
others have focused on soluble, bacterial P450 BM3 (also known as CYP102A1) (8) as a C-H 
oxidation platform (9 – 11). Derived from Bacillus megaterium, P450 BM3 has properties that 
greatly facilitate its engineering and use in synthesis: it can be expressed at high levels in E. coli 
(~ 12% dry cell mass), and, unlike nearly all other CYPs, its hydroxylase, reductase, and 
electron-transfer domains are all in one contiguous polypeptide chain. This last feature might 
contribute to its relatively high activity (> 1,000 turnovers per min) on its preferred fatty acid 
substrates (8). Like most CYPs implicated in anabolic pathways, P450 BM3 is substrate specific, 
and hydroxylates a C20 fatty acid over a C12 fatty acid with more than 200-fold higher efficiency 
(12). 
We chose three structurally diverse drug compounds with known patterns of mammalian 
CYP-dependent clearance to evaluate whether P450 BM3 variants can catalyze similar C-H 
oxidations. Verapamil is a calcium channel blocker used in the treatment of hypertension and 
arrhythmia (13). Astemizole is a potent H1-histamine receptor antagonist used for treatment of 
common sinus allergy symptoms (14). The third compound, LY294002, is an antiproliferative 
agent that inhibits phosphatidylinositol 3-kinase, a target with potential for treatment of 
malignancies (15). We report here that a small collection of P450 BM3 variants can produce 
nearly all the known human (or rat) metabolites for each of the three drugs. Within each set of 




activities suitable for preparative scale synthesis. We also identified variants that generate 
metabolites not produced by rat liver microsome controls or known to be human metabolites; the 





C. Results  
C.1. Selection of P450 variants  
From our extensive collections we selected 120 P450 BM3 variants that had previously 
demonstrated activity on substrates not in the wild-type enzyme’s repertoire. These variants were 
constructed by using a variety of commonly implemented genetic diversification techniques, 
including error-prone PCR and targeted mutagenesis of active site residues. We also included 
variants derived from structure-guided recombination of BM3 and its homologs, CYP102A2 and 
CYP102A3 (16). These enzymes had been selected based on their activities toward a variety of 
substrates, including straight-chain alkanes, cycloalkanes, alkyl ethers (17 – 19), aromatic 
compounds (20), derivatives of fatty acids (21), and drug compounds (10, 22). 
We also distinguished between enzyme variants that function as monooxygenases and 
use NADPH to reduce the catalytic FeIII center and peroxygenases that contain only the heme 
domain and use H2O2 in place of O2 and NADPH. Each has its own catalytic and operational 
advantages and disadvantages that have been described elsewhere (21). Although we had 
evidence that the presence of a reductase domain impacts activity favorably (20), we were unsure 
what effect, if any, this domain would have on regioselectivity. The variants, their sequences 
relative to wild type, and the criteria for their prior selection from mutant libraries are described 
in Appendix E. 
C.2. Reactions with human and bacterial CYPs  
Verapamil and astemizole undergo extensive biotransformation by the major human 
CYPs to produce demethylated and dealkylated products (23) by hydroxylation of activated 




conducted with rat liver microsomes in vitro indicate that LY294002 metabolism is confined to 
single- and double- alkyl hydroxylations of the morpholine ring (Table 7.3), a pattern also 
observed in other drugs possessing this moiety. Reactions of the 120 P450 BM3 variants with 
each of the three drugs were assessed by HPLC. Metabolite products were evident in the HPLC 
traces for a significant number of variants (43 exhibited some activity on verapamil, 42 on 
astemizole, and 18 on LY294002); the metabolites and their distributions were subsequently 
characterized by using LCMS and MS/MS. Metabolite structure assignments were aided by 
comparison of MS and MS/MS spectra with spectra of known metabolites obtained in our 
laboratory using rat microsomal systems. 
C.3. Verapamil 
 Table 7.1 summarizes the performance of selected enzymes on verapamil (all 43 active 
enzymes and their product distributions are listed in Appendix E). For example, entry 4 displays 
the activity of chimera 22313333 on verapamil. It converts 34% of the starting material into an 
assortment of products, the distribution of which is 41% 2, 15% 5, 20% 6, 9% 7, and 15% 10. 
Variants 2C11 and 9C1 furnished the widest array of products, with six and eight individual 
metabolites, respectively. In particular, 9C1 produced several metabolites that had undergone 
two hydroxylation events (1, 4, and 8). Variant 22313333 (entry 4) was the only enzyme capable 
of producing double hydroxylation product 5, while 32313233 (entry 6) best produced 
norverapamil (3). Interestingly, the addition of a reductase as a fusion to the 32313233 heme 
domain (entry 7) rendered the enzyme unable to produce new metabolite 7. Variant 7-11D (entry 
13) differs by no more than two mutations from the variants in each of entries 9–12, but its 




was the most active, with conversions exceeding 30% (entries 9–12), and produced metabolite 7 
with excellent selectivity. 
Table 7.1: Conversion of verapamil to: (a) its most abundant[a] human metabolites, and (b) new 
metabolites by different P450 BM3 variants 
 
Variant[b] % Conversion 1 2 3 4 5 6 7 8 9 10 
1 2C11 25  8 28   20 8  8 28 
2 9C1[c] 31 3  29 3  6 13 3  12 
3 D6H10 78   26 8  31    24 
4 22313333 34  41   15 20 9   15 
5 22313231 43  46    33 5   16 
6 32313233 24   50   21 13   17 
7 32313233-R1 25   40   44    16 
8 21312332 6   17   33 17   33 
9 9-10A A78F 30  10     83    
10 9-10A A82L 51      2 94    
11 9-10A F87L 49      6 94    
12 12-10C 34   6   6 79  3  
13 7-11D 21   28   29 14   29 
[a] Defined as > 1% abundance following oral 14C verapamil administration in humans (23).  
[b]
 Variants shown in italics were selected for activity on propranolol (22),  variants in bold are 
chimeras (16), variants in normal type were selected for activity one alkanes (18 – 19) chimeras 
were written according to fragment composition: 32313233-R1, for example, represents a protein 
that inherits the first fragment from parent CYP102A3, the second from CYP102A2, the third 
from CYP102A4 and so on. R1 connotes a fusion to the reductase domain from parent A1. 
Chimera fusions were used as monooxygenases; chimera heme domains were used as 
peroxygenases. 
[c]
 Because not all P450 BM3 oxidation products could be identified, product distribution totals 
can be less than 100%. 
The enzymes that best mimicked human CYP reactivity on verapamil were derived from 
two variant families. Three had been isolated by directed evolution for activity on propranolol 




metabolites were derived from the alkane-hydroxylating 9-10A variant (18 – 19). These enzymes 
catalyzed a new regioselective demethylation reaction at position R4 and a new benzylic 
oxidation at position R3. Even without optimization of the reaction conditions, some enzymes 
were highly active on verapamil; D6H10 (entry 3), for example, transformed verapamil into 
metabolites at 78% conversion and a total turnover number (TON) greater than 1500. 
The enzymes possess contrasting degrees of regioselectivity. Some were unselective and 
produced a spectrum of metabolites (e.g., propranolol-evolved enzymes 2C11, 9C1, D6H10). By 
contrast, chimera 22313231 produced metabolite 2, chimera 32313233-R1 made dealkylated 
compound 6 (entries 5 and 7), and many variants produced new metabolites 7 and 10 (entries 8–
13) with sufficient selectivity (> 30%) for larger scale production without further optimization. 
To demonstrate that useful quantities of metabolites can be produced, we used purified 9-10A 
F87L to produce metabolite 7 (9.4 mg) from verapamil (25 mg) in 39% yield (1560 TON, 0.025 
mol% catalyst).  
C.4. Astemizole  
Activity of the enzyme panel on astemizole resulted in the seven metabolites described in 
Table 7.2 (all 42 active enzymes and their product distributions are listed in Appendix E). 
Variants DE10, 21313311, 22313333, and 32313233 (entries 1–3 and 9) produced dealkylated 
metabolite 14 in preference to other compounds. The identity of the residue at position 78 had a 
strong impact on the product distribution within the 9-10A backbone; mutations A78F, A78T, 
and A78S (entries 4, 5, and 12) produced metabolites 11, 13, and 15 as the most abundant 
respective products. Furthermore, 41-5B (entry 8), a 9-10A family member that contains the 




A82S, and 9-10A F87L both produced metabolite 13 in good yield and selectivity (entries 6 and 
7). Two chimeric monooxygenases, 32313233-R1 and 32312333-R1 (entries 10 and 11), were 
effective in generating new aromatic hydroxylation product 15. 
Table 7.2: Conversion of astemizole to: (a) its most abundant[a] human metabolites, and (b) new 
metabolites by different P450 BM3 variants 
 
Variant[b] % Conversion 11 12 13 14 15 16 17 
1 DE10 9    56    
2 21313311 10 20   40   40 
3 22313333 9 22   56   22 
4 9-10A A78F 21 48  38   14  
5 9-10A A78T 27 37 7 44   4  
6 9-10A A82S 30 20 7 70   3  
7 9-10A F87L 36  3 88   6  
8 41-5B 5 100       
9 32313233 11    45 27  27 
10 32313233-R1 16    13 69   
11 32312333-R1 78    4 67  9 
12 9-10A A78S 15 13 7   80   
13 9-10A A82L 49 24    61 4  
14 9-10A A82I 32 31 6 63     
15 9-10A F87A 31   23 16 45   
[a] Defined as > 1% abundance following oral 14C verapamil administration in humans (25)  
[b] See Table 7.1 for further explanation of variant nomenclature. 
The 9-10A-derived monooxygenases were the most adept at producing human 
metabolites of astemizole (entries 4–8). However, these enzymes were unable to dealkylate 
astemizole and produce metabolite 14. Oxidation of this more hindered C-H bond was best 
accomplished by the propranolol active variants and chimeric peroxygenases (entries 1, 2, and 3, 




chimeric BM3 enzymes to produce 17. A second benzimidazole site was hydroxylated (as 
demonstrated by metabolites 15 and 16), which is different from that observed in human 
metabolites 12 and 13. Discrimination of these sterically and electronically identical sp2 C-H 
bonds is virtually impossible by using traditional transition metal catalysts and emphasizes the 
power of molecular recognition as a regiocontrolling element. 
Small changes in the substrate channel can affect the regioselectivity of aromatic C-H 
oxidation. For instance, the presence and position of a single methyl group in Thr78 vs. Ser78 
(entry 5 vs. 12) and Ile82 vs. Leu82 (entry 14 vs. 13) were sufficient to bias oxidation at C6 
instead of at another position on the benzimidazole ring. Product 16 has undergone two 
oxidations. Although this metabolite was observed in reactions with ten variants, it was produced 
in greater than 10% abundance by only one variant (entry 4). New metabolite 15 is a candidate 
for scale-up and could be produced at high conversion (> 25% selectivity) by 15 variants of 
different lineages (Table E.4 in the Appendix E). Even without optimization of reaction 
conditions, several enzymes showed good activity towards astemizole. Variant 32312333- R1, 
for example, converted 78% astemizole into metabolites (70 TON). 
C.5. LY294002  
The most abundant metabolites of LY294002 produced by rat liver microsomes are 
detailed in Table 7.3. Both single hydroxylation products 19 and 20 were identified in BM3-
variant reactions with very good regioselectivity. Aminoalcohol 18 is the sole metabolite of all 
three drugs not observed in the reactions. Derivative 18 requires two oxidations and might not 




Table 7.3: Conversion of LY294002 by different P450 BM3 variants into the most abundant[a] 
metabolites produced by rat liver microsomes 
 
Variant[b] % Conversion 18 19 20 
1 9-10A L75I 10  50  
2 9-10A A78S 7  71  
3 9-10A F87V 6   100
4 9-10A T260S 11  9  
5 68-8F 9  11  
[a] Define as > 1% abundance following in vitro reaction of LY294002 with rat liver microsomes.  
[b] Variants in normal type were selected for activity on alkanes (18 – 19).  
The P450s catalyzing the single hydroxylations were monooxygenases derived from 9-
10A (Table 7.3). Although several variants could produce metabolite 19, only 9-10A F87V 
oxidized the other position of the morpholine ring and made derivative 20 (entry 3). The 
remaining twelve metabolite-producing variants were also monooxygenases of both 9-10A and 
chimeric origin, and produced a metabolite with Mw=238; this indicates morpholine loss and 
addition of water to the bis-aryl backbone. In all cases, LY294002 conversion was very low (< 
15%) and correlated with the low rat liver microsome conversion for LY294002 (40%) relative 
to microsome activity on verapamil (85%) and astemizole (85%). LY294002 better evades both 
mammalian and bacterial P450-catalyzed C-H oxidation than verapamil and astemizole under the 
same conditions. 
C.6. Activities on singly-hydroxylated metabolites 
 Of the twelve mammalian metabolites produced by the P450 BM3 variants, eight were 




optimization (2, 3, 6, 11, 13, 14, 19, and 20). Of the seven new metabolites to which structures 
could be assigned, four were made with sufficiently high regioselectivity to enable preparative 
scale production (7, 10, 15, and 17). All eleven of the highly produced metabolites arose from 
single oxidations. Seven of the eight remaining metabolites are the products of two or more 
oxidations and are present as minor components in mixtures with the singly-hydroxylated 
products. Of the 69 individual reactions that underwent appreciable conversion (> 10% drug 
consumed) only five generated products of multiple C-H oxidations in > 10% abundance.  
The remainder contained single-oxidation products, including mixtures of singly-
oxidized species. The lack of bishydroxylated products could reflect a regiochemical effect in 
which the second C-H site is less reactive. In this case, one of the two possible single-
hydroxylation products would be favored. Sixteen variants produced only one single-
hydroxylation product; reaction mixtures from ten additional variants contained two (metabolites 
were present in 1:1 to 3:1 ratios in 6/11 reactions). It is also possible that the relative lack of bis-
hydroxylation products reflects discrimination on the part of the enzymes in which the BM3 
binds and hydroxylates the parent drug in preference to its metabolites. Because BM3-catalyzed 
C-H oxidation increases polarity by either unmasking heteroatoms or formally substituting 
hydrogen with a hydroxyl group, production of polyhydroxylated metabolites could be 
disfavored, for example, if the enzyme prefers a more hydrophobic substrate.  
To assess enzyme activity on the metabolites produced by a single oxidation, all 120 
enzymes were incubated with purified demethylated metabolites norverapamil (3) and 
desmethylastemizole (26) (11). Product distributions and extents of reaction were determined by 




regioselectivities were unchanged; this indicates that the metabolite and parent drug bind in 
similar orientations. Comparison of each enzyme’s activity on the parent drug and the associated 
metabolite showed that enzymes from the alkane-evolved 9-10A lineage tended to be more 
active on astemizole and verapamil than on their metabolites (true of 49 out of 55 active 
enzymes; Table 7.4).  
Table 7.4: Preference for more hydrophobic parent drug over its metabolite depends on 
evolutionary history of the variant. 
P450 Variant family Number of P450s more active on parent drug 
Number of P450s more active 
on metabolite 
Alkane-selected lineage 48/55 6/55 
Propranolol-selected and 
chimera lineages 18/30 12/30 
Because neither the N-methyl group of verapamil nor the O-methyl group of astemizole 
is the preferred site for C-H oxidation by the alkane-evolved variants, this bias could reflect a 
preference for the more hydrophobic substrate. In contrast, when this pairwise reaction matrix is 
analyzed across the propranolol-evolved and chimeric P450 BM3 lineages, there is no statistical 
difference from random at the 95% confidence interval (0.43 < p = 0.60 < 0.77). 
C.7. Directed evolution can improve metabolite production 
None of the 120 members of this catalyst panel had been selected for activity on any of 
the three drugs. Thus, any initial activity represents a promiscuous activity; such side activities 
are often easy to improve by directed evolution (27 – 28). Of the 103 enzymes that reacted with 
these substrates, 9-10A F87L possessed the best combination of activity and regioselectivity 
(Table 7.2, entry 7); its reaction with astemizole, which produces metabolite 13 with 88% 
selectivity. We screened 2,000 variants made by error-prone PCR of the 9-10A F87L gene using 




sequences with improved metabolite production (Table 7.5). The new variants improved the 
conversion to 51–52% while preserving high regioselectivity (~ 80% for metabolite 13). 
Table 7.5: Production of astemizole metabolites by 9-10A F87L variants 
Variant % Conversion % Selectivity 13
1 9-10A F87L 34 88 
2 E4D D68G 51 80 
3 C205R D338G 51 80 
4 E4D H92Q 52 75 
 
D. Discussion 
A small, 120-member panel of P450 BM3 variants captured nearly all of the mammalian 
P450 scope of reactivity by producing 12 of 13 known metabolites. In their ability to mimic 
human CYPs, the P450 BM3 variants demonstrated considerable versatility, activating C-H 
bonds of varying strength (90–105 kcal mol-1) and steric encumbrance (sp2 vs. sp3 and 1o vs. 2o 
carbon centers). We were able to assign structures to seven new metabolites (Table 7.1 (b), 7.2 
(b)), all of which have undergone oxidation at new carbon centers.  
Cytochrome P450 enzymes are versatile catalysts, the biological activities of which are 
encoded in a wide range of primary sequences. The 26 CYPs, for which the crystal structures 
have been solved, possess as little as 15% sequence identity (30), but share a highly conserved 
fold. Emphasizing the versatility of the P450 fold, P450cam and P450cin catalyze the oxidation 
of isosteres camphor and cineole. Although the substrates are nearly identical, the two enzymes 
differ not only in sequence (27% identity), but also in the structure of their active sites, most 
notably a complete lack of the B’ helix in P450cin (31 – 32). Whereas large changes in sequence 




For example, CYP2A4 and CYP2A5 differ by only eleven amino acids, yet catalyze 
hydroxylations on structurally dissimilar coumarin and testosterone substrates (33) .  
Only 57 human enzymes (34) are responsible for known CYP-dependent drug 
metabolism, and a single enzyme, CYP3A4, accounts for > 50% of the burden for xenobiotic 
CYP-mediated clearance (35). Because CYPs can be broadly or narrowly specific, we and others 
have speculated that it should be possible to take advantage of the high native activity of P450 
BM3 and use mutation to either relax or shift its substrate specificity in order to generate useful 
C-H oxidation catalysts (11, 36 – 39). For example, BM3 variant 9-10A, which is 13 mutations 
away from the wild type, exhibits broad activity across short- and medium-chain alkanes—
activity that is low or completely absent in its wild-type parent (18 – 19). Furthermore, 9-10A 
could be respecialized to hydroxylate propane, preferring it over alkanes that differ by a single 
methylene group (40). We also showed previously that a variant of 9-10A was able to 
hydroxylate drug-like compounds efficiently and selectively (10). Here, we wanted to determine 
whether variants of 9-10A and other BM3-derived enzymes could cover or even exceed the 
broad substrate range of mammalian CYPs. Within any catalyst panel, both extremes of 
regioselectivity can be useful: enzymes that already possess the desired selectivity can be used to 
produce individual metabolites, whereas less selective enzymes can be used to survey metabolite 
possibilities. Both can serve as starting sequences for directed evolution to enhance activity or 
tune selectivity. That a systematic and general evolutionary algorithm can be used for catalyst 
improvement is a particularly appealing aspect of DNA-encoded reagents. Complementary 
optimization studies used in traditional synthesis methods usually rely on chemical intuition to 




When we examined conversion of the parent drug versus its demethylated metabolite, we 
noted that one enzyme family consistently converted more of the parent drug than the 
demethylated and more polar metabolite. These enzymes tend to catalyze single hydroxylations, 
while enzymes evolved for activity on propranolol and the chimeric variants often catalyze bis-
hydroxylations. Structure–activity relationships of this type should help in the future to select 
enzymes that are most likely to react with as-of-yet-untested substrates and could also help 
predict product profiles. 
E. Conclusion 
This panel should enable rapid identification and production of relevant quantities of the 
human metabolites of drug candidates for pharmacological and toxicological evaluations in 
preclinical species (41 – 42). Although we have highlighted the potential of these enzymes to 
accelerate preparation of metabolites for pharmacological and toxicological testing, this enzyme 
panel is likely also to be useful further upstream in the drug-development process as general 
reagents for lead diversification. Reagents that rely on molecular recognition will always be 
restricted in their scope of use. However, because the functionality of small molecules is not 
evenly distributed across all possible molecular architectures (43), it should be worthwhile to 
engineer P450-derived reagents that are active on privileged scaffolds that reside in these densely 
functional regions of structure space. The plurality of C-H sites targeted by this small P450 BM3 
variant set—including and extending human P450 metabolism—augurs well for the development 
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All chemicals, including liquid alkanes and product standards, were purchased from 
Sigma-Aldrich (St. Louis, MO). Solvents (hexanes, chloroform, methylene chloride) were 
purchased from EMD (Gibbstown, NJ). Ethane (99.95% or 99.99%), propane (99.5 %), dimethyl 
ether (99.8%), and methane (99.5%) were purchased from Special Gas Services (Warren, NJ) 
and Airgas (El Monte, CA). Methane (99.0%), ethane (99.99%), propane (99.975), butane 
(99%), and gaseous halomethanes, chloromethane (99.8%), and bromomethane (99.5%) were 
purchased from Sigma-Aldrich. NAD+, DL-isocitric acid trisodium salt, and recombinant 
isocitrate dehydrogenase used as an NADPH regeneration system in experiments described in 
Chapters 2 – 4 were purchased from Sigma-Aldrich. NADP+ and NADPH were also purchased 
from Codexis, Inc. (Redwood City, CA). Recombinant isocitrate dehydrogenase was also 
purchased from OYC, Inc. (Azusawa Japan). Alcohol oxidase, horse radish peroxidase, and 
ABTS used in ethanol and methanol detection assays in experiments described in Chapters 3 and 
5, were purchased from Sigma-Aldrich. Restriction enzymes (BamHI, SacI, EcoRI, NdeI, XhoI, 
KpnI) and T4 DNA ligase were purchased from New England Biolabs (Ipswich, MA), Taq DNA 
polymerase from Roche (Indianapolis, IN), Pfu turbo DNA polymerase from Stratagene (La 
Jolla, CA), and Phusion DNA polymerase from Finnzymes (Woburn, MA). Isopropyl β-D-1-
thiogalactopyranoside (IPTG) was purchased from MP Biomedicals, Inc. (Aurora, OH). 
B. Expression of P450s 
B.1. BM3 holoenzymes (Chapters 2, 3, 5, and 7) 
The P450 BM3 gene was cloned downstream of a double tac promoter of the expression 




to introduce a SacI site 130 bp upstream of the end of the heme domain and a KpnI site at 81 bp 
downstream of the end of the heme domain to facilitate cloning of heme libraries. Escherichia 
coli Dh5 cells transformed with the plasmids containing P450 BM3 and its derived variants 
were used for the expression on both 50 – 500 mL scales as well as in 96-well plates. For protein 
production, terrific broth (TB) medium containing 100 g/ml ampicillin was inoculated with an 
overnight culture at 1:500 dilution for shake flask cultures and 1:20 dilution for 96-well plates. 
The cultures were initially incubated at 37 oC and 250 rpm for 4.5 hours, and after cooling to 25 
oC, expression was induced by the addition of a mixture of IPTG (1 mM) and δ-aminolevulinic 
acid hydrochloride (δ-ALA; 0.5 mM). The cultures were harvested by centrifugation at 4 oC and 
5,000 rpm for 10 min 20 to 24 hours after induction and stored at -20 oC. The protein yields varied 
from about 10 to 100 mg/L depending on the variant identities. 
B.2. Expression of P450cam, CYP153A6, fdrA6, fdxA6, and BM3 heme domain (Chapter 6) 
The genes of P450cam, CYP153A6, CYP153A6 ferredoxin, and CYP153A6 ferredoxin 
reductase were cloned into the pET-22b(+) expression vector downstream of a T7 promoter 
using flanking restriction sites NdeI and XhoI. A his6 affinity tag along with the amino acid pair 
of leucine and glutamic acid corresponding to the XhoI site were also introduced to the C-
terminus of the P450cam and CYP153A6 constructs. The heme domain of P450 BM3 and its 
derived variants (amino acids 1-463) were cloned into a modified pCwori vector with flanking 
restriction sites BamHI and XhoI. The same his6-tag with the leucine and glutamic acid 
appendage was also introduced to the C-terminus. E. coli BL21(DE3) cells transformed with 
these plasmids were used for expression in 50 – 500 mL scales. For expression, supplemented 




 MnSO4, 10  ZnSO4, 2  CoSO4, 2  CuCl2, 2  NiCl2, 2  NaMoO4, and 2  
H3BO3) was inoculated with TB overnight culture to an initial optical density at 600 nm (OD600) 
of 0.5. After 3.5 hours of incubation at 37 oC and 250 rpm, the cultures were cooled to 25 oC, and 
expression was induced with the addition of IPTG (1 mM). The cells were harvested by 
centrifugation at 4 oC, 5,000 rpm for 10 mins, 20 to 24 hours after induction and stored at -20 oC. For 
the expression of fdrA6 and fdxA6, the cultures were cooled to 30 oC for induction and allowed to 
express for 24 to 30 hours at 30 oC. 
C. Purification of P450s and Reductase Components 
C.1. Single-step purification of P450 BM3 (Chapters 2, 3, 5,and 7) 
A single-step purification protocol was developed based on a published procedure (1). 
During the purification, all samples were kept on ice or at 4 oC. Cell pellets of BM3 and its 
derived variants were resuspended in Tris-HCl (25 mM, pH 8.0, 0.5 ml/gram cell weight) and 
lysed by sonication (2 x 30 s, output control 5, 50% duty cycle; Sonicator, Heat Systems–
Ultrasonic, Inc.). The lysate was centrifuged at 20,000 rpm for 30 min, and the supernantent was 
filtered with a 22 M filter (Millipore, Billerica, MA) before loading on a pre-equilibrated 
Toyopearl® Super Q-650M column for ion exchange chromatography. After washing with five 
column volumes of 25 mM Tris-HCl and five column volumes of 0.15 M NaCl in 25 mM Tris-
HCl, the protein was eluted with 0.34 M NaCl in 25 mM Tris-HCl. The P450 fractions were 
collected and concentrated using a 30 kDa molecular weight cut-off centrifugal (mwco) filter 
(Millipore, Billerica, MA). The protein solution was then buffer-exchanged with potassium 
phosphate buffer (100 mM, pH 8.0) by either using PD-10 desalting columns (GE heathcare, 




P450 enzyme concentrations were quantified by CO-binding difference spectra as described (2), 
using 91 mM-1 cm-1 as the extinction coefficient. The protein solutions were flash-frozen with 
dry ice and stored at -80 oC. 
C.2. Three-step purification of P450cam, CYP153A6, and BM3 heme domains (Chapter 6) 
To obtain highly pure protein preparations for terminal oxidant reactions described in 
Chapter 6, a three-step purification was employed. During the purification, all samples were kept 
on ice or at 4 oC. Cell pellets were resuspended in Ni-NTA buffer A, (25 mM Tris-HCl, 100 mM 
NaCl, 30 mM imidazole, pH 8.0, 0.5 ml/gcw) and lysed by sonication (2 x 30 s, output control 5, 
50% duty cycle; Sonicator, Heat Systems–Ultrasonic, Inc.). The lysate was centrifuged at 20,000 
rpm for 30 min, and the supernantent was filtered with a 22 M filter before loading on a pre-
equilibrated Ni-NTA column.  
After washing with five column volumes of Ni-NTA buffer A, the P450 was eluted with 
buffer B (25 mM Tris-HCl, 100 mM NaCl, 100 mM imidazole, pH 8.0). After buffer-exchange 
with 25 mM Tris-HCl, the desalted protein solution was loaded onto a pre-equilibrated Q 
sepharoseTM column (HiTrapTM Q HP, GE healthcare, Piscataway, NJ). A wash step with five 
column volumes of 25 mM Tris-HCl was followed by elution of the P450 with a linear gradient 
of NaCl from 0 to 500 mM over 10 column volumes.  
The P450 fractions were collected and concentrated using a 30 kDa mwco centrifugal 
filter. Following buffer exchange with 20 mM HEPES buffer, the protein solution was loaded 
onto a pre-equilibrated HiPrep 16/60 Sephacryl S-100 HR column (GE healthcare, Piscataway, NJ). 
The protein was eluted with a flow rate of 0.5 ml/min; purified fractions were concentrated to 2 mL 




protein was flash-frozen with dry ice and lyophilized overnight on a bench-top lyophilizer 
(Millrock Technology, Kingston, NY). P450 concentration was determined in triplicate after 
resuspension in potassium phosphate buffer (100 mM pH 8.0) by CO-difference spectroscopy. 
C.3. Two-step purification of fdrA6 and fdxA6 (Chapter 6) 
To obtain the A6 reductase components for NADH/O2-supported alkane reactions 
described in Chapter 6, a two-step purification was employed. During the purification, all 
samples were kept on ice or at 4 oC. Cell pellets were resuspended in 25 mM Tris-HCl at 0.5 
ml/gcw and lysed by sonication (2 x 30 s, output control 5, 50% duty cycle; Sonicator, Heat 
Systems–Ultrasonic, Inc.). The lysate was centrifuged at 20,000 rpm for 30 min, and the 
supernantent was filtered with a 22 M filter before loading on a pre-equilibrated Q sepharoseTM 
column (HiTrapTM Q HP, GE healthcare, Piscataway, NJ). A wash step with five column volumes 
of 25 mM Tris-HCl was followed by elution of the P450 with a linear gradient of NaCl from 0 to 
500 mM over 10 column volumes.  
The protein fractions were collected and concentrated using a 10 and 30 kDa mwco 
centrifugal filter for fdxA6 and fdrA6, respectively. Following buffer exchange with 20 mM 
HEPES buffer, the protein solution was loaded onto a pre-equilibrated HiPrep 16/60 Sephacryl S-
100 HR column (GE healthcare, Piscataway, NJ). The proteins were eluted with a flow rate of 0.5 
ml/min; purified fractions were concentrated and flash-frozen with dry ice before lyophilization with 






D. Mutagenesis and Library Construction of P450 BM3 Variants 
D.1. Thermostabilization of variant 35E11 (Chapter 2) 
In our effort to thermostabilize variant 35E11, we grafted known stabilizing mutations of 
the P450 heme domain (3). The following mutations L52I, S106R, M145A, L324I, V340M, 
I366V, and E442K in conjunction were found to stabilize a P450 BM3-derived peroxygenase by 
18 oC. Each of these mutations was first individually introduced into the pCwori_35E11 plasmid 
by site-directed overlap extension PCR (SOE-PCR) (4). BamHI_Fwd and SacI_rev served as 
flanking primers. For all primer sequences see section D.10. For each mutation, two separate 
PCRs were performed with Pfu turbo (Stratagene), each using a perfectly complementary flanking 
primer and a mutagenic primer. The two resulting overlapping fragments containing the nucleotide 
substitutions were then annealed in a second PCR to amplify the complete mutated gene. The 
amplified gene was then digested with BamHI and SacI restriction enzymes and ligated with T4 
DNA ligase into pCwori_WT, previously digested with BamHI and SacI to remove the wild-type 
gene. The ligation mixtures were used to transform electro-competent E. coli DH5α cells. The 
transformed cells were plated onto Luria-Bertani (LB) (5) agar plates containing ampicillin to form 
single colonies. Colonies from each of the seven variants were expressed and purified as described 
above. Mutations that resulted in an improved T50 (see Section J) and less than 20% loss of propane 
turnover number (TON) (see Section F.1) were recombined in a pair-wise fashion using SOE-PCR. 






D.2. Random mutagenesis of ETS8 (Chapter 2) 
A random mutagenesis library of the heme domain of variant ETS8 (aa 1-433) was created 
by error-prone PCR based on published protocols (6). Four different concentrations of MnCl2 (50, 
100, 200, 300 μM) were used to induce mutations with Taq DNA polymerase (Roche) in the 
mutagenic PCR containing approximately 50 ng of plasmid DNA as template, and BamHI_Fwd and 
SacI_rev serving as end primers. The PCR product was then digested with BamHI and SacI 
restriction enzymes and ligated with T4 DNA ligase into pCwori_WT, previously digested with 
BamHI and SacI to remove the wild-type gene. The ligation mixtures were then electoporated into 
electro-competent E. coli DH5α cells. The transformed cells were plated onto LBamp agar plates to 
form single colonies. For each Mn2+
 
concentration, a small library of 88 mutants in a 96-well plate 
(four wells containing parent ETS8, four blank wells) was picked and screened for both folding by 
CO-binding difference spectroscopy (E.2) as well as activity toward dimethyl ether as described 
below (E.3). The library prepared with a Mn2+
 
concentration of 200 μM yielded ~ 50% inactive 
mutants, and thus it was selected for screening of 2,500 members for activity towards dimethyl ether. 
Variant 19A12 was selected from the DME screening with roughly twice the parental activity. 
D.3. Site-saturation mutagenesis and recombination of variant 19A12 (Chapter 2) 
Using pCwori_19A12 as template, 17 residues along the active site channel, identified 
from the P450 BM3 crystal structure 1JPZ, were selected for saturation mutagenesis. NNK 
libraries were constructed individually at positions 74, 75, 78, 82, 87, 88, 181, 184, 188, 260, 
264, 265, 268, 328, 401, 437, and 438 by SOE-PCR. The mutagenic primer for each library 
contained an NNK (N = A, T, G or C, K = T or G) codon at the mutation site, which encoded all 
20 possible amino acids and only one stop codon out of the possible 32 codons. For each library, 




mutagenic primer. The two resulting overlapping fragments were then annealed in a second PCR to 
amplify the complete mutated gene. For the libraries at residue 437 and 438, BamHI_Fwd and 
EcoRI_rev were used as the end primers, and digestion with BamHI and EcoRI was employed. For 
all other libraries BamHI_Fwd and SacI_Rev were used. End primers and the subsequent cloning 
into pre-digested pCwori_WT occurred as previously described (D.1).  
For each library, 88 mutants in a 96-well plate (four wells containing parent 19A12, four 
blank wells) were picked and screened for folding and activity toward dimethyl ether. The five 
beneficial mutations A74S, A74Q, V184S, V184T, and V184A were recombined using degenerate 
primers or a mixture of primers. A second recombination library was also constructed that allowed 
for 74NNK, 82S/G, and 184NNK. Screening these two libraries produced variants 1-3 (19A12-
A74S, V184A) and 7-7 (19A12-A74E, S82G) with comparable propane TTN. 
D.4. Reductase libraries construction (Chapter 2) 
The FMN and FAD sub-domains of the BM3 reductase were mutated separately by error-
prone PCR with Taq Polymerase (Roche). Using pCwori_35E11 as template, the primer pairs 
FMN_for/ FMN_rev and FAD_for/FAD_rev were used in the PCR relying on MnCl2 (100, 200, 
300 M) as the mutation inducer. The amplified genes were cloned into pre-digested 
pCwori_35E11 using restriction sites SacI and NsiI for FMN libraries and NsiI and EcoRI for the 
FAD libraries. Screening for improved DME activity yielded beneficial mutations at positions 
443, 445, 515, 580, 654, 664, 698, and 1037.  
Using pCwori_11-3 as template, site-saturation libraries were constructed at all eight 
positions identified from the 35E11 random reductase libraries using NNK primers and SOE 




reductase. Following SacI and EcoRI digest, the mutagenized genes were ligated into a pre-
digested pCwori_11-3 and electoporated into E. coli Dh5. Screening of 88 colonies from each 
library identified beneficial mutations G443A, P654K, T664G, D698G, and E1037G. A 
recombination library was constructed using degenerate or mixed primers allowing for both the 
wild-type amino acid and mutated amino acid at each position. This reductase library was fused 
to pCwori_7-7 through the SacI and EcoRI restriction sites. Screening of the resulting library 
yielded P450PMO R1 (7-7-G443A, P654K, and E1037G) and P450PMO R2 (7-7-G443A, D698G).  
D.5. Targeted mutagenesis of the P450 BM3 active site (Chapter 3) 
Ten residues along the active site channel, identified from the P450 BM3 crystal structure 
1JPZ, were selected for saturation mutagenesis. Using pCwori_WT as template, NNK libraries 
were constructed individually at positions 74, 75, 78, 82, 87, 181, 184, 188, 328, and 330 by 
SOE-PCR as described (D.1). At least 91 colonies of each library were screened for folding by 
CO-binding difference spectroscopy and activity for dimethyl ether. 
Combinatorial active site saturation test with a reduced set of allowed amino acid 
(reduced CASTing) libraries targeting two and three sites simultaneously were constructed at 
positions 78, 82, and 328 with degenerate codons that encoded for L, I, F, V, A, M, and W. To 
obtain the desired amino acid restriction at each site, three primers containing the codons GYN 
(encodes A and V), WTS (encodes L, I, M and F), and TGG (encodes W) were mixed to a 2:4:1 
ratio to achieve equal representation of each amino acid. A modified SOE-PCR strategy was 
used for two-site focused libraries, where the target residues were more than 20 nucleotides 
apart, A328+V78 and A328+A82. Three overlapping fragments were first generated using the 




separate reactions. A second PCR annealed these three fragments and amplified the full length 
gene with the end-primers BamHI_Fwd and SacI_Rev. The two-site focused library with target 
residues less than 20 nucleotides apart, V78+A82, was constructed with a sequential SOE-PCR 
strategy. Standard SOE-PCR was used to introduce the first mutagenic codon into the full-length 
gene, which then served as template for a second round of SOE-PCR. The three-site focus 
library, A328+V78+A82, was constructed similarly by sequential SOE-PCRs.  
D.6. Random mutagenesis of P450 BM3 (Chapter 3) 
A random mutagenesis library of the heme domain of P450 BM3 (aa 1-433) was created by 
error-prone PCR as described (D.2). Four different concentrations of MnCl2 (50, 100, 150, and 200 
μM) were used to induce mutations with Taq DNA polymerase (Roche). From screening 88 colonies 
of each of the four libraries for both folding and activity toward dimethyl ether, the library prepared 
with a 150 μM Mn2+ concentration, which contained ~ 50% inactive mutants, was selected for full 
screening. Ten variants were randomly selected for sequencing, which revealed an average error rate 
of 2.1 amino acids/protein. In the subsequent full screening, 1,408 members of this library were 





D.7. Construction of CRAM- and Corbit- designed libraries (Chapter 3) 
The CRAM and Corbit libraries were constructed to allow for two possible amino acids at 
ten selected residues. The allowed amino acids were determined for each design following the 
algorithms detailed in Appendix B. The selected amino acids and the degenerate codons or 
mixed codons that were used in library construction are summarized below in Table 8.1.  
Table 8.1 CRAM and Corbit designs; allowed amino acids and codon usage. (K = T or G, S = C or 
G, W = A or T, Y = C or T, R = A or G) 
 CRAM Design Corbit Design 
Target Residue Allowed Amino Acid Codon 
Allowed Amino 
Acid Codon 
A74 L/W TKG A/V GYC 
L75 L/F TTS L/F TTS 
V78 F/I WTT L/V STG 
A82 L/V STG A/S KCG 
F87 F/A TTC/GCA F/A TTC/GCA 
L181 L/W TKG L/F TTS 
A184 A/V GYC A/T RCG 
L188 L/W TKG L/W TKG 
A328 F/V KTC A/F TTC/GCA 
A330 L/W TKG A/V GYC 
For both libraries, the ten target positions were clustered into three different nodes for 
ease of primer design and PCR. The first node included residues 74, 75, 78, 82, and 87. A single 
mutagenic primer was able to span this entire node and introduce the desired codon mixture to all 
five positions. For the remaining targeted positions, residues 181, 184, and 188 were grouped 
into a second node, and residues 328 and 330 were grouped into a third node. Four overlapping 
fragments were first generated using BamHI_Fwd and SacI_Rev in conjunction with forward 
and reverse mutagenic primers at each node. These four fragments were annealed in a second 
PCR to amplify the full-length gene. Digestion with BamHI and SacI was followed by ligation 
with T4 DNA ligase into a pre-digested pCwori_WT. The ligation mixture was then 




were picked into 96-well plates and screened for protein folding and activity for dimethyl ether 
as described above. 
D.8. Random mutagenesis of AlkB and Cyp153A6 (Chapter 4) 
Mutagenesis of pCom plasmids was performed in E. coli XL1-Red strains according to 
the manufacturer’s manual (Stratagene) and in E. coli JS200 (pEPPol I) as described previously 
(7). Mutated alkB genes or the CYP153A6 gene along with the fdrA6 and fdxA6 operons were 
cloned into the original pCom10 or into pCom8* plasmids as EcoRI-HindIII or KpnI-digested 
fragments, respectively. Plasmid pCom8_alkBFG was constructed by amplifying the alkBFG 
operon from plasmid pblaP4_alkJBFG-luxAB (8) using the primers alkBFG_1 and alkBFG_2 in 
a standard PCR. The resulting fragment was cloned into the pCom8 vector using the NdeI and 
XmaI restriction sites introduced by the primers. The resulting plasmid was digested with SpeI, 
and the alkB-containing 3.7 -kb fragment was replaced with the appropriate fragment from SpeI-
digested pCom10_alkB, pCom10_alkB-BMO1, and pCom10_alkB-BMO2 by cloning, resulting 
in constructs pCom8_alkBFG, pCom8_alkB-BMO1_alkFG, and pCom8_alkBBMO2_alkFG.  
D.9. Site-saturation and random mutagenesis of variant E31 (Chapter 5) 
Ten residues along the active site channel, identified from the P450 BM3 crystal structure 
1JPZ, were selected for saturation mutagenesis. Using pCwori_E31 identified from the CRAM 
and Corbit screening as template, NNK libraries were constructed individually at positions 74, 75, 
78, 82, 184, 263, 264, 328, 436, and 437 by SOE-PCR as described (D.1). At least 88 colonies of 
each library were screened for protein folding by CO-binding difference spectroscopy and 




The first-generation random mutagenesis library targeting the heme domain of variant 
E31 (aa 1-490) was created by error-prone PCR using the Genemorph II kit (Stratagene, La Jolla, 
CA) according to the manufacturer’s protocol. Approximately 100 ng of plasmid DNA were 
used as template along with primers Heme_fwd_1 and KpnI_rev in the PCR. Sequencing of ten 
randomly selected variants revealed an average nucleotide substitution rate of 3.7/protein was 
obtained for this library. After screening 3,000 members of this library, we obtained variants 
24F8 and 22F11 with improved ethane hydroxylation activity with three and two mutations, 
respectively. SOE-PCR was used to generate a recombination library with these five mutations. 
From screening 90 colonies of this library for improved ethane hydroxylation activity, we 
obtained variant RD2 with only two of the five mutations. 
The second-generation random mutagenesis library targeting the heme domain was 
constructed using pCwori_RD2 as the template at three different concentrations of MnCl2 (175, 
200, and 300 μM) to induce mutations with Taq DNA polymerase (Roche). Sequencing of ten 
randomly selected variants revealed that an average nucleotide substitution rate of 4.3/protein 
was obtained for this library. A pre-screen of 88 colonies from each library led us to choose the 
175 μM Mn2+ library for screening. After screening 3,000 members of this library for improved 
ethane hydroxylation activity, we obtained variants 20D4. 
D.10. Primer list 





















































































































































































































































E. High-Throughput Screening of P450 BM3 Libraries 
E.1. Lysate preparation of high-throughput screening (Chapters 2, 3, 5, and 7) 
96-well plates with 1-mL wells containing LB medium (300 μL, supplemented with 100 




picking robot (Genetix, Beaverton, OR). Two to four wells were also inoculated with the parent 
by hand, and one to four wells was left uninoculated as sterility and negative control for high-
throughput screening. After overnight incubation (at least 12 hrs) at 37 oC, 250 rpm, and 80% 
relative humidity in a Kühner shaker (Kühner, Birsfeden, Switzerland), 50 μL of the LB culture 
was used to inoculate 96-well plates with 2-mL wells containing TB medium (600 – 800 μL, 
supplemented with 100 mg/mL ampicillin). The TBamp expression culture was incubated at 37 
oC, 250 rpm, and 80% relative humidity for four hours before the temperature was reduced to 25 
oC. After thirty minutes at the reduced temperature, protein expression was induced with 0.5 mM 
IPTG and 0.5 mM δ-ALA. After 20 – 24 hours of expression at 25 oC, the cultures were 
harvested by centrifugation at 5,000 rpm and 4 oC, and stored at -20 oC. 
The frozen cell pellets were resuspended in 0.1 M phosphate buffer, pH 8.0, containing 
10 mM MgCl2, 0.5 mg/ml lysozyme (Sigma), and 2.0 U/mL DNaseI. After lysis at 37 oC for 60 
minutes, the lysates were centrifuged at 5,000 rpm and 4 oC for 10 min, and the supernatants 
were transferred to 96-well microtiter plates for high-throughput assays.  
E.2. High-throughput P450 protein folding assay (Chapters 2 – 7) 
The CO-binding difference spectroscopy has been well established for determination of 
folded P450 concentrations. Following a modified protocol (9) for the CO-binding assay in 96-
well microtiter plates, 40 – 100 μL of 0.4 M sodium hydrosulfite were added to 100 – 160 μL of 
lysate in each well of a 96-well microtiter plate. The UV/Vis absorbance from 400 to 500 nm 
was taken using a microtiter plate reader before exposure to carbon monoxide. The microtiter 
plates were placed in a vacuum chamber, which was evacuated to 20 mmHg. Carbon monoxide 




the 400 – 500 nm spectrum was obtained and subtracted from the pre-incubation spectrum. The 
extinction coefficient of 91 mM cm–1 was used to obtain the P450 concentration of each well. 
E.3. High-throughput demethylation assay using Purpald (Chapters 2, 3 and 7) 
For quantifying the demethylation reaction of P450 with substrates such as dimethyl 
ether, purpald was used to detect the resulting aldehydes (10). In a 96-well microtiter plate, 120 
μL of 0.1 M, pH 8.0 phosphate buffer pre-saturated with dimethyl ether were added to 30 μL of 
cell lysate, and the reaction was initiated with 50 μL of 4 mM NADPH. The reaction was 
allowed to proceed for 15 – 30 minutes, after which 50 μL of 168 mM purpald in 2 M NaOH 
were added to quench the reaction and develop the purple adduct with the released aldehydes. 
After 15 minutes, the purple color was quantified by absorbance at 550 nm using a microtiter 
plate reader.  
E.4. High-throughput ethane hydroxylation assay (Chapters 3 and 5) 
The ethanol product from the ethane hydroxylation reaction was quantified with a 
coupled enzyme assay utilizing alcohol oxidase and horseradish peroxidase. The alcohol oxidase 
converted the ethanol product from the P450 reaction into one molecule of acetaldehyde and one 
molecule of hydrogen peroxide. The horseradish peroxidase was then able to oxidize ABTS into 
a green soluble end-product using hydrogen peroxide.  
To minimize ethanol fermentation from intact cells, the lysate was first filtered through a 
0.2 micron filter plate (Pall, Ann Arbor, MI). In a 96-well Symx reactor (Symx, Miami, FL), 20 
μL of lysate were added to each well along with 440 μL of 0.1 M phosphate buffer, pH 8.0, pre-
saturated with ethane, and the reaction was initiated with 40 μL of an NADPH regeneration 




isocitrate dehydrogenase. The reactor was then pressurized to 30 psi with ethane and allowed to 
react for 24 – 48 hours at 4 oC. After the reactor was vented to atmospheric pressure, the reaction 
mixture was transferred to a 2-mL 96-well plate. To each well, 15 μL of 5 M HCl were added to 
oxidize the remaining NADPH to NADP+ to prevent the NADPH from reducing the oxidized 
ABTS product. The 96-well plate was then shaken to mix at 150 rpm, 25 oC for 10 minutes. 
After centrifugation to pellet the denatured protein, 150 μL of the reaction mixture were 
transferred to a 96-well microtiter plate. Another 3 μL of 5 M HCl were added followed by 75 
μL of 1 M phosphate buffer, pH 8.0, to raise the solution to a neutral pH. In the final color 
development setup, 50 μl of ABTS (1.3 mg/mL), 10 μL of HRP (3 mg/ml), and 10 μL of AOX 
(0.5 U/ml) were added in this sequence, and after 10 minutes of incubation, the green color was 
quantified at 420 nm. 
E.5. Determination of NAD(P)H consumption rates (Chapter 2 – 7) 
The P450 enzymes were purified and quantified by CO-binding as described above. 
Initial rates of NADPH consumption were determined by monitoring the absorption decrease at 
340 nm measured with a 1 cm pathlength cuvette on a Cary 100 UV/VIS spectrophotometer 
(Varian, Walnut Creek, CA) or with a 96-well microtiter plate (pathlength 0.48 cm for 150 μL 
sample volume) on a Tecan plate reader (Tecan, Durham, NC). For liquid substrates such as 
alkanes, substrate stock solutions in ethanol (50-fold) were added to a protein solution (50 to 200 
nM) in 0.1 M, pH 8.0 phosphate buffer and incubated for at least 30 seconds. The reaction was 
initiated by the addition of NAD(P)H varying from 200 μM to 1 mM depending on the rate of 




solution was made in pre-saturated buffer. The consumption rates were determined using an 
extinction coefficient of ε340nm = 6,210 M-1 cm-1. Each rate was determined at least in triplicate.  
E.6. Growth selection of AlkB and CYP153 libraries (Chapter 4) 
Luria-Bertani broth and modified M9 medium with 1.5% yeast extract (11) supplemented 
with appropriate antibiotics, or E2 (12) and M9 (13) minimal media supplemented with carbon 
sources, were used for growth. All cultures were grown aerobically at 30 °C (P. putida) or 37 °C 
(Escherichia coli). Antibiotic concentrations were 100 g/ml ampicillin, 15 g/ml tetracycline, 
20 g/ml chloramphenicol, and 10 g/ml gentamicin for E. coli cultures and 50 g/ml for 
Pseudomonas. Bacterial strains were grown on solid E2 minimal medium with liquid alkanes 
provided through the gas phase as described previously (14). Solid minimal medium growth tests 
on gaseous alkanes were conducted in gas-tight plastic containers (GasPak 150 large anaerobic 
vented system; VWR), pressurized at 20 psi  for 20 s (ethane and propane) or 10 psi  for 6 s 
(butane). Liquid minimal medium cultures growing on alkanes were shaken in custom-made gas-
tight flasks with 1% liquid alkane (pentane and octane) in a reservoir or in gas-tight serum 
bottles (Alltech), pressurized with gaseous alkanes as described above. For growth tests of P. 
putida GPo12(pGEc47B) on alkanols, cells from an LB preculture were washed three times 
with M9 medium and used to inoculate the 5-mL M9 main cultures in 14-mL tubes to an optical 
density (OD600) of 0.1, then grown at 30 °C with continuous shaking. Libraries of P. putida 
GPo12(pGEc47B) strains expressing AlkB or CYP153A6 variants were precultured on E2 
minimal medium plates with antibiotics and 0.2% (wt/vol) citrate as carbon source and then 
enriched for improved strains through continuous growth in liquid E2 minimal medium with 




F. P450 Reactions (Chapters 2 – 7) 
F.1. Gaseous alkane hydroxylation with P450 BM3 variants (Chapter 2 and 3) 
Gaseous alkane reactions were carried out in 10 or 20 mL crimp-top head-space vials 
(Agilent, Santa Clara, CA). The 1.0 – 5.0 mL reaction mixture contained 20 – 200 μM P450 in 
0.1 M phosphate buffer, pH 8.0, saturated with alkane and oxygen. The buffer was saturated with 
the gaseous alkane through vigorous bubbling for at least 10 minutes. After the addition of the 
P450 mixture, the crimp-top vial was sealed and stirred moderately at 25 oC. The reaction was 
then initiated by the addition of 0.5 mL of a NADPH regeneration system consisting of 10 
mg/mL isocitrate, 0.2 mg/mL NADP+, and 10 U/mL of isocitrate dehydrogenase. For 
determination of the TON, the reaction was carried out at 4 oC over 24 hrs. For initial rate of 
formation determination, the reaction was initiated by the addition of 500 μM NADPH and was 
quenched with 200 μL of concentrated H2SO4 after an appropriate time depending on the enzyme 
activity (20 second to 10 minutes) at 25 oC. 
The alcohol product was initially analyzed as alkyl nitrites using a published method 
(15). To a 5.0 mL reaction mixture, 0.3 g of sodium nitrite and 2 mL of hexanes were added 
along with 1-butanol as an internal standard, and the mixture was cooled on ice. The reaction 
was initiated with the addition of 0.2 mL concentrated sulfuric acid and quenched by dilution 
with 5 mL of deionized water after 15 minutes. The reaction mixture was further washed with 20 
mL of water in a separatory funnel. The organic phase was collected and analyzed with GC-ECD 
(see H.1). Alternatively, the alcohol products were also analyzed by GC-FID using Supelco SPB-





F.2. Alkane hydroxylation with CYP153A6 (Chapter 6) 
For alkane reactions with CYP153A6, 0.15 – 0.3 mL reaction mixtures contained 0.5 – 
2.0 μM A6 and 0.5 – 2.0 μM FDR and 5.0 – 20.0 μM FDX at a 1:1:10 ratio in 0.1 M phosphate 
buffer, pH 8.0. In the case of liquid alkanes, a stock solution in ethanol was used to add 25 μM to 
10 mM alkane in a final solution containing 2% ethanol. For gaseous alkanes, the reaction was 
carried out in crimp-top head-space vials pressurized to 20 psi with the alkane. The reaction was 
initiated with the addition of 1 – 2 mM NADH. For determination of the initial rate, the reactions 
were quenched with 20 μL of 3.0 M HCl after 5 minutes.  
Reactions with liquid alkanes were extracted with 100 – 150 μL of chloroform after the 
addition of 2-nonanol as an internal standard. The mixture was then vortexed for 30 seconds 
before centrifuging at 14,000xg for 2 minutes. The bottom organic phase was collected and 
analyzed by GC-FID, see H.2 for details. Reactions with gaseous alkanes were quenched with 20 
μL of 3.0 M HCl and neutralized with 75 μL of 1.0 M phosphate buffer, pH 8.0. This 
acidification and neutralization sequence resulted in the desired precipitation of the enzymes in 
solution. After centrifuging at 14,000xg for 2 minutes to pellet the denatured protein, the 
clarified solution was analyzed by GC-MS (see H.3 for details). 
F.3. Alkane hydroxylation with terminal oxidants (Chapter 6) 
For alkane reactions with P450s using terminal oxidants, 0.3 mL reaction mixture 
contained 50 – 250 μM of highly pure enzyme, as described in C.2, in 0.1 M phosphate buffer, 
pH 8.0. The liquid alkanes were added from an ethanol stock solution, to yield a final solution 
containing 2.5 mM alkane and 2% ethanol. For gasesous alkanes, lyophilized protein was added 




alkane substrate for 2 minutes before the addition of 0.27 mL of pre-saturated 0.1 M phosphate 
buffer, pH 8.0. The reaction was then pressurized to 20 psi with the gaseous alkane. For reactions 
with PhIO, the reaction was initiated with the addition of 0.03 mL of 5 mM PhIO, solubilized in 
deionized water by sonication. For reactions with MCPBA, the reaction was initiated with the 
addition of 5 mM MCPBA in an ethanol or isopropanol stock solution. Reactions with H2O2 
were similarly initiated with the addition of 5 mM H2O2. All reactions were allowed to proceed 
for 10 minutes at 25 oC. The work-up and analysis of the alcohol products followed the same 
protocol as described in Section F.2. 
F.4. Iodomethane reaction with CYP153A6 (Chapter 6) 
For iodomethane reactions with CYP153A6, 0.15 – 0.3 mL reaction mixtures contained 
0.5 μM A6 and 0.5 μM FDR and 5.0 μM FDX at a 1:1:10 ratio in 0.1 M phosphate buffer, pH 
8.0. Iodomethane in an ethanol stock solution was used to add 25 μM to 10 mM alkane in a final 
solution containing 2% ethanol. The reaction was initiated with the addition of 1 mM NADH and 
quenched after 5 minutes with either 168 mM purpald in 2 M NaOH or 20 μL of 3.0 M HCl. 
Reactions quenched with purpald were quantified by absorbance at 550 nm after 10 minutes of 
color development. For reactions quenched with acid, a neutralization step followed with 75 μL 
of 1.0 M phosphate buffer, pH 8.0, to precipitate the proteins in solution. After centrifuging at 
14,000xg for 2 minutes, the clarified solution was analyzed by GC-MS (see H.3 for details). 
F.5. Metabolite production with P450s (Chapter 7) 
Reactions of verapamil, astemizole, and LY294002 with a panel of 120 P450s were 
conducted in 96-well microtiter plates. For P450 holoenzymes, 60 μL of lysate, generated as 




substrate (5 mM). The reaction was initiated with the addition of 20 μL NADPH (20 mM). For 
P450 peroxygenases, 50 μL lysate were added along with 100 μL of 0.1 M EPPS buffer, pH 8.2, 
and 10 μL of substrate (20 mM). The reaction was initiated with the addition of 40 μL of H2O2 (5 
mM). The plates were shaken briefly after the addition of NADPH or H2O2, and incubated for 
two hours at 25 oC. After this time, 200 μL of acetonitrile were added to quench the reaction. The 
resulting mixture was centrifuged, and the supernatant was used for subsequent HPLC and 
LC/MS analysis. 
G.  Absorption Spectra of P450s (Chapter 6) 
The absorption spectra over the range from 350 to 500 nm were taken using a 5 μM 
solution of purified P450 in 0.1 M, pH 8.0, phosphate buffer with 1 cm pathlength cuvette on a 
Cary 100 UV/VIS spectrophotometer. Liquid substrate in an ethanol stock solution was used to 
add 10 mM substrate in a final solution containing 2% ethanol. For gaseous substrates, the 
protocol for alkane hydroxylation with terminal oxidants (see F.3) was used to expose the 
enzymes to substrates. The differences in absorption spectra at A418nm corresponding to a low-
spin ferric state and A390nm corresponding to a high-spin state were used to determine the extent 
of the induced spin-shift. 
H. Gas Chromatography 
All peak assignments in our gas chromatographs were determined by comparison to 
authentic standards. Analyte peaks were quantified using calibrations curves containing at least 
four standard concentrations. Unless stated otherwise, every analysis was done with a 1 μL 





H.1. GC-ECD analysis of alkane reactions 
Analysis of the ethanol and propanol products as their alkyl nitrite derivatives followed 
published procedures (15), using a Hewlett-Packard 5890 Series II Plus gas chromatograph 
(Agilant, Santa Clara, CA) with a HP-1 column (30 m length, 0.32 mm ID, 0.25 μm film 
thickness) connected to an electron capture detector (ECD). A typical temperature program used 
was: 60 °C injector, 150 °C detector, 35 °C oven for 3 min, 10 °C/min gradient to 60 °C, 25 
°C/min gradient to 200 °C, and then 200 °C for 5 min. 
H.2. GC-FID analysis of alkane reactions 
Analysis of hydroxylation products of small alkanes was performed on a Hewlett Packard 
5890 Series II Plus gas chromatograph with a flame ionization detector (FID) and fitted with a 
HP-7673 autosampler system. Direct analysis of ethane, propane, butane, and pentane, 
hydroxylation products was performed on a Suplerco SPB-1 column, (60 m length, 0.32 mm ID, 
0.25 μm film thickness). A typical temperature program used for separating the alcohol products 
was 250 °C injector, 300 °C detector, 50 °C oven for 3 minutes, then 10 °C/minute gradient to 
200 °C, 25 °C/minute gradient to 250 °C, then 250 °C for 3 minutes.  
Analysis of hydroxylation products of hexane and octane was similarly performed as 
described above using a DB-624 column, (30 m length, 0.53 mm ID, 3.0 μm film thickness) 
connected to a FID detector. A typical temperature program used for separating the alcohol 
products was 250 °C injector, 300 °C detector, 40 °C oven for 5 minutes, then 10 °C/minute 





H.3. GC-MSD analysis  
Analysis of hydroxylation products of methane, ethane, propane, and iodomethane was 
performed on Hewlett Packard 6890 Series II Plus gas chromatograph with a 5975C mass 
selective detector (MSD). Direct analysis of the alcohol products in buffer were performed using 
a DB-624 column, (30 m length, 0.53 mm ID, 3.0 μm film thickness) with a 0.5 μL sample 
injection. A typical temperature program used for separating the alcohol products consisted of 
250 °C injector, 300 °C detector, 45 °C oven for 5 minutes, then 10 °C/minute gradient to 150 
°C, then 25 oC/minute gradient to 250 °C, and a hold for 3 minutes at 250oC. 
I. HPLC/ LCMS 
Analysis of the reactions of drug compounds verapamil, astemizole, and lead compound 
LY294002 with a panel of P450s was performed using a Supelco Discovery C18 column (2.1 x 
150 mm, 3 μm) on a Waters 2690 Separation module in conjunction with a Waters 996 PDA 
detector. Clarified supernantant (25 μL) was analyzed with 0.2% formic acid (solvent A) and 
acetonitrile (solvent B) at the following conditions: 0 – 3 min, A/B 90:10; 3 – 25min, linear 
gradient to A/B 30:70; 25 – 30 min, linear gradient to A/B 10:90. LCMS and MS/MS spectra 
were obtained with a ThermoFinnigan LCQ classic (San Jose, CA), using identical conditions to 
the HPLC method detailed above for the LC conditions. The MS was operated in positive ESI 
mode, and the MS/MS spectra were acquired for the most abundant ions.  
J. Half-Denaturation Temperature (T50) Determination 
Samples of purified enzyme (3 – 5 μM) were incubated for 15 minutes at various 
temperatures from 25 oC at the bench top to 65 oC using a PCR thermocycler or a thermoblock. 




supernatant were mixed with 40 μL of 0.4 M sodium hydrosulfite one a microtiterplate for CO-
difference spectroscopy, see E.2 for details. The T50 values were determined by data fitting to a 
2-state denaturation model using Sigmaplot (Systat, San Jose, CA). 
K. Whole-Cell Bioconversion with P450 BM3 Variants (Chapters 2 and 5) 
Propane bioconversions were carried out at 80 mL and 300 mL scale using temperature 
controlled 100-mL (Ochs-Labor, Bovenden, Germany) and 1-L fermenter (DasGip, Jülich, 
Germany), respectively. Freshly transformed Escherichia coli Dh5cells were grown in 
modified M9 medium supplemented with 0.4% glucose, and 1.5% yeast extract. In addition to 
the standard salts, the modified M9 contained additional nutrients: calcium pantothenate, p-
aminobenzoic acid, p-hydroxybenzoic acid, thiamine, and trace metals (CoCl2, CuSO4, MnCl2, 
ZnSO4). After reaching an OD600 of 1.2, the cells were induced with 0.25 mM IPTG and 0.25 
mM δ-aminolevulininc acid, and harvested after 10 – 12 hours of expression. The cells were 
centrifuged at 5,000 rpm and 4 oC for 10 minutes.  
The resulting pellet was resuspended in nitrogen-free modified M9 medium supple-
mented with 1% glucose. A gas mixture of propane and air at 1:2 ratio was bubbled through the 
resting cells at a flow rate of 15 L/hr. A bubbler filled with an equal volume of water as the 
reaction volume was connected to the reactor’s gas outlet to retain any alcohol product removed 
by the gas flow. At defined time intervals, 1-mL samples of the cell suspension and the bubbler 
fraction were removed for GC analysis of the alcohol product. The cell suspension samples were 
centrifuged and filtered prior to GC analysis. In addition, the P450 concentration was also 
determined by CO-binding difference spectroscopy on cell lysate obtained by sonication of the 




L. Whole-cell bioconversion with AlkB and CYP153 (Chapter 4) 
Freshly transformed E. coli BL21(DE3) cells expressing AlkB variants were precultured 
in LB medium supplemented with the appropriate antibiotic at 37 oC and shaken at 250 rpm for 
24 hours. LB cultures (12 mL) in 1-L flasks were then inoculated to a staring OD600 of 1.0 and 
incubated at 37 °C, 250 rpm, for 2.5 h. These cultures were then cooled to 25 °C and induced 
with 0.4 mM dicyclopropylketone (Sigma-Aldrich) after 30 minutes. After 20 hours of protein 
expression, the cell cultures were centrifuged at 3,300xg, 10 min, and 25 oC. CYP153A6 variants 
were similarly cultured, with the exception of using modified M9 medium supplemented with 
1.5% yeast extract for only 14 hours of expression. 
The cell pellets were resuspended in equal volume of either 0.1 phosphate buffer, pH 7.0, 
for AlkB or nitrogen-free modified M9 medium for CYP153. For bioconversion of liquid 
alkanes, 250 μL of alkane, 1% glycerol were added to 1-mL cell suspensions in a glass vial. The 
reaction was capped and shaken at 200 rpm for 1 hour at 25 oC. The addition of 200 μL of 1 M 
HCl and 250 μL of hexanes and vigorous vortexing quenched the reaction and extracted the 
alcohol products to the organic phase. After centrifuging at 14,000xg for 5 minutes, the organic 
layer was collected for GC analysis. 
For bioconversion of gaseous alkanes, 80 mL of the cell suspension and 15 μL of 
antifoam (Sigma-Aldrich) were stirred in a 100-mL fermenter at 25 oC. The gaseous alkane was 
bubbled through the reaction mixture with air at 10 L/hr and at a 1:3 ratio. The reaction was 
initiated with the addition of 1% final concentration of glycerol for AlkB and 20 mM glucose for 
CYP153A6. Similar to the bioconversion of P450 BM3, at defined time intervals, 1-mL samples 




product. The P450 concentration was also determined by CO-binding difference spectroscopy on 
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The gene encoding for cytochrome P450 BM3 (GenBank number J04832) was cloned in 
the expression vector pCWori (pBM3_WT18-6) downstream of the double tac promoter with 
flanking BamHI and EcoRI sites. This plasmid was used for all subsequent cloning procedures 
and protein expression.   
Figure A.1 lists the nucleotide sequence of full-length, wild-type cytochrome P450 BM3.  
Figure A.2 lists the amino acid sequence of full-length, wild-type cytochrome P450 BM3.  
Table A.1 lists the mutations and activities of P450 BM3 variants generated by random 
mutagenesis using error-prone PCR, site-saturation mutagenesis, combinatorial active site 
saturation with a reduced set of amino acids, and structure-based computational library design, as 




 Figure A.1: Nucleotide sequence of full-length, wild-type cytochrome P450 BM-3  
1 ATGACAATTA AAGAAATGCC TCAGCCAAAA ACGTTTGGAG AGCTTAAAAA  
51 TTTACCGTTA TTAAACACAG ATAAACCGGT TCAAGCTTTG ATGAAAATTG  
101 CGGATGAATT AGGAGAAATC TTTAAATTCG AGGCGCCTGG TCGTGTAACG  
151 CGCTACTTAT CAAGTCAGCG TCTAATTAAA GAAGCATGCG ATGAATCACG  
201 CTTTGATAAA AACTTAAGTC AAGCGCTTAA ATTTGTACGT GATTTTGCAG  
251 GAGACGGGTT ATTTACAAGC TGGACGCATG AAAAAAATTG GAAAAAAGCG  
301 CATAATATCT TACTTCCAAG CTTCAGTCAG CAGGCAATGA AAGGCTATCA  
351 TGCGATGATG GTCGATATCG CCGTGCAGCT TGTTCAAAAG TGGGAGCGTC  
401 TAAATGCAGA TGAGCATATT GAAGTACCGG AAGACATGAC ACGTTTAACG  
451 CTTGATACAA TTGGTCTTTG CGGCTTTAAC TATCGCTTTA ACAGCTTTTA  
501 CCGAGATCAG CCTCATCCAT TTATTACAAG TATGGTCCGT GCACTGGATG  
551 AAGCAATGAA CAAGCTGCAG CGAGCAAATC CAGACGACCC AGCTTATGAT  
601 GAAAACAAGC GCCAGTTTCA AGAAGATATC AAGGTGATGA ACGACCTAGT  
651 AGATAAAATT ATTGCAGATC GCAAAGCAAG CGGTGAACAA AGCGATGATT  
701 TATTAACGCA TATGCTAAAC GGAAAAGATC CAGAAACGGG TGAGCCGCTT  
751 GATGACGAGA ACATTCGCTA TCAAATTATT ACATTCTTAA TTGCGGGACA  
801 CGAAACAACA AGTGGTCTTT TATCATTTGC GCTGTATTTC TTAGTGAAAA  
851 ATCCACATGT ATTACAAAAA GCAGCAGAAG AAGCAGCACG AGTTCTAGTA  
901 GATCCTGTTC CAAGCTACAA ACAAGTCAAA CAGCTTAAAT ATGTCGGCAT  
951 GGTCTTAAAC GAAGCGCTGC GCTTATGGCC AACTGCTCCT GCGTTTTCCC  
1001 TATATGCAAA AGAAGATACG GTGCTTGGAG GAGAATATCC TTTAGAAAAA  
1051 GGCGACGAAC TAATGGTTCT GATTCCTCAG CTTCACCGTG ATAAAACAAT  
1101 TTGGGGAGAC GATGTGGAAG AGTTCCGTCC AGAGCGTTTT GAAAATCCAA  
1151 GTGCGATTCC GCAGCATGCG TTTAAACCGT TTGGAAACGG TCAGCGTGCG  
1201 TGTATCGGTC AGCAGTTCGC TCTTCATGAA GCAACGCTGG TACTTGGTAT  
1251 GATGCTAAAA CACTTTGACT TTGAAGATCA TACAAACTAC GAGCTCGATA  
1301 TTAAAGAAAC TTTAACGTTA AAACCTGAAG GCTTTGTGGT AAAAGCAAAA  
1351 TCGAAAAAAA TTCCGCTTGG CGGTATTCCT TCACCTAGCA CTGAACAGTC  
1401 TGCTAAAAAA GTACGCAAAA AGGCAGAAAA CGCTCATAAT ACGCCGCTGC  
1451 TTGTGCTATA CGGTTCAAAT ATGGGAACAG CTGAAGGAAC GGCGCGTGAT  
1501 TTAGCAGATA TTGCAATGAG CAAAGGATTT GCACCGCAGG TCGCAACGCT  
1551 TGATTCACAC GCCGGAAATC TTCCGCGCGA AGGAGCTGTA TTAATTGTAA  
1601 CGGCGTCTTA TAACGGTCAT CCGCCTGATA ACGCAAAGCA ATTTGTCGAC  
1651 TGGTTAGACC AAGCGTCTGC TGATGAAGTA AAAGGCGTTC GCTACTCCGT  
1701 ATTTGGATGC GGCGATAAAA ACTGGGCTAC TACGTATCAA AAAGTGCCTG  
1751 CTTTTATCGA TGAAACGCTT GCCGCTAAAG GGGCAGAAAA CATCGCTGAC  
1801 CGCGGTGAAG CAGATGCAAG CGACGACTTT GAAGGCACAT ATGAAGAATG  
1851 GCGTGAACAT ATGTGGAGTG ACGTAGCAGC CTACTTTAAC CTCGACATTG  
1901 AAAACAGTGA AGATAATAAA TCTACTCTTT CACTTCAATT TGTCGACAGC  
1951 GCCGCGGATA TGCCGCTTGC GAAAATGCAC GGTGCGTTTT CAACGAACGT  
2001 CGTAGCAAGC AAAGAACTTC AACAGCCAGG CAGTGCACGA AGCACGCGAC  
2051 ATCTTGAAAT TGAACTTCCA AAAGAAGCTT CTTATCAAGA AGGAGATCAT  
2101 TTAGGTGTTA TTCCTCGCAA CTATGAAGGA ATAGTAAACC GTGTAACAGC  
2151 AAGGTTCGGC CTAGATGCAT CACAGCAAAT CCGTCTGGAA GCAGAAGAAG  
2201 AAAAATTAGC TCATTTGCCA CTCGCTAAAA CAGTATCCGT AGAAGAGCTT 
2251 CTGCAATACG TGGAGCTTCA AGATCCTGTT ACGCGCACGC AGCTTCGCGC  
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2301 AATGGCTGCT AAAACGGTCT GCCCGCCGCA TAAAGTAGAG CTTGAAGCCT  
2351 TGCTTGAAAA GCAAGCCTAC AAAGAACAAG TGCTGGCAAA ACGTTTAACA  
2401 ATGCTTGAAC TGCTTGAAAA ATACCCGGCG TGTGAAATGA AATTCAGCGA  
2451 ATTTATCGCC CTTCTGCCAA GCATACGCCC GCGCTATTAC TCGATTTCTT  
2501 CATCACCTCG TGTCGATGAA AAACAAGCAA GCATCACGGT CAGCGTTGTC  
2551 TCAGGAGAAG CGTGGAGCGG ATATGGAGAA TATAAAGGAA TTGCGTCGAA  
2601 CTATCTTGCC GAGCTGCAAG AAGGAGATAC GATTACGTGC TTTATTTCCA  
2651 CACCGCAGTC AGAATTTACG CTGCCAAAAG ACCCTGAAAC GCCGCTTATC  
2701 ATGGTCGGAC CGGGAACAGG CGTCGCGCCG TTTAGAGGCT TTGTGCAGGC  
2751 GCGCAAACAG CTAAAAGAAC AAGGACAGTC ACTTGGAGAA GCACATTTAT  
2801 ACTTCGGCTG CCGTTCACCT CATGAAGACT ATCTGTATCA AGAAGAGCTT  
2851 GAAAACGCCC AAAGCGAAGG CATCATTACG CTTCATACCG CTTTTTCTCG  
2901 CATGCCAAAT CAGCCGAAAA CATACGTTCA GCACGTAATG GAACAAGACG  
2951 GCAAGAAATT GATTGAACTT CTTGATCAAG GAGCGCACTT CTATATTTGC  
3001 GGAGACGGAA GCCAAATGGC ACCTGCCGTT GAAGCAACGC TTATGAAAAG  
3051 CTATGCTGAC GTTCACCAAG TGAGTGAAGC AGACGCTCGC TTATGGCTGC  
        3101 AGCAGCTAGA AGAAAAAGGC CGATACGCAA AAGACGTGTG GGCTGGG   
 
 Figure A.2: Amino acid sequence of full-length, wild-type cytochrome P450 BM-3  
 
1 MTIKEMPQPK TFGELKNLPL LNTDKPVQAL MKIADELGEI FKFEAPGRVT  
51 RYLSSQRLIK EACDESRFDK NLSQALKFVR DFAGDGLFTS WTHEKNWKKA  
101 HNILLPSFSQ QAMKGYHAMM VDIAVQLVQK WERLNADEHI EVPEDMTRLT  
151 LDTIGLCGFN YRFNSFYRDQ PHPFITSMVR ALDEAMNKLQ RANPDDPAYD  
201 ENKRQFQEDI KVMNDLVDKI IADRKASGEQ SDDLLTHMLN GKDPETGEPL  
251 DDENIRYQII TFLIAGHETT SGLLSFALYF LVKNPHVLQK AAEEAARVLV  
301 DPVPSYKQVK QLKYVGMVLN EALRLWPTAP AFSLYAKEDT VLGGEYPLEK  
351 GDELMVLIPQ LHRDKTIWGD DVEEFRPERF ENPSAIPQHA FKPFGNGQRA  
401 CIGQQFALHE ATLVLGMMLK HFDFEDHTNY ELDIKETLTL KPEGFVVKAK  
451 SKKIPLGGIP SPSTEQSAKK VRKKAENAHN TPLLVLYGSN MGTAEGTARD  
501 LADIAMSKGF APQVATLDSH AGNLPREGAV LIVTASYNGH PPDNAKQFVD  
551 WLDQASADEV KGVRYSVFGC GDKNWATTYQ KVPAFIDETL AAKGAENIAD  
601 RGEADASDDF EGTYEEWREH MWSDVAAYFN LDIENSEDNK STLSLQFVDS  
651 AADMPLAKMH GAFSTNVVAS KELQQPGSAR STRHLEIELP KEASYQEGDH  
701 LGVIPRNYEG IVNRVTARFG LDASQQIRLE AEEEKLAHLP LAKTVSVEEL  
751 LQYVELQDPV TRTQLRAMAA KTVCPPHKVE LEALLEKQAY KEQVLAKRLT  
801 MLELLEKYPA CEMKFSEFIA LLPSIRPRYY SISSSPRVDE KQASITVSVV  
851 SGEAWSGYGE YKGIASNYLA ELQEGDTITC FISTPQSEFT LPKDPETPLI  
901 MVGPGTGVAP FRGFVQARKQ LKEQGQSLGE AHLYFGCRSP HEDYLYQEEL  
951 ENAQSEGIIT LHTAFSRMPN QPKTYVQHVM EQDGKKLIEL LDQGAHFYIC 
          1001 GDGSQMAPAV EATLMKSYAD VHQVSEADAR LWLQQLEEKG RYAKDVWAG 
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BM3 - - - - - - - - - - - 0 0 0 0 0 54.5 
V78C - - C - - - - - - - - 0.14 200 2.3 4 0 - 
V78S - - S - - - - - - - - 0.18 210 1.8 6 0 - 
V78T - - T - - - - - - - - 0.14 370 1.8 9 0 - 
A82E - - - E - - - - - - - 0.20 330 - - 0 - 
A82Q - - - Q - - - - - - - 0.22 120 - - 0 - 
A328I - - - - - - - - I - - 0.47 1,500 3.5 3 0 - 
A328P - - - - - - - - P - - 0.16 1,300 4.7 10 0 - 
A328L - - - - - - - - L - - 0.50 860 4.0 8 0 - 
A328V - - - - - - - - V - - 0.17 2,300 7.1 8 0 59.1 
A330L - - - - - - - - - L - 0.22 1,700 - - 0 - 
A330P - - - - - - - - - P - 0.13 590 - - 0 - 
A330V - - - - - - - - - V - 0.23 1,700 - - 0 - 
4F9 - - - - - - - - - - F162L 0.47 3,300 19 18 0 - 
8D12 - - - - - - - - - - I260V 0.20 650 11 14 0 - 
4B1 - - - - - - - - - - E4D,I153V 0.50 2,000 9 15 0 - 
1G9 - - - - - - - - - - T235M 0.46 1,700 - - - - 
7F12 - - - - - - - - - - D232V 0.28 133 - - - - 
3F1 - - - - - - - - - - Q359R 0.27 364 - - - - 
2C11 - - L - - - - L - - 0.83 440 10 31 0 61.3 
1B4 - - - L - - - - L - - 0.74 1,500 25 16 140 59.5 
4E10 - - - L - - - - V - - 0.59 4,200 40 44 200 55.4 
1B1 - - - W - - - - F - - 0.15 380 8 2 0 48.4 
1E5 - - L W - - - - - - - 0.23 1,400 27 8 0 54.5 
6C8 - - L L - - - - L - - 0.78 760 6 16 0 52.5 
4F7 - - L M - - - - L - - 0.66 1,700 8 38 0 63.1 
7B7 - - L V - - - - L - - 0.74 1,500 8 32 0 61.9 






















E 32 W - I L - - V W F W - 2.61 16,800 236 36 1,200 56.6 
E 30 W - I L - - A - F W - 2.59 16,600 188 41 520 53.0 
CC2 W - F L - - V - F W - 0.52 12,600 - - 0 - 
E 92 W - I L - - V W V L - 1.11 11,000 138 36 360 52.5 
CF3 W - I V - - A W V L - 1.53 10,900 - - 0 - 
E 35 W - I L - - V W V W - 1.58 10,400 - - 530 - 
E 66 W - I L - - A W F W - 2.61 10,300 195 52 890 52.1 
CE5 W - I L - - A - V L - 1.82 9,600 - - 0 - 
E 31 L - I L - - V W F W - 1.52 9,350 208 68 1,200 56.2 
CA3 W - F L - - A W V L - 1.32 9,130 - - 0 - 
CC5 W F I L - - V W V L - 1.55 9,120 - - 0 - 
CF1 W - I L - W A W V L - 1.64 8,850 - - 390 - 
E 77 L - I L - - A W V L - 1.79 8,840 - - 430 - 
E 78 L - I L - - A W F W - 1.90 8,820 - - 870 - 
CB8 W - F L - - V W V W - 1.17 8,050 - - 300 - 
CE4 L - I L - - V W V W - 1.91 7,640 - - 670 - 
OB6 W - F V - - V - V W - 1.42 7,330 - - 0 - 
CA1 W - F L - - V W V L - 1.95 6,720 - - 520 - 
OD3 W - I V - - A - F W - 1.55 6,510 - - 0 - 
CG3 L F I L A - A W F W - 1.67 6,060 - - 0 - 
CD3 L F I L - - V W F W - 2.05 6,050 - - 0 - 
CG2 L - F V - - V W F W - 1.96 6,030 - - 540 - 
CE7 W - I V - - V - F W - 1.29 5,600 - - 0 - 
CH1 W - I L - W V - F W - 1.47 4,260 - - 0 - 
CA4 W F I V - W V W F W - 1.73 3,590 - - 0 - 
OD2 V - - - - F - - F - - 0.88 11,600 168 42 660 50.8 
OC5 - - L S - - T W F - - 0.80 10,400 - - 0 - 
OD1 V - - S - F - - F V - 0.93 10,300 - - 0 - 






















OC6 V - - S - F - - F - - 1.44 9,430 - - 0 - 
OG9 - - - S - - T W F V - 0.99 8,230 - - 0 - 
OH3 - F L - - - - - - - - 2.51 8,160 - - 0 - 
OD7 - F - S A - T - F V - 1.74 7,900 86 39 720 53.1 
OC9 - - - S - - - W F - - 0.51 7,710 - - 0 - 
OH9 - - - S - F T W - V - 0.69 6,790 - - 0 - 
OE5 V F - - - - - W F V - 0.69 6,210 131 41 380 51.9 
OA2 V - - - - F - W F - - 1.31 4,450 - - 0 - 
[a] DME demethylation activity was determined in cell-free extract, corrected for background Purpald ® oxidation. 
[b] TON determined as nmol product/nmol enzyme. Alkane reactions contained 25 – 250 nM protein, potassium phosphate buffer saturated with propane, and an 
NADPH regeneration system containing 100 μM NADP+, 2 U/mL isocitrate dehydrogenase, and 10 mM isocitrate. Standard errors are within 15% of average. 
[c] Propanol formation rates were determined over 1 – 10 minutes with 100 nM protein, propane saturated potassium phosphate buffer, and 1 mM NADPH.  
[d] Coupling determined by ratio of product formation rate to NADPH consumption rate 
[e] T50 calculated based on a two-state denaturation model using the percentage of 450 nm CO-binding peak of P450 variants remaining after 15-

















B.1 Corbit algorithm and frequency table of mutations 
Under the Corbit design, all amino acids except C, M, and P were allowed at the ten target 
residues 74, 75, 78, 82, 87, 181, 184, 188, 328, and 330, resulting in a total possible sequence 
space of 1017. In the first step of the modeling process, the structure of the BM3 with N-
palmitoyl glycine bound (pdb: 1JPZ), was subjected to 50 steps of conjugate gradient 
minimization using the DREIDING force field (1). After the minimization, the substrate was 
removed and the backbone of “substrate-less” structure was used for the computational analysis. 
In addition to mutating the ten target residues, a shell of 26 residues with side chain atoms within 
4 Å of these design positions, 20, 25, 69, 71, 72, 73, 77, 81, 88, 177, 180, 185, 189, 205, 259, 
260, 263, 264, 267, 268, 329, 354, 356, 436, 437, and 438, were allowed to change side chain 
conformation, but not amino acid identity.  
The globally optimal sequence was determined using the FASTER algorithm (2) with a 
backbone- independent conformer library with binning level of 1.0 (3) and scoring by the energy 
function previously demonstrated for mutagenesis of GFP (4). From this optimal sequence, 
Monte Carlo sampling with 100 temperature cycles between 150 K and 4,000 K at 106 steps per 
cycle was carried out to sample sequences around the global optimum. The top 20,000 scoring 
sequences were compiled to generate a frequency table (see table B.1). From this table, the most 
frequent amino acid sharing a degenerate codon with the wild-type residue was selected as the 




Table B.1: Frequency table for the most stable 20,000 sequences as determined by Corbit  
Amino 
acid a  74  75  78  82  87  181  184  188  328  330 
ALA  0.14  0.00  0.00  0.27 0.01 0.00 0.69 0.24  0.01 0.01
ARG  0.00  0.01  0.00  0.03 0.00 0.00 0.00 0.00  0.01 0.00
ASN  0.00  0.00  0.00  0.02 0.00 0.00 0.01 0.02  0.00 0.00
ASP  0.00  0.00  0.00  0.04 0.00 0.00 0.05 0.04  0.00 0.00
GLN  0.00  0.01  0.00  0.20 0.00 0.00 0.00 0.01  0.01 0.00
GLU  0.01  0.00  0.00  0.13 0.00 0.01 0.00 0.03  0.02 0.00
GLY  0.02  0.00  0.01  0.02 0.00 0.00 0.06 0.02  0.00 0.00
ILE  0.00  0.00  0.36  0.00 0.00 0.00 0.00 0.01  0.00 0.08
LEU  0.01  0.84  0.37  0.02 0.00 0.73 0.01 0.44  0.01 0.31
LYS  0.00  0.01  0.04  0.11 0.00 0.04 0.00 0.01  0.08 0.01
PHE  0.36  0.12  0.00  0.00 0.99 0.16 0.00 0.01  0.74 0.43
SER  0.02  0.00  0.00  0.15 0.00 0.00 0.09 0.04  0.00 0.00
THR  0.01  0.00  0.00  0.01 0.00 0.00 0.09 0.02  0.00 0.00
VAL  0.03  0.00  0.19  0.00 0.00 0.00 0.00 0.01  0.00 0.03
TRP  0.32  0.00  0.01  0.00 0.00 0.00 0.00 0.11  0.03 0.01
TYR  0.03  0.00  0.00  0.00 0.00 0.01 0.00 0.00  0.00 0.02
His  0.06  0.01  0.01  0.00 0.00 0.06 0.00 0.01  0.08 0.10
MET  0.00  0.00  0.00  0.00 0.00 0.00 0.00 0.00  0.00 0.00
PRO  0.00  0.00  0.00  0.00 0.00 0.00 0.00 0.00  0.00 0.00




A, V  L, F  V, L  A, S  F, A  L, F  A, T  L, W  A, F  A, V 
a Amino acid and values shown in bold correspond to wild-type residues, values shown with green 












B.2 CRAM algorithm and energy evaluation of mutations 
As a counterpoint to the minimum energy strategy, we decided to test a partially 
structure-guided design. The principal objective of this latter design was to maximally reduce the 
binding channel volume through incorporation of the largest possible amino acids. However, we 
recognized that incorporation of tryptophan at all positions would likely result in a largely non-
functional library. Also, requiring a degenerate codon that specified exactly the wild-type amino 
acid and the largest permitted amino acid was overly restrictive. Therefore to aggressively reduce 
volume, we relaxed our constraint to always include the wild-type residue.  
To prevent the incorporation of residues that would inevitably result in a steric clash, we 
performed side-chain optimization calculations as follows. First, we mutated the targeted ten 
active positions (74, 75, 78, 82, 87, 181, 184, 188, 328, and 330) to glycine. Second, we 
individually mutated each position to all amino acids except C, M, P, R, K, E, and D. Holding all 
other amino acids in the protein fixed in place, we performed a thorough optimization of the 
mutated side chain to determine if a van der Waal clash was avoidable. This optimization used 
the RosettaDesign software (5), the all-atom Rosetta force field (6), and several non-standard 
RosettaDesign settings to minimize the occurrence of van der Waal clashes. These include an 
expanded rotamer library (-ex1, –ex2aro_only, -extrachi_cutoff 18), reduced van der Waal radii 
(-small_radii), and a non-rotameric energy minimization of the side chain position (-
mcmin_trials).   
With this resulting map of unavoidable van der Waal clashes, we manually customized a 
degenerate codon library enriched for wild-type representation and for representation of the 




Table B.2: Best case repulsive van der Waal energy as determined by ROSETTA  
Amino acid  74  75  78  82 87 181 184 188  328  330
ALA  115.73  114.82  115.57 115.57 115.9 115.61 115.9 115.77  115.59 115.81
PHE  115.87  92.81  181.1  385.92 97.92 144.2 536.66 160.32  91.19 116.46
GLY  115.8  115.56  115.98 115.98 115.66 115.73 115.34 115.89  116.07 115.47
HIS  115.99  115.26  127.99 161.58 115.49 99.65 202.6 101.42  114.96 98.98
ILE  138.8  129.53  98.29  147.43 117.49 144.09 143.7 117.65  235.98 143.34
LEU  125.58  115.89  97.78  118.73 115.76 114.86 150.74 97.69  116.3 117.1
ASN  92.96  115.7  92.17  93.18 89.65 91.03 94.7 115.55  116.05 93.39
GLN  92.45  115.33  115.26 115.77 90.75 114.98 185.13 114.84  94.78 92.58
SER  90.66  116.3  115.58 115.8 116.21 89.83 115.83 89.67  115.87 90.58
THR  115.62  93.73  116.38 97.42 115.67 92.08 116.52 92.32  123.17 116.42
VAL  147.03  36.98  116.05 122.11 94.63 121.52 135.11 118.18  131.04 123.42
TRP  94.32  97.06  115.15 354.69 93.83 155.82 983.14 116.54  93.76 115.79




L, W  L, F  I, F  V, L  F, A  L, W  A, V  L, W  V, F  L, W 
a Amino acid and values shown in bold correspond to wild-type residues, values shown with green 
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C.1 Halomethane Dehalogenation Screen 
 Halomethanes (CH3X) are an obvious surrogate for methane and ethane as they share 
similar molecular size and C-H bond dissociation energies. The P450 catalyzed dehalogenation 
of halomethanes ultimately yields formaldehyde (see equation (C.1)), which can be quantified 
calorimetrically with the use of Purpald®, similarly as the DME screen detailed in Chapter 8.E.3.   
 
 After assaying BM3 variants for CH3I, CH3F, CH3Br, and CH3Cl dehalogenation, we 
determined CH3Cl to be the most amenable substrate for high-throughput screening as it had the 
highest activity (20 – 70 TON) and assay signal (A550nm = 0.2 – 0.5). While the assay captured 
differences in dehalogenation activity of BM3 variants (see Figure C.1), when it was used to 
evaluate mutant libraries, the variants with improved dehalogenation activity did not frequently 
exhibit improved ethane hydroxylation activity.   
 
Figure C.1: Colorimetric screen for chloromethane dehalogenation; each column contains eight reactions 
with the same variant–the top four wells contain reactions with chloromethane, the bottom four wells are 
control reactions without chloromethane. Column one contains variant 35E11, columns two through 





C.2 Dichloromethane Dehalogenation Screen 
 In addition to using chloromethane dehalogenation as surrogate for ethane or methane 
hydroxylation, we also attempted to use dehalogenation of dichloromethane as a high throughput 
screen. The P450 catalyzed dehalogenation of dichloromethane results in the in situ formation of 
carbon monoxide (see equation (C.2)), which when bound to P450 heme generates the 
characteristic 450 nm soret peak.   
 
Despite having a weaker C-H bond as compared to chloromethane (93 kcal/mol vs. 98 
kcal/mol), the activity of BM3 variants for dehalogenation of dichloromethane was equally poor, 
20 – 50 TON. In order to quantify the catalytic release of CO, purified P450 heme domains are 
needed in excess. The final drawback of this assay is the inhibitory nature of CO of the P450 
reaction. 
C3. Methanol Oxidation Screen 
The small size of methane and ethane significantly limits the molecules that can serve as 
a suitable surrogate. In addition to halomethanes, methanol is another compound with an 
intermediate size between methane and ethane. While methanol oxidation activity is non-ideal 
for a selective methane oxidizing catalyst, it is present in MMOs. Since ethanol is a known P450 
substrate, pursuing methanol oxidation as a high-throughput screen was appealing. The P450 
catalyzed methanol oxidation resulted in the production of formaldehyde, which can be 





Figure C.2: High-throughput methanol oxidation screen: (a) the methanol hydroxylation activity of 7-7 
AB2, a P450PMO-derived BM3 variant, at various methanol concentrations; (b) a sample screening plate 
from 7-7 AB2 random heme library assayed for DME demethylation and methanol oxidation activity 
 Methanol oxidation activity was not observed in wild-type BM3 and most variants in the 
P450PMO lineage. P450PMO and its derived variants were able to oxidize methanol with detectable 
activity with more than 50 mM methanol present in the reaction. From screening of a random 
heme domain library for both DME demethylation and methanol oxidation it was evident that 
these two activities were well-correlated (see Figure C.2 (b)). As a result, there was not a 




















D.1 GC/MS analysis of terminal oxidant-supported methane reactions 
Figure D.1: GC/MS-SIM chromatogram of 12C and 13C methanol calibration standards. (a) 12C methanol standards quantified by m/z 
31 ion with peak retention at 2.26 min, shown with a vertical offset. Peak at 3.0 min corresponds to background ethanol. (b) 13C 





Figure D.2: GC/MS-SIM chromatogram of PhIO-supported 12C-methane reactions with BM3, 
CAM, and A6 with controls reactions containing PhIO, PhIO, and hemin dissolved in ethanol, 
and PhIO-supported 13C-methane reaction with A6, shown with a vertical offset. The methanol 
peak has a retention time of 2.26 min with background ethanol found as a peak at 3.0 min. 
 
 
Figure D.3: GC/MS-SIM chromatogram of PhIO-supported A6 methane reactions with 12C-and 
13C-methane, shown with a vertical offset: (a) m/z 31 ion chromatogram with methanol peak 
with retention of 2.26 min and background ethanol with retention of 3.0 min; (b) m/z 33 ion 





Figure D.4: GC/MS-SIM (m/z 33) chromatogram of terminal oxidant-supported A6 methane 
reactions with 16O-and 18O-water, shown with a vertical offset. Methanol peak with retention of 




D.2 Quantification of fdrA6 and fdxA6 and determination of optimal reductase component 
ratios 
As a type I P450, A6 differs from BM3 in that its reductase components fdrA6 and fdxA6 
are separate proteins rather than being fused on a single polypeptide chain. We sub-cloned fdrA6 
and fdxA6 individually into the pET-22b(+) expression vector and expressed the enzymes in E. 
coli BL21(DE3) transformed with the resulting plasmids. Following literature protocols 
established for the purification of putidaredoxin and putidaredoxin reductase of P450cam (1), we 
purified fdrA6 and fdxA6 with the characteristic UV-Vis spectra for the FAD and [Fe2-S2] 
cofactors (see Figure E.5). The concentrations of fdrA6 and fdxA6 were determined using the 
extinction coefficients, 455nm = 10.4 mM-1 cm-1 and 412nm = 11.0 mM-1 cm-1 (1), respectively. 
 
Figure D.5: UV/Vis spectrum of purified FdrA6 and FdxA6 
To determine the optimum ratio of reductase components, the A6 NADH consumption 
rate was determined in the presence and absence of octane at various ratios of the reductase 
components (see Figure E.6). The substrate-free NADH consumption rate was found to be 3 – 5 
min-1 at moderate ratios of fdxA6:A6, 2.5 – 10:1, independent of fdrA6. At higher ratios of 
fdxA6:A6, the substrate-free NADH consumption increases linearly with increasing fdxA6 
reaching a rate of 15 min-1 at 80:1 fdxA6:A6. In the presence of octane, the rate of NADH 
consumption asymptotes above a ratio of 10:1 fdxA6:A6 and 1:1fdrA6:A6 at ca. 80 min-1. Based 
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on these results, a ratio of 1:1:10 for A6:fdrA6:fdxA6 was chosen for all NADH/O2-supported 
reactions with A6. 
 
Figure D.6: (a) Substrate-free NADH consumption in the presence of various ratios of fdxA6 and 
fdrA6 as determined by absorption at 340 nm. (b) NADH consumption in the presence of octane 






D.3 Determination of Michaelis-Menten kinetics parameters 
  
 
Figure D.7: Plots of initial product formation rates at various substrate concentrations. (a) Octane 
and hexane reactions; (b) Ethane reactions; (c) Iodomethane and d3-Iodomethane reactions; (see 




D.4 UV/Vis spectroscopy 
 
Figure D.8: Difference UV/Vis spectra of CYP153A6 in the presence of different alkanes. 
Hexane and octane were present at 1 mM in 1% ethanol and referenced against an A6 solution 
containing 1% ethanol. Gaseous alkanes were present at 60 -psi headspace pressure and 


















Variant Selection for Production of Drug Metabolites and 









Table E.1: Identity of engineered P450 BM3 variant panel: enzyme family, name, sequence, 
number of mutations from closest wild-type parent, and required oxidant 





1  WT  P450 BM3  WT 0 fatty acid  O2
2  WT  CYP102A2  CYP102A2 0 fatty acid  O2
3  WT  CYP102A3  CYP102A3 0 fatty acid  O2
4  WT  A1  CYP102A1  Heme Domain Only 0  none  H2O2 
5  WT  A2  CYP102A2  Heme Domain Only 0  none  H2O2 
6  WT  WT F87A  WT F87A 1 none  O2
7  Propranolol  9C1  21B3 I102T A145V L324I I366V E442K 14  Propranolol  O2 
8  Propranolol  D6H10  9C1 L75H V78E A82P 17 Propranolol O2
9  Propranolol  DE10  9C1 A74V A82L A87G 16 Propranolol H2O2
10  Propranolol  2C11  DE10 K24R R47H 18 Propranolol H2O2
11  Chimera  11113311  chimera 35 none  H2O2
12  Chimera  12112333  chimera 96 none  H2O2
13  Chimera  21112233  chimera 98 none  H2O2
14  Chimera  21112331  chimera 85 none  H2O2
15  Chimera  21112333  chimera 89 none  H2O2
16  Chimera  21113312  chimera 97 none  H2O2
17  Chimera  21113333  chimera 75 none  H2O2
18  Chimera  21212233  chimera 89 none  H2O2
19  Chimera  21212333  chimera 87 none  H2O2
20  Chimera  21311231  chimera 81 none  H2O2
21  Chimera  21311233  chimera 97 none  H2O2
22  Chimera  21311311  chimera 63 none  H2O2
23  Chimera  21311313  chimera 95 none  H2O2
24  Chimera  21311331  chimera 81 none  H2O2
25  Chimera  21311333  chimera 81 none  H2O2
26  Chimera  21312133  chimera 100 none  H2O2
27  Chimera  21312211  chimera 76 none  H2O2
28  Chimera  21312213  chimera 99 none  H2O2
29  Chimera  21312231  chimera 94 none  H2O2
30  Chimera  21312233  chimera 96 none  H2O2
31  Chimera  21312311  chimera 76 none  H2O2
32  Chimera  21312313  chimera 98 none  H2O2
33  Chimera  21312331  chimera 94 none  H2O2
34  Chimera  21312332  chimera 83 none  H2O2
35  Chimera  21312333  chimera 80 none  H2O2
36  Chimera  21313111  chimera 58 none  H2O2
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37  Chimera  21313231  chimera 96 none  H2O2
38  Chimera  21313233  chimera 82 none  H2O2
39  Chimera  21313311  chimera 78 none  H2O2
40  Chimera  21313313  chimera 84 none  H2O2
41  Chimera  21313331  chimera 96 none  H2O2
42  Chimera  21313333  chimera 66 none  H2O2
43  Chimera  21333233  chimera 61 none  H2O2
44  Chimera  22112233  chimera 81 none  H2O2
45  Chimera  22112333  chimera 93 none  H2O2
46  Chimera  22212333  chimera 88 none  H2O2
47  Chimera  22223132  chimera 55 none  H2O2
48  Chimera  22311233  chimera 92 none  H2O2
49  Chimera  22311331  chimera 98 none  H2O2
50  Chimera  22311333  chimera 85 none  H2O2
51  Chimera  22312231  chimera 78 none  H2O2
52  Chimera  22312233  chimera 79 none  H2O2
53  Chimera  22312331  chimera 94 none  H2O2
54  Chimera  22312333  chimera 84 none  H2O2
55  Chimera  22313231  chimera 92 none  H2O2
56  Chimera  22313233  chimera 86 none  H2O2
57  Chimera  22313331  chimera 102 none  H2O2
58  Chimera  22313333  chimera 70 none  H2O2
59  Chimera  23132233  chimera 70 none  H2O2
60  Chimera  32312231  chimera 101 none  H2O2
61  Chimera  32312333  chimera 53 none  H2O2
62  Chimera  32313233  chimera 55 none  H2O2
63  Chimera  11113311‐R1  chimera 35 none  O2
64  Chimera  12112333‐R1  chimera 96 none  O2
65  Chimera  21113312‐R1  chimera 97 none  O2
66  Chimera  21113312‐R2  chimera 97 none  O2
67  Chimera  21311231‐R1  chimera 81 none  O2
68  Chimera  21311233‐R1  chimera 97 none  O2
69  Chimera  21313311‐R1  chimera 78 none  O2
70  Chimera  21333233‐R2  chimera 61 none  O2
71  Chimera  22132231‐R1  chimera 77 none  O2
72  Chimera  22223132‐R1  chimera 55 none  O2
73  Chimera  22312333‐R1  chimera 84 none  O2
74  Chimera  22313233‐R1  chimera 86 none  O2
75  Chimera  23132233‐R1  chimera 70 none  O2
76  Chimera  23132233‐R2  chimera 70 none  O2
77  Chimera  32312231‐R1  chimera 101 none  O2
78  Chimera  32312333‐R1  chimera 53 none  O2









81  Propane  J  139‐3  Y138H  I178V F205C S226R A290V 10  propane  O2 
82  Propane  9‐10A  J R47C K94I P142S 13 propane  O2
83  Propane  9‐10A A328F  9‐10A A328F 14 propane  O2
84  Propane  9‐10A A328M  9‐10A A328M 14 propane  O2
85  Propane  9‐10A A328V  9‐10A A328V 14 propane  O2
86  Propane  9‐10A A78F  9‐10A A78F 13 propane  O2
87  Propane  9‐10A A78S  9‐10A A78S 13 propane  O2
88  Propane  9‐10A A78T  9‐10A A78T 13 propane  O2
89  Propane  9‐10A A82C  9‐10A A82C 14 propane  O2
90  Propane  9‐10A A82F  9‐10A A82F 14 propane  O2
91  Propane  9‐10A A82G  9‐10A A82G 14 propane  O2
92  Propane  9‐10A A82I  9‐10A A82I 14 propane  O2
93  Propane  9‐10A A82L  9‐10A A82L 14 propane  O2
94  Propane  9‐10A A82S  9‐10A A82S 14 propane  O2
95  Propane  9‐10A A82T  9‐10A A82T 14 propane  O2
96  Propane  9‐10A F87A  9‐10A F87A 14 propane  O2
97  Propane  9‐10A F87I  9‐10A F87I 14 propane  O2
98  Propane  9‐10A F87L  9‐10A F87L 14 propane  O2
99  Propane  9‐10A F87V  9‐10A F87V 14 propane  O2
100  Propane  9‐10A L75I  9‐10A L75I 14 propane  O2
101  Propane  9‐10A L75W  9‐10A L75W 14 propane  O2
102  Propane  9‐10A T260L  9‐10A T260L 14 propane  O2
103  Propane  9‐10A T260N  9‐10A T260N 14 propane  O2
104  Propane  9‐10A T260S  9‐10A T260S 14 propane  O2
105  Propane  9‐10A T88L  9‐10A T88L 14 propane  O2
106  Propane  9‐10A A82L A328V  9‐10A‐A82L‐A328V    15  propane  O2 
107  Propane  9‐10A A82F A328V  9‐10A A82F A328V    15  propane  O2 
108  Propane  9‐10A F87V A328L  9‐10A F87V A328L    15  propane  O2 
109  Propane  9‐10A A82G F87V A328V  9‐10A A82G F87V A328V  16  propane  O2 





9‐10A  A78T  A82G  F87V 
A328L  16  propane  O2 
112  Propane  9‐10A A82F A328F  9‐10A A82F A328F    15  propane  O2 
245 
 
113  Propane  9‐10A A78F A82G A328F  9‐10A A78F A82G A328F  14  propane  O2 
114  Propane  9‐10A A78F A82S A328L  9‐10A A78F A82S A328L   14  propane  O2 





9‐10A  A78T  A82G  F87V 
A328L  16  propane  O2 
117  Propane  9‐10A A82G F87L A328L  9‐10A A82G F87L A328L   16  propane  O2 
118  Propane  9‐10A A78F A82S A328F  9‐10A A78F A82S A328F   15  propane  O2 
119  Propane  9‐10A A78F A82G A328L  9‐10A A78F A82G A328L  15  propane  O2 
120  Propane  9‐10A A78T A82G A328L  9‐10A A78T A82G A328L  15  propane  O2 
aUnderlined variants contain wild‐type sequences, variants in italics were selected for propranolol 
activity, variants in bold are chimeras, variants in normal type were selected for activity on alkanes. 21B3 
contains  the  following  mutations  relative  to  wild‐type:  I58V,  H100R,  F107L,  A135S,  M145V,  N239H, 
S274T, K434E and V446I. Chimeras are written according  to  fragment  composition: 32313233‐R1,  for 
example, represents a protein which inherits the first fragment from parent CYP102A3, the second from 
CYP102A2,  the  third  from  CYP102A3,  and  so  on.  The  specific  amino  acid  sequence  of  each  block  is 
























































Table E.3 Complete list of active enzymes and their metabolite distributions with verapamil 
 
Entry  Variant a  % Conversion % 1 % 2 % 3 % 4 % 5 % 6 % 7  % 8  % 9 % 10
1  2C11  25    8  28      20  8    8  28 
2  9C1  31  3    29  3    6  13  3  10  13 
3  D6H10  78      26  8    31      3  24 
4  DE10  20            15  35    10  15 
5  11113311  25      48      28  8      16 
6  21113312  17    6  12      12  41  6  6  12 
7  21113333  5            20  40  20    20 
8  21312332  6      17      33  17      33 
9  21313111  6            67        33 
10  21313311  12      33      33  8      25 
11  21313331  5      20      20  20  20    20 
12  22313231  43    47        33  5      16 
13  22313233  12  8          8  17  8  17  8 
14  22313333  34    41      15  21  9      15 
15  32313233  24      50      21  13      17 
16  23132233‐R1  15      27      73         
17  32312231‐R1  23      30      43        26 
18  32312333‐R1  44    7  7        36       
19  32313233‐R1  25      40      44        16 
20  139‐3  14    14  14      14  57       
21  9‐10A  27    7  7      7  63  7     
22  L75I  34    6  6      6  74  3     
23  A78F  30    10          83       
24  A78S  20      25      35  35      5 
25  A78T  25    8  8      8  64  4     
26  A82C  16      6      6  81       
27  A82F  30      10      3  83       
28  A82G  13      31      46  23       
29  A82I  33    3  6      3  79  3  3   
30  A82L  51            2  94       
31  A82S  32    3  3      6  88       
32  A82T  28    4  7      4  86       
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Entry  Variant a  % Conversion % 1 % 2 % 3 % 4 % 5 % 6 % 7  % 8  % 9 % 10
33  F87A  12      8      17  58       
34  F87I  13    8        8  69       
35  F87L  49            6  94       
36  F87V  24  4  4        8  63       
37  T88L  14      21      43  21      14 
38  T260S  34      12      29  38  9    12 
39  A328M  36  3  3  3      6  75    6   
40  1‐12G  19      16      21  53       
41  7‐11D  21      29      29  14       
42  12‐10C  34      6      6  79  3    29 
43  41‐5B  18      11      6  67       
aVariants in italics were selected for propranolol activity (1), variants in bold are chimeras (2), variants in 
normal type were selected for activity on alkanes (3 – 4). 
 
 
Table E.4 Complete list of active enzymes and their metabolite distributions with astemizole 
 
 
Entry  Variant a  % Conversion % 11 % 12 % 13 % 14 % 15  % 16  % 17
1  2C11  4        100       
2  9C1  2        100       
3  DE10  9        56       
4  21113312  6  33      67       
5  21313111  4  25      75       
6  21313311  10  20      40      40 
7  22313231  9  22      44      33 
8  22313233  7  14      57      29 
9  22313333  9  22      56      22 
10  32312333  3        100       
11  32313233  11        45  27    27 
12  21313111‐R1  11  27    27  18  27     
13  22313233‐R1  6  33      33      33 
14  32312333‐R1  78        4  67    9 
15  32313233‐R1  16        13  69     
16  139‐3  6      67    33     
17  J  23  26  4  65         
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Entry  Variant a  % Conversion % 11 % 12 % 13 % 14 % 15  % 16  % 17
18  9‐10A  50  14  10      70  6   
19  L75I  15  33    47         
20  A78F  21  48    38      14   
21  A78S  15  13  7      80     
22  A78T  27  37  7  44      4   
23  A82C  24  33    67         
24  A82F  15  60             
25  A82G  35  29  6  63      3   
26  A82I  32  31  6  63         
27  A82L  49  24        61  4   
28  A82S  30  20  7  70      3   
29  A82T  34  24  12  59      6   
30  F87A  31      23  16  45     
31  F87I  50      48    36  4   
32  F87L  36    3  88      6   
33  F87V  26      38    31     
34  T88L  28      75    25     
35  T260L  2      100         
36  T260N  40    25  75         
37  T260S  25      32  8  44     
38  11‐8E  2  100             
39  12‐10C  26  38      12  46     
40  23‐11B  2  100             
41  41‐5B  5  100             
42  49‐9B  5  60      40       
aVariants in italics were selected for propranolol activity (1), variants in bold are chimeras (2), variants in 





Table E.5 Complete list of active enzymes and their metabolite distributions with LY294002 
 
Entry  Variant a  % Conversion % 18 % 19 % 20 % metabolite A b 
1  12112333‐R1  8        100 
2  21113312‐R1  8        100 
3  21313111‐R1  7        100 
4  21333233‐R1  4        100 
5  22132231‐R1  7        100 
6  32312231‐R1  6        100 
7  32313233‐R1  8        100 
8  J  9        100 
9  L75I  10    50     
10  A78S  7    71     
11  A82S  2    100     
12  F87V  6      100   
13  T260S  11    9    91 
14  A328F  7        100 
15  7‐11D  7        100 
16  29‐10E  12        83 
17  68‐8F  9    11    89 
18  77‐9H  11        91 
a Variants in italics were selected for propranolol activity (1), variants in bold are chimeras (2), variants in 
normal type were selected for activity on alkanes (3 – 4). 
b Metabolite of unknown structure, Mw = 238. 
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